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Summarv. 
The molecular, enzymic and physiological characteristics, 
methods of assay and the clinical significance of human 
serum cholinesterase are reviewed. The existence of 
multiple forms of enzymes and the particular inherited 
polymorphism of human cholinesterase which results in 
abnormal responses to the muscle relaxant, suxamethonium, 
are summarised. 
The effect of reaction temperature on the hydrolysis 
of substrates by cholinesterases has been investigated and 
significant differences have been demonstrated. The 
temperature/activity relationships have been found to reflect 
the sensitivity of the different phenotypes to suxamethonium. 
At the physiological temperature of 37 0C the cholinesterases 
of the three phenotypes which exhibit an abnormal response 
to the drug have been shown to undergo a pronounced 
reversible Inactivation. This suggests that the prolonged 
response to suxamethonium in these cases is not entirely 
due to the reduced enzymic affinity but' is in some part 
caused by the Inactivation of the enzyme species at its 
functional temperature. This in turn'indicates that only 
by conducting assays at 37 0C is a valid indication of serum 
cholinesterase activity obtained and also explains the 
anomalies recorded in the literature concerning activities 
obtained at different temperatures. 
Thermodynamic data derived from these studies indicate 
that both genes regulate enzyme synthesis at equal rates, 
that is, heterozygous sera contain equal molecular pro- 
portions of both variants. The same data is employed to 
show that the different molecular activities of the 
isoenzymes on this equal synthesis basis explain. s the 
skewed distributions of inhibitions in heterozygote sera. 
The methods of dif. ferentiating the allelic isoenzymes 
of human serum cholinesterase by inhibitions have been 
examined and extended. The use of succiny1dicholine as a 
differential inhibitor reveals anomalies in the limited 
number of allelic variants which are currently recognised. 
It is postulated that a larger number exists. The action 
of some non-depolarising muscle re laxant drugs on enzymic 
hydrolysis has also been investigated in vitro. Of these, 
pancuronium has been shown to inhibit not only human serum 
cholinesterase but also erythrocyte acetylcholinesterase. 
The effect of reaction temperature on the inhibition 
of the cholinestorase isoenzymes by a variety of agents 
hits also been examined. Variation with type of inhibitor 
and allelic variant has been demonstrated and because of 
t1lis the ability to precisely categorise a phenotype is 
only possible at the definition temperature, that is, 
about 25 0 C. he'anomalous inhibitions found at this 
temperature for the "fluoride-resistant" enzyme are explained 
by temperature sensitivity and at 37 0C the inhibitions 
accord with the observed drug response of this variant. 
By means of inhibitions, by relative substrate hydrolysis 
rates or by ratios of activities at two reaction temperatures, 
techniques have been evolved, employing thiocholine ester 
substrates capable. of screening large numbers for 
I'suxamethonium sensitivity". 
Population surveys gave no direct support to the 
postulate of numerous cholinesterase variants. It has 
been found however that there is an apparent modification 
of the "fluoride-resistant"*isoenzyme during pregnancy. 
This indicates how readily a new identifiable variant can 
be produced and opens avenues for further elucidation of 





(a) Cholinesterase (E. C. 3.1.1.8 Acylcholinc acyl-hydrolase). 
The term "choline-esterasell was first used by Stedman, 
Stedman and Easson (1932) to describe an enzyme which 
hydrolysed acetylcholine (Engblhart and Loewi ' 1930), the 
substance which is liberated at the motor end plates 
during a nerve impulse. The importance of the enzyme in 
the physiology of the nervous system was readily realised 
for by hydrolysing the acetylcholine after transmission it 
permitted the nerve fibre to accommodate the next impulse. 
What was not appreciated until the studies of Alles and 
Hawes (1940) was that there are two enzymes which hydrolyse 
choline esters present in human tissues. 
The enzyme predominating in nerve tissue and present 
in erythrocytes has variously been termed "specific", 
"true", Ilaceto-11 or Ile-type" cholinesterase in distinction 
to the "non-specific", "pseudo-", "butyro-11 or I's-type" 
cholinesterase found in blood serum and synthesised by 
the liver. These hydrolases have wide and overlapping 
substrate specificities but the former has a specificity 
directed towards acetyl esters and is correctly termed 
acety1cholinesterase (E. C. 3.1.1.7 acetylcholine acetyl- 
hydrolase) while the latter, cholinesterase, is active 
against choline esters and a few other compounds and is 
given the systematic name acyleholine acyl-hydrolase. 
(E. C. 3.1.1.8). 
Since there are innumerable naturally occurring esters 
there must be enzymes capable of hydrolysing all. of them. 
An elementary knowledge of protein structure denies the 
possibility of one enzyme being capable of hydrolysing all, 
and equally it can be inferred that there is not an enzyme 
for each ester 'since a protein capable of binding and 
activating one will also be effective against other esters 
with closely related electronic configurations. Thus most 
of the simple choline esters are also hydrolysed by the 
so-called ali-esterases which act on aliphatic esters and 
glycerides. Similarly compounds such as benzoylcholine or 
phenylacetate which are substrates for cholinesterase are 
also hydrolysed by the arylesterases which are present in 
human blood plasma. However both acetyleholinesterase and 
cholinesterase are extremely sensitive to eserine (physo- 
stigmine) being completely inhibited at a concentration of 
10- 5M and it is upon this rather tenuous point that the 
specific existence of these enzymes is recognised. 
Acetyleholinesterase and cholinesterase are readily 
differentiated from each other by specific substrates such 
as acetyl-0-methyl choline for acetylcholinesterase and 
benzoyleholine for cholinesterase. Differentiation can be 
achieved even by substrate concentration; acetyleholinester- 
ase is inhibited at concentrations of acetylcholine greater 
I than 10- 3 11 at which levels cholinesterase exhibits maximal 
activity. Selective inhibitors have also been employed, 
tri-o-cresyl phosphate for cholinesterase (Ifendel and Myers, 
1952) and Ral-dichlorodiethyl-N-methylamine for acetyl- 
cholinesterase (Adams and Thompson, 1948). In any case 
since the present study was mainly concerned with investi- 
gation of human blood the two enzymes are already separated, 
acetylcho, linesterase in the erythrocytes and cholinesterase 
in the plasma or serum. 
Molecular Properties 
Wilkinson (1970) gives the molecular weight of 
cholinesterases as 2-12xIO 
6 
without however quoting the 
source of this information. Certainly the molecular weight 
of human serum cholinesterase is greater than 200,000 since 
it appears immediately after the void volume in gel filtra- 
tion on Sephadex G-200. After purifying human serum 
cholinesterase 3400-fold Surgenor and Ellis (1954) found 
the preparation to contain four protein fractions with the 
major part of the activity in the 10 S fraction with a 
molecular weight calculated as 300,000. With material 
purified 10 
4 times from human serum Haupt, Heide, Zwisler 
and Schwick (1966) found a molecular weight of 348,000 and 
measured immunologically the serum concentration of cholin- 
esterase was about 9 mg/litre. With an even more highly 
purified preparation Das and Liddell (1970) calculated a 
molecular weight of 366,000 from ultracentrifuge data. 
Jansz and Cohen (1962) by titration with diisopropylfluoro- 
phosphate (DFP) calculated a molecular weight of 84,000 per 
active site. From these data it would. appear that the 
cholinesterase molecule possesses four active sites. 
From ethanol-water solubility studies Surgenor, StroTig, 
Taylor, Gordon and Gibson (1949) estimated the isoelectric 
point of human serum cholinesterase to be pli 4.6-4.9. 
Svensmark (1961) showed the enzyme to be an acid glycoprotein 
containing several sialic acid residues and in a classical. 
paper electrophoresis study, Svensmark and Kristenren (1.963) 
showed the isoelectric point of native human cholinesterase 
to be pII 2.9-3.0, that of neuraminidase treated enzyme 
pH 6.7-7.0. These experiments showed that at p1l 8.6 native 
human cholinesterase behaves as an a2 globulin migrating 
slightly more slowly than the main fraction. At pH 11.0 
the enzyme behaves as a ý-globulin at p1l 6.0 as an aI 
globulin and at pH 5.0 as an albumin. At a p1l lower than 
4 . 7, the isoelectric point of albumin, cholinesterase can 
therefore be expected to migrate as a pre-albumin fraction. 
Das and Liddell (1970) found an isoelectric point of 
pH 3.99 on a high purified enzyme sample by isoelectro- 
focusing technique. 
Electrophoresis of human serum on starch gel has 
resulted in contradictory reports. Thompson and Cook 
(1961) and Ecobichon and Kalow (1962) found one fraction 
while one or more weaker bands have been recorded by Dubbs, 
Vivonia and Hilburn (1960) Bersohn, Barron and 11css, (1901), 
Harris, Hopkinson, Robson and Whittaker (196). Harris ; u)d 
co-workers employed two-dimensional electrophoresis at 
p1l 8.6 on filter paper for the first run followed by starch 
gel in the second. In fresh normal serum four zone.,.,, of " 
activity termed C1 to C4 were separated migrating on paper 
between the a2 and a globulins, C2 slightly fastest. The 
C4 fraction which was slowest moving in both directions 
contained about 90% of the total activity. All four 
fractions were sialo-proteins and mobilities were reduced 
by neuraminidase treatment (Harris, Hopkinson and Robson, 
1962). Fresh foetal or cord blood had an additional zone 
overlapping the C4 fraction and after storage two more 
minor, faint and fast-moving spots appeared. 
La Motta, McComb and 17etst(3ne (1965) also separated 
five cholinesterase fractions from human serum concentrates 
by starch-gel electrophoresis. The forms were found to be 
interconvertible and multiplicity was attributed to poly-; 
merisation. Two further fractions were later reported by 
La Motta, McComb, Noll, Wetstone and Reinfrank (1968) 
which like the others could be converted into a single 
fraction by concentration. Harris and Robson (1963) 
reported that the C1 to C4 fractions isolated by starch- 
gel electrophoresis could also be separated in reverse 
order by gel-filtration through a Sephadex column thereby 
confirming that the molecular sizes increased from C1 to 
C 4' Despite these findings a simple polymerisation is 
doubtful as a single explanation of the heterogeneity 
since it does not account for the increased mobility of 
the C2 fraction on paper electrophoresis. This fraction 
and the foetal cholinesterase may differ in sialic acid 
content. 
Enzyme Characteristics 
The sialic acid moieties are in no way concerned with 
the catalytic properties of serum cholinesterase. Removal 
of the sialic acid does not alter the enzyme activity and 
it has been shown (Svensmark, 1961; Augustinsson and 
Eskedahl, 1962) that carbohydrate-free serum cholinester- 
ase is identical to the native enzyme with regard to 
neostigmine inhibition and to hydrolysis of acetylcholine, 
propionylcholine and butyryleholine as determined by 
Michaelis constants. Dibucaine and fluoride inhibitions 
of native and neuraminidase-treated cholinesterase is 
identical (Echibicon and Kalow, 1963). 
No prosthetic groups have been proposed or found for 
serum cholinesterase and there is no evidence that the 
enzyme is a metalloprotein. Ammon (1943) however suggested 
that magnesium or calcium ions were required for maximum 
activation and some reduction in activity was found on 
removal of these ions and by addition of fluoride, oxalate 
or citrate. 
The three-stage mechanism of hydrolysis by cholin- 
esterase elaborated by Davies and Green (1958) in which 
the last two stages are not reversible is now generally 
accepted. 





Where EH is the enzyme, XY the ester, EH-XY the Michaolis- 
Menten complex and EX the acylated enzyme. 
To explain the affinity of choline ester hydrol-aseri 
for cationic substrates and inhibitors (Piguro 1), Zollor 
and Bissegger (1943) postulated the presence of an 
"anionic" and an Ilesteratic" site at the active centre of 
acetylcholinesterase. Since cholinesteraso was not 
inhibited by high substrate concentrations it was assumed 
to have only an esteratic, site. Wilson (1954) suggested 
the presence of both sites in the active centre of cholin- 
esterase and Bergmann (1958) explained the substrate 
inhibition by attributing two anionic sites -to acetylcholin-- 
esterase. The problem is still controversial. 
The amino-acid sequence of a peptide assumed to come 
from the active contre by its binding to labelled diiso- 
propy1fluorophosphate has been analysed (CoheD, Oosterbaan, 
71 
Jansz and Berends, 1959) and found to be similar to that 
of a large group of hydrolases containing a serine resi- 
due with one of the dicarboxylic aspartic or glutamic 
acids on one side and glycine or alanine on the other 
(Sanger, 1963). 
Assay Procedures 
For the assay of cholinesterase activity, procedures 
of every type exist, fixed-time, fixed end point and initial 
reaction rate methods. In general these assays may be 
divided into three categories. First there are those 
measuring the liberation of acid, by estimating the carbon 
dioxide released from a bicarbonate-containing medium in 
the Warburg manometric apparatus (Ammon, 1933; McArdle, 
1940), by the time taken to achieve a fixed pH electromet- 
rically (Michel, 1949; Courville and Ledington, 1951), 
or colorimetrically by means of such indicators as phenol 
red (Reinhold, Tourigny and Yonan, 1953; Molander, Friedman 
and LaDue, 1954; Caraway, 1956), bromthymol blue (Biggs, 
Carey and Morrison, 1958) or m-nitrophenol (Rappaport, 
Fishl and Pinto, 1959), or by rate of manual (Stedman, 
Stedman and Easson, 1932; Glick, 1938; Alles and Hawes, 
1940) or automatic (Jorgensen, 1959; Nabb and Whitefield, 
1967) continuous titration to maintain a constant pH. 
In the second group use is made of chromogenic 
substrates such as 0-carbonaphthoxycholine, coupling the 
liberated $-naphthol with tetrazotised diorthoanisidine 
(Ravin, Tsou and Seligman, 1951) or non-choline esters 
such as phenylbenzoate with which the phenol liberated 
by enzymic hydrolysis is estimated with the Folin- 
t 
Ciocalteau reagent (Smith, Lowenthal, Lehmann and Ryan, 
1959). Reaction rate procedures with substrates of 
doubtful specificity for cholinesterase such as indo- 
phenylacetate at 625nm (Kramer and Ganeson, 1958) or 
o-nitrophenylbutyrate at 414nm (Main, Miles and Braid, 
1961; McComb, La Motta and I'letstone, 1965; Szasz, 1968; 
Whittaker and Hardesty, 1969) have also been published. 
Perhaps the most generally successful approach has been 
I 
that using thiocholine esters and the estimation of the 
sulphydryl released by enzyme hydrolysis. This has been 
followed by means of the nitroprusside colour reaction 
(McOsker and David, 1959) or by iodometric titration 
(Augustinsson, 1955) in two-point assays or in reaction 
rate procedures by coupling to the reduction of, 2: 6 
dichlorophenolindophenol reading at 600nm (Gal and Roth, 
1957); by complexing with 2121 or 4141 dithiodipyridine and 
reading at 324 or 343nm respectively (Uete et al., 1972) 
or with 5,5'-dithiobis (2-nitrobenzoicacid) following the 
reaction at 410nm (Ellman, Courtney, Andres and Featherstone, 
1961; Garry and Routh, 1965; Szasz, 1968a, b; Garry, 1971). 
The last is a most simple and sensitive procedure. 
In the final group the unreacted ester is estimated. 
This has been done in fixed-time assays employing an 
acetylcholine substrate by means of the ferric-hydroxa- 
mate reaction (De La Huerga, Yesinick and Popper, 1952) 
or in reaction rate procedures with thiocholine substrates 
using absorption of the ester at 226nm or with benzoyl- 
choline by following the change in absorption at 240nm 
(Kalow and Lindsay, 1955). The last method is of particular 
.4 
interest because of the recognised specificity of the 
substrate, the fact that it is an initial reaction rate 
assay and was found to have an excellent precision. 
Further reasons for interest in this assay are expanded 
upon in the next section. 
Methods for the determination of cholinesterase 
activity have recently been reviewed by Augustinsson 
(1971). 
Physiological Function 
Plasma cholinesterase is synthesised in the liver 
but. cholinesterases are widespread in human tissues, in 
intestine, muscle, lung, uterus, pancreas and other glands 
and in certain ganglia. Cholinesterase is present in 
lymph and effusion fluids. Activity is detectable in 
cerebrospinal fluid but not normally in urine, bile, 
gastric juice or saliva. 
The physiological role of cholinesterase and its 
natural substrates are matters for speculation. At its 
simplest Funnell and Oliver (1965) have suggested that 
cholinesterase plays a part in the homeostatic mechanism 
controlling the levels of free choline. Again since 
butyryleholine, which has a possibly undesirable nicotinic 
effect, may be synthesised by the choline acetylase 
system from butyryl- coenzyme A during fatty acid 
metabolism, Clitherow, Mitchard and Harper (1963) have 
speculated that the function of the enzyme may be to 
prevent accumulation of this substance. Similarly 
y-aminobutyryl choline which is present in brain tissue 
may be a substrate for cholinesterase (Holmstedt and 
101 
Sjoquist, 1960). 
Perhaps the discovery that acety1cholinesterase and 
cholinesterase were different enzymes, the former in high 
concentration at neural junctions was misleading since it 
lead to the assumption that cholinesterase was not 
concerned with nervous transmission (Ilendel and Rudney, 
1943p 1944). Certainly the lack of pharmacological 
reaction to selective cholinesterase inhibition (Hawkins 
and Gunter, 1946; Mazur and Bodansky, 1946) appeared to 
confirm this but more recent work has shown that such 
inhibition affects. intestinal motility (Jamieson, 1963) 
and the enzyme may play a part in transmittory processes 
in other tissues also (Koelle, 1963). 
However speculation concerning the role of cholin- 
esterase must take into account that normal healthy 
individuals have been found devoid of serum cholinesterase 
activity from which it would appear that the function of 
the enzyme is not critical or else can be taken over by 
alternative mechanisms. 
Following enzyme blocking with diisopropylfluoro- 
phosphate Neitlich (1966) has calculated from the 
generation curve that the biological half-life of 
cholinesterase is ten days. This value has been corrobor- 
ated independently by Jenkins, Balinsky and Patient (1967) 
from the rate of disappearance of transfused normal plasma 
activity into a patient lacking plasma cholinesterase. 
Clinical Significance 
The activity of most enzymes in human blood plasma 
is low and their presence there in health is a result of 
I '1' 
normal tissue wear and tear. They are cellular detritus 
and form part of the circulating protein pool. In 
clihical enzymology it is an increase in the activity of 
these enzymes which is sought, an increase which would 
indicate an abnormal efflux into the circulation as a 
result of some pathological situation. Apart from the 
enzymes of the coagulation mechanism, cholinesterase is 
the only enzyme of interest in clinical enzymology which 
may be termed plasma or serum specific. As such cholin- 
esterase is normally present in human blood serum in 
relatively high concentration and it is a decrease in 
activity which is clinically meaningful. Further, since 
cholinesterase is synthesised in the liver, it should be 
a useful. index of the protein synthesising function of the 
liver. In this respect it is very similar to serum albumin 
and indeed there would appear to be a concomitance in the 
synthesis of these two proteins. 
Hence in hepatitis, liver metastases (Molander, 
Friedman and La Due, 1954; Burnet , 1960) and cirrhosis 
(Kunkel and Ward, 1947; La Motta, Williams and Wetstone, 
1957; Hunt and Lehmann, 1960) where there is a lesion of 
the synthesising mechanism, low levels of both cholinesterase 
and albumin are found in serum. In obstructive jaundice 
both are essentially normal (Antopol, Schifrin and Tuchman, 
1938; McArdle, 1940; Burnett, 1960) except where the 
causative factor is malignant (Mann, Mandel, Eichman, 
Knowlton and Sborov, 1952; Williams, La Motta and Wetstone, 
1957). The last instance is probably a reflection of the 
effect of the tumour on protein metabolism and, like 
I 
malnutrition (Vorhaus and Kark, 1953), the low serum levels 
are a result of d. epletion of material for synthesis. The 
only lack-of coincidence occurs in nephrosis, in which 
albumin., the much smaller molecule, but not cholinesterase 
is lost through the damaged kidney. The compensatory 
increase in protein synthesis results in high serum cholin- 
esterase activity in the presence of low serum albumin 
levels (Kunkel and Ward, 1947; Vorhaus and Kark, 1953; 
Vincent, 1958). The finding of normal albumin levels in 
individuals having a total lack of serum cholinesterase 
activity or of normal cholinesterase activity in analbumin- 
aemia (Dietz, Rubinstein and Lubrano, 1966) in no way negates 
the speculation that there is an intimate connection between 
the hepatic'synthesis of albumin and serum cholinesterase. 
In myocardial infarction there is a characteristic 
fall in serum cholinesterase activity (Oka, 1954) which 
reaches a minimum about the fifth day and then increases 
to normal levels; a failure to rise carries a grave prognosis 
(Moore, Birchall, Horack and Batson, 1957). Not only in 
myocardial infarction, but also in pulmonary embolism, 
acute infectious, surgery, indeed any precipitation of the 
"acute phase reaction" (Hauss and Leppelmann, 1958) gives 
rise to lowered serum cholinesterase activity. 
Increased serum activity is found in cases of thyro- 
toxicosis and reduced levels in myxoedema (Thompson, 1959; 
Thompson and Whittaker, 1965) but the high values reported 
in diabetes mellitus are a reflection of obesity, not of 
the disease (Thompson and Trounce, 1956). In myastheilia 
gravis, a disease characterised by muscle weakness which 
-P -" A IW 
responds to eserine and prostigmine treatment, Stedman and 
Russell (1937) found low serum cholinesterase activities 
but later studies did not confirm this (Vorhaus and Kark, 
1953). Stedman and Russell also noted low serum activities 
in progressive muscular dystrophy and myotonia congenita 
and Moore, Birchall, Horack and Batson (1957) reported 
similar results in dermatomyositis but normal levels in 
other collagen diseases. 
Some observers have reported, lowered serum cholinester- 
ase activity in schizophrenia and increased levels in 
anxiety states. Plum (1960) however noted increased 
cholinesterase activity in manic depressive psychosis and 
schizophrenia as well as in anxiety and depressive neurosis 
but while Antebi and King (1962) observed increased levels 
in 207o of chronic schizophrenics, they found no correlation 
between the enzyme abnormality and the disease type or 
clinical state 
ýf the patients. 
Although assay of serum cholinesteraso activity would 
appear capable of yielding information of clinical value 
in the correct setting, only in Germany has it gained such 
recognition. This is probably a result of the fact that 
normal serum cholinesterase activity is so high and the 
range of activities so wide that unless the patient's usual 
activity is at the lower end of the range such variations 
are not readily obvious.. 
As it is, it is not in the diagnosis or monitoring 
of any pathology that assay of serum cholinesterase is 
most often sought but rather in the field of pharmaco- 
genetics, that is, the study of genetic variants in man 
4 
which are responsible for alterations in the response to 
drugs. 
Polymorphism 
Some of the pharmacological properties of succinyl- 
dicholine (suxamethonium, Scoline (R)-) were first described 
by Hunt and Taveaux (1906) but forty-three years were to 
elapse before its potential as a short-acting muscle 
relaxant was discovered (Bovet, Bovet-Nitti, GuarinoLongo 
and Marotta., 1949). Succiny1dicholine produces a depolaris- 
ing type of neuromuscular block since it acts as a compet- 
itive inhibitor of acetylcholinesterase. The short period 
of action, three to five minutes, results from the hydrolysis 
of the drug by the cholinesterase of the circulation. It 
was therefore to be expected that in any pathology in 
which serum cholinesterase was low that the duration of 
paralysis would be extended and indeed not long after its 
introduction cases were reported of prolonged apnocit 
following administration of usual doses of suxamethonium. 
JIowever these episodes, up to two hours duration, occurred 
in individuals not suffering from liver disease, malnutrition 
or other disease which might account for their low serum 
cbolinesterase activity (Evans, Gray, Lehmann and Silk, 
1952; 1953; Bourne, Collier and Somers, 1952; Forbat, 
Lehmann and Silk, 1953). 
A great advance in understanding of this phenomenon 
came from the family studies of sensitive individuals 
(Lehmann and Ryan, 1956; Lehmann, Patston and Ryan, 1958) 
which resulted in the hypothesis of an inherited enzyme 
defect, the enzyme level determined by two allelic genes 
I 
ýýJý 
neither of which showed dominance. However although Calvert, 
Lehmann, Silk and Slack (1954) demonstrated a close 
correlation between suxamethonium dose and duration of 
paralysis, and that when the serum cholinesterase activity 
was doubled by injection of purified enzyme the apnoeic 
response was halved, patients who suffered what came to be 
known as I'Scoline apnoeall often had serum cholinesterase 
levels higher than other patients who showed no unusual 
response to the drug. Lehmann and Simmons (1958) while 
confirming the hereditary nature of the phenomenon stated 
the anomaly as "it is often difficult to understand why 
patients with an identically low pseudocholinesterase level 
show a varying duration of apnoea following the same dose 
of suxamethonium; the duration may vary from no excessive 
prolongation to a very prolonged apnoeall. 
The explanation of this was unfolded by the work of 
Kalow and colleagues in Toronto who showed that the affinity 
of the enzyme in the sera of sensitive individuals for a 
wide range of substrates was lower than that of the serum 
enzyme of normal individuals (Kalow, 1959a; Davies, Marton 
and Kalow, 1960). Indeed the enzyme in the serum of 
sensitive patients had no detectable activity against 
succiny1dicholine at therapeutic concentrations. The 
behaviour of the two enzymes to various inhibitors also 
varied considerably, the normal enzyme in most cases being 
more strongly affected (Kalow and Davies, 1958). The 
compound which produced the greatest differential inhibition 
was dibucaine (cinchocaine, Nupercaine) at a concentration 
of 10- 
5 It and this gave a means of detecting the "atypical" 
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Figure 1. Structural formulae of some substrates and inbibitors 
of cholinesterase. 
Further examples are illuotrated in Figure 20. 
Iq 
enzyme as it was called (Kalow and Staron, 1957). With a 
50 VM benzoyleholine substrate (Kalow and Lindsay, 1955) 
the usual enzyme was inhibited about 80%, the atypical 
enzyme about 207o and heterozygous sera about 60%. The 
percentage inhibition was termed the dibucaine number (DN) 
and this procedure clearly segregated the three genotypes 
irrespective of the level of cholinesterase activity. 
In view of the apparent particular affinity of cholin- 
esterase for compounds containing a positively charged 
nitrogen atom particularly when linked to methyl groups 
(Figure I) it is not surprising that most of the inhibitors 
examined by Kalow and co-workers contained such a positively- 
charged nitrogen. That this constitution was not essential 
in a differential inhibitor was shown by Harris and 
Whittaker (1961) who found that sodium fluoride provided 
a similar inhibition segregation to that of dibucaine. 
However when'these workers compared the dibucaineý and 
fluoride numbers of individuals from families of suxamethonium- 
sensitive patients besides the three groups already segregated, 
two further groups were recognisable with slightly lower 
dibucaine numbers and much lower fluoride numbers. Further 
work (Harris and Whittaker, 1962,1963) showed that this 
increased resistance to fluoride inhibition is inherited 
through a gene allelic to the usual and atypical genes. 
The heterozygote for the atypical and fluoride-resis-il. -ant 
genes is sensitive to suxamethonium (Lehmann, Liddell, 
Blackwell, O'Connor and Daws, 1963) as is the homozygote 
for the fluoride-resistant cholinesterase (Liddell, Lehmann 
and Davies., 1963; Griffiths, Davies and Lebmann, 1966). 
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Sodium chloride at high concentration (0.5M) also differ- 
entially inhibits the cholinesterase variants (Whittaker, 
1968b). The chloride number differs from both dibucaine 
and fluoride numbers in that suxamethonium-sensitive 
individuals have the higher values and normals the lower 
f igures. 
Cases have also been described (Liddell, Lehmann and 
Silk, 1962; Hart and Mitchell, 1962; Gutsche, Scott and 
Wright, 1967) with little or no cholinesterase activity, 
attributable to a homozygous state for a "silent" gone, 
which is allelic with the other cholinesterase variants 
(Simpson and Kalow, 1964). The locus of these genes is 
closely linked to the transferrin locus (Robson, Sutherland 
and Harris, 1966). 
A further serum cholinesterase variant was discovered 
by two-dimensional clectrophoresis, the first run on paper 
being followed by starch-gel at pH 8.6 (Harris, Hopkinson 
and Robson, 1962). In normal serum four zones, of activity 
termed CI to C4 are separated. The C4 fraction is the 
slowest moving and contains about 907o of the total activity. 
In about 107o of the British population an even slower fifth 
zone, C 51 is found, which is genetically determined and 
possessors have on the average 257a more serum cholinesterase 
activity than those without it (Harris, Hopkinson and 
Robson, 1962; Harris, Hopkinson, Robson and Whittaker, 1963; 
Robson and Harris, 1966). This variant is determined by a 
gene acting at a locus distinct and separate from that 
determining the inhibitor-sensitive variants (Harris, Robson, 
Glen-Blott and Thornton, 1963; Simpson, 1968). The mode of 
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action of the C5 gene and the relationship of the two loci 
are not understood. 
Two conventions have been proposed for classifying the 
generally-recognised genes. In the first nomenclature 
(Motulsky, 1964) the two loci are designated E1 and E2 
while that of Goedde and Baitsch (1964) uses Ch, and Ch 2* 
The four variants at the first locus are symbolised Eu or 1 
Ch U for the usual enzyme, Ea or Ch 
D for the atypical 
(dibucaine-resistant) gene, Ef or Ch 
F for the fluoride- 11 
resistant allele and Es or Ch 
S for the silent gene. At the 11 
second locus the two variants are designated as E2 or Ch2 
for normals or as E+ or Ch+ for the C variants. In that 225 
which follows, the convention of Motulsky (1964) is used 
exclusively. 
1. (b) Multiple Forms of Enzymes. 
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(b) Multiple Forms of Enzymes 
The knowledge that certain basic metabolic pathways 
such as the glycolytic system and the citric acid cycle 
occur, with, at most, only minor modification, in almost 
all living cells of animals, plants and micro-organisms would 
suggest that the enzymes constituting these systems are 
similar. This concept was supported by the knowledge that 
all the important prosthetic groups and coenzymes, such as 
pyridoxal. phosphate, coenzyme A, nicotinamide-adenine di- 
nucleotide had the same chemical structures regardless of 
their derivation. 
The basic conviction was definitively stated by Dixon 
and Webb (1958). 
"It is a remarkable fact that in general the catalytic properties, specificity, 
activity, affinities, etc. of a given 
enzyme vary little with the source. Although there may be slight physical differences in 
a given enzyme when it is produced by 
different cell s, they are usually unimportant, 
and the enzyme remains essentially the -same enzyme. This is in fact a commonplace of 
enzymology; for all practical purposes the 
source of an enzyme is usually regarded as a 
somewhat secondary matter. " 
This creed may still be valid for enzymologists but to the 
clinical biochemist the source of an enzyme is of paramount 
importance and any facet of enzyme existence which will 
disclose this origin is earnestly examined. Again, to the 
geneticist, any ontogenic or phylogenic variation in a 
specific enzyme is meaningful. 
As Fischer (1895) observed "the various maltases that 
undoubtedly exist should be termed corn, yeast, etc. 
maltases depending on their origin", it is the exception 
rather than the rule to find molecular or enzymic identity 
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between functionally similar enzymes from different species 
(Paul and Fottrell, 1961). Even within the same species 
differences in functionally similar enzymes had been noted 
as early as 1937 when Bodansky by means of bile acid inhibi- 
tion showed that the alkaline phosphatases of human intestine 
and bone were not identical. Abul-Fadl and King (1949) 
showed that in the same tissue, the human erythrocyte, there 
were two acid phosphatases which differed in pH optima and 
stability and in the ultimate case, that of a crystalline 
enzyme, ox-heart lactate dehydrogenase, Meister (1950) noted 
that it was composed of two protein fractions both of which 
possessed lactate dehydrogenase activity (Neilands, 1952). 
While because of these and other similar observations, the 
existence of functionally similar but distinguishable enzymes 
had been superficially accepted it was not until the demon- 
stration by Wieland and Pfleiderer (1957) of the presence 
in a single tissue of several physically-separable lactate 
dehydrogenases that the phenomenon was generally accepted. 
This appreciation of the existence of multiple molecular 
forms of enzymes has provided a source for research which 
has spilled over into the fields of protein chemistry, 
physiology, pharmacology, genetics, evolutionary and 
developmental biology. 
Obviously the many multiple forms of enzymes which have 
been described, even the few mentioned above, are of different 
types. The alkaline phosphatases would appear to be 
distinctly different proteins which are tissue specific within 
a species. Acid phosphatases are probably similar but there 
is also heterogeneity within tissues as Abul-Fadl and King 
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(1949) showed. Hopkinson, Spencer and Harris (1963,1964) 
later demonstrated that the patterns of human red cell acid 
phosphatases separated electrophoretically are genetically 
determined and have recognised six phenotypes in European 
populations. Following the work of Vessell and Bearn (1957, 
1958)*, IVieme (1959) and Wroblewski and Gregory (1960) who 
demonstrated the existence of five forms of human lactate 
dehydrogenase, Patterns of which were tissue specific., the 
studies of Appella and Markert (1961) Cahn, Kaplan, Levine 
and Zwilling (1962), and Markert (1963,1968) showed that 
these enzymes were tetramers composed of two different 
polypeptide subunits. 
Nomenclattre 
Markert and Moller (1959) proposed the name isozyme, 
or isoenzyme (Wroblewski and Gregory, 1960), for the 
"different molecular forms in which proteins may exist with 
the same enzymatic specificity". This was meant to define 
the forms of lactate dehydrogenase since, Markert and Moller 
found that "all of the lactate dehydrogenase isozymes were 
alike in the relative catalytic efficiency displayed towards 
different substrates". However this judgement was only 
based on qualitative evidence using hydroxyacid substrates 
to visualise the positions of the lactate dehydrogenase 
following electrophoresis. It had already been shown by 
Hess (1958) that the different forms showed differences in 
affinity for pyruvate, in optimum pH and in sulphite inhibi- 
tion, while Hill (1958) had reported differences in heat 
stability. This definition did not therefore categorise the 
types of multiple enzyme forms which were to be called 
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isoenzymes, except possibly to exclude that one for which 
it was specifically introduced. I 
Webb (1960) pointed out that there was probably 'a 
continuous range of cases and that any division of this 
range must be completely arbitrary. He further suggested 
that the fundamental distinction between those proteins 
which are recognised as different enzymes and those as 
isoenzymes might be that the former were synthesised under 
the control of different genes and the latter were modifica- 
tions of a single gene product. However neither this 
definition nor that of Augustinsson (1961) who suggested 
that the term isoenzyme be "restricted to enzymes the 
molecular structures of which differ, only in those parts of 
the molecule that are not directly involved in the enzymatic 
reaction" appear capable of practical implementation in our 
present state of knowledge. 
More practicable was the suggestion of Wieland and 
Pfleiderer (1962) that the name heteroenzyme be given to 
proteins of different origin which had the same biological 
action but differed in physical, chemical and biochemical 
properties and that the term isoenzyme or multiple form be 
given to enzymes from the same source with very similar but 
distinguishable proteins. This system would categorise the 
alkaline phosphatases as heteroenzymes and the red cell acid 
phosphatases and lactate dehydrogenases as isoenzymes. 
The Standing Committee on Enzymes of the International 
Union of Biochemistry (Webb, 1964) then put forward the 
recommendation that "multiple enzyme forms in a single species 
should be known as isoenzymes, although since either form 
is readily intelligible, this recommendation is not to be 
interpreted as excluding the use of lisozymel if any ' 
individual author prefers it". This retrograde recommendation 
classified all multiple forms as isoenzymes and the situation 
concerning definition and nomenclature became so confused 
that King (1965) noted that unless the International Union 
of Biochemistry clarified and defined the new concepts of 
different molecular forms of enzymes, many of the terms would 
soon cease to have any meaning. 
Recently further recommendations have been published 
(International Union of Biochemistry, 1972) dealing specific- 
ally with isoenzymes and genetic variants. Basically two 
recommendations were made; that "the-term 'multiple forms 
of an enzyme' should be used as a broad term covering all 
proteins possessing the same enzymatic activity and occurring 
naturally in a single species" and that "the term lisoenzymel 
or lisozymel should apply only to those multiple forms of 
enzymes arising from genetically determined differences in 
primary structures and not to those derived by modification 
of the same primary sequence". Of the seven groups of multiple 
forms-listed, only three, those due to genetically independent 
proteins as alkaline phosphatases, heteropolymers of two or 
more polypeptide chains, non-covalently bound such as lactate 
dehydrogenase and allelic variants such as red cell acid 
phosphatases are isoenzymes. Multiple forms derived from 
proteins conjugated with other groups, proteins derived from 
one polypeptide chain, protein polymers of a single subunit 
and proteins differing in conformation, that is allosterically 
modified, are not to be classed as isoenzymes. 
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It may be a moot point as to whether acetyl-cholinesterase 
and cholinesterase possess "the same enzymatic activity" to 
a lesser degree than placental and liver alkaline phosphatases 
but for the present undertaking they will be treated as 
distinctly separate entities. The cholinesterases synthesised 
at the first and second loci are certainly of the first 
category that of genetically independent isoenzymes while 
the variants at the first locus are obviously allelic. 
isoenzymes. Of the fractions separated by electrophoresis 
the foetal cholinesterase probably differs only in its 
conjugation with sialic. acid while the others most likely 
represent polymers of a single subunit and therefore these 
multiple forms are not. classed as isoenzymes. 
Methods of Characterisation 
The means available for the recognition and differentia- 
tion of isoenzymes fall into four categories, physical, 
chemicalp immunological and biochemical. 
Physical*Methods 
Most of these techniques require extensive preparation 
and handling; preferably the enzyme should be in a high state 
of purity, ideally in crystalline form. Then determination 
of molecular weight by ultracentrifuge, potentiometric 
titration of acidic and basic groups, determination of 
solubility and isoelectric point, ultraviolet absorption, 
rotational dispersion and X-ray crystallography may be 
attempted. Column chromatography on ion-exchange resins or 
uncharged adsorbers and gel filtration are also available 
without obligatory preliminary purification. Human serum 
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cholinesterase has been purified 13,000 fold (Das and Liddell, 
1970) but crystalline preparations of the enzyme have not 
yet been obtained. The data obtained from such means have 
been summarised earlier (page 3). 
Electrophoresis has undoubtedly played the single most 
important role in the recognition and separation of multiple 
forms of enzymes. It has certain inherent advantages in 
that it has wide applicability, is rapid, achieves a high 
degree of-resolution and is less likely to produce artifacts 
than some other methods. This technique has been success- 
fully applied to the separation of the polymeric multiple 
forms of serum cholinesterase and the first and second loci 
isoenzymes (page 4 an d17). However, physical methods have 
not been so efficacious with regard to the allelic isoenzymes 
and conflicting reports have appeared concerning their 
electrophoretic and chromatographic separation. Kalow (1959) 
obtained no differentiation by fractional precipitation with 
ammonium sulphate nor by chromatography on DEAE cellulose. 
Attempts-to separate the usual and atypical variants by 
means of electrophoresis were also unsuccessful (Kalow, 1959; 
Ecobichon-and Kalowp 1963; Svensmark, 1963). However, 
Liddell, Lehmann, Davies and Sharih (1962) claimed to obtain 
complete separation of the usual and atypical variants by 
paper electrophoresis at pH 9.7 and partial separation of 
the fluoride-resistant isoenzyme (Liddell, Lehmann and Davies, 
1963). Separation on DEAE-cellulose was also reported by 
Liddell and colleagues (1962). Again Hodgkin, Giblett, 
Levine, Baur, and Motulsky (1965) found no difference between 
sera of usual and atypical homozygotes by starch-gel 
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electrophoresis nor by immunoelectrophoresis. 
Chemi'c'al* lietho*ds 
Procedures in this category include determination of 
terminal and functional groups, of component groups either 
by two-dimensional paper chromatography or electrophoresis 
following proteolysis and indeed sequential analysis of the 
primary structure. In this field even moreso than in the 
last, enzyme purity is mandatory and accounts for the 
depressed statement of the International Union of Biochemistry 
(1972) that "with regard to structural criteria, it has long 
been the hope of many workers in the field that the inter- 
relationships of multiple forms might soon be delineated in 
chemical terms. However, such information is available only 
for a very few enzyme systems ....... 11 
Immunological Methods 
Again these techniques require the enzyme proteins in 
individual states of high purity for the preparation of the 
antibody and it must be confessed that such methods are not 
as quantitative and reproducible as required where minor 
differences in protein structure are being investigated. 
This is indicated by the work of Hodgkin, Giblett, Levine, 
Baur and Motulsky (1965) who found that neutralisation of 
anti-human usual cholinesterase was obtained by similar 
amounts of serum from both usual and atypical homozygotes. 
The technique however has proved useful in establishing 
heterogeneity within the silent gene homozygote, phenotype. 
Thus Hodgkin et al. (1965), Szeinberg, Pipano, Ostfeld and 
Eviator (1966) and Kattamis, Davies and Lehmann (1967) 
found a lack of cross-reacting material in the sera of such 
individuals but Goedde, Gehring and Hoffmann (1965) described 
two similar serum specimens which neutralised the antibody 
to almost the same extent as normal serum. Presumably the 
latter cases represented structural alterations which resulted 
in loss of enzyme activity without loss of ability to react 
with normal enzyme antibodies. 
Biochemical Methods 
In contrast to the foregoing categories most of the 
biochemical criteria can be obtained without extensive 
preparatory work. Determinations of optimum pH, of substrate 
and cofactor affinities, of the effects of activators or 
inhibitors and of temperature coefficients are not unduly 
influenced by use of the enzyme in its natural milJou or in 
crude preparations. Vindication of this statement as far 
as human serum cholinesterase is concerned is given by the 
studies of Das and Liddell (1970) who purified the enzyme 
13,000 fold. These workers found that the Michaelis con- 
stants with benzoylcholine, acetylthiocholine and butyryl- 
thiocholine did not differ significantly for the untreated 
plasma and the purified enzyme. Similarly the inhibitory 
effects of various concentrations of dibucaine hydrochloride, 
sodium fluoride and the neostigmine analogue R02-0683 
(11offman La Roche) were recorded with 50 VII benzoylcholine, 
5mll acetylthiocholine and 7.5 mM butyrylthiocholine and 
identical results obtained with the purified enzyme and 
untreated plasma. 
Further the findings of Kalow (1962) and Liddell, 
Newman and Brown (1963) indicate that in this particular 
instance, studies on serum provide a valid picture of the 
cholinesterase present in other tissues. These workers 
obtained post-mortem specimens, in the studies of Liddell 
and colleagues, of liver, kidney, brain, ileum and skin 
from subjects homozygous and heterozygous for the usual and 
atypical serum variants and found the inhibition character- 
istics of the cholinesterase of the tissue extracts to be 
the same as serum. Doenicke, Gurtner, Kreutzberg, Remes, 
Spiess and Steinbereithner (1963) found, in a silent gene 
homozygote, that a liver biopsy specimen, like the serum, 
was devoid of cholinesterase activity. Evidently the 
mutant gene products are found throughout the body and their 
synthesis is controlled by the same genes in all tissues. 
Of the biochemical criteria used in isoenzyme differ- 
entiation, that of the effect of pIl, buffer and substrates 
has been extensively investigated for serum cholinesterase 
as indicated earlier (p. 7 et seq. ). The use of differential 
inhibitors was the means by which the allelic isoenzymes 
were first distinguished and there is now a considerable 
literature on this aspect (p. 16 et seq. ). However little 
or no attention has been given to the effect of heat on 
cholinesterase kinetics although Kalow and Lindsay (1955) 
observed that "the effects of temperature on the rate of 
hydrolysis of benzoylcholine and procaine are almost identical, 
while the hydrolysis of acetylcholine is differently affected". 
Apparently no attempt has been made to investigate the possible 
differential effect of temperature on the enzymic kinetics 
of the allelic cholinesterases and Harris (1970) could 
conclude "it should be noted that in a number of properties, 
a"I 
for example thermostability and electrophoretic mobility 
the two forms of the enzyme do not apparently differ". 
Accordingly this appeared to be an area in which investi- 
gation was required and one which might provide insight 
into structural differences in the allelic cholinesterase 
isoenzymes. 
1. (c) Effect of Heat on Isoenzymes. 
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(c) Effect of Heat on Isoenzymes. 
Herbert (194 4) was, if not the first, among the earliest 
workers to employ differences in thermolability as a means 
of differentiating enzyme species. She found that the acid 
phosphatase of prostate extract was irreversibly inactivated 
by incubation for one hour at 37 0C at p1l 7.4. At pH 4.8 
the enzyme was more stable. The same result was obtained 
with prostatic extract added to human serum but the acid 
phosphatase of normal serum was not affected by this treat- 
ment. The pH of. the sera during incubation was not recorded 
but was probably in excess of 8.0 since the pH of serum 
separated from cells rises from PH 7.4 to 8.0 in fifteen 
minutes at room temperature due to loss of carbon dioxide 
(King, 1965). In a later report (Herbert, 1946), the 
destruction of the acid phosphatase of prostatic extract 
in one hour at 37 0 C. in a variety of buffers at p1l 7.4 was 
confirmed but only a slight reduction in activity occurred 
at pIl 4.8 under the same conditions. 
This phenomenon was re-examined by Woodard (1951) who 
confirmed that the thermostability of prostatic acid 
phosphatase was pll-dependent. However she found that heating 
for one hour at 370C at pII 8.0 or above, nearly, or quite 
completely, inactivated not only the acid phosphatase of 
the serum of patients with metastasising carcinoma of the 
prostate but also the acid phosphatase of normal female 
sera. 
The difference in observations may have been the result 
of the different substrates employed; phenylphosphate by 
Herbert and B-glycerophosphate by Woodard. The latter 
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author indicated that she was aware that the behaviour of 
phosphatases varied considerably with different substrates 
but neither she nor Herbert appear to have examined the 
thermostability of the enzymes bver a range of temperature. 
Herbert (1946) did note that during the five hour incubation 
proposed by Gutman and Gutman (1938) that although hydrolysis 
was constant at first there came a sharp fall-off in 
activity, sometimes before two hours, but always evident 
by three hours and progressing until hydrolysis almost ceased. 
Accordingly she reduced the reaction time to one hour. 
Again however she did not study the thermostability of the 
enzyme over a range of temperatures in the presence of 
substrate. In any case this possible_means of different- 
iating the tissue-specific acid phosphatases does not appear 
to have been generally accepted and employed. 
Indeed no further use of the phenomenon was apparently 
made in clinical enzymology until Wroblewski and Gregory 
(1961) utilised the differences in heat stability of the 
human lactate dehydrogenases earlier noted by Hill (1958). 
Wri5blewski and Gregory showed that the electrophorctically- 
fastest fractions which predominate in heart muscle vvere 
unaffected by beating for 30 minutes at 57 0C in the presence 
of reduced nicotinamide-adenine dinucleotide (NADII) which 
increased heat stability. A scheme for determining the 
relative amounts of isoenzymos present in serum was proposed. 
This consisted of adding 0.2 ml NADII solution (2.5 mg/ml) 
to 2 ml of serum, dividing into three aliquots which were 
then incubated for 30 minutes at bench temperature (A), 
57 0C (B) and 650C (C) prior to assay of lactate dehydrogenase 
activities. Total serum lactate dehydrogenase activity 
was given by specimen (A) the heat-labile fraction (LD115) 
by (A) - (B), the heat-stable LDH1 by specimen (C) and 
intermediate fractions (LDH2,, LDH3 and LDI14) by (B) - (C). 
A good correlation with electrophoretic separation was 
found in a 
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variety of disease states by means of this 
heat stability test which however tended to give relatively 
high values for LDH5. This difference was attributed to 
inactivation of LDH5 by the heat generated during electro- 
phoresis. 
Independently, Strandjord and Clayson (1961) found that 
heating liver homogenates for 30 minutes at 65 0C resulted 
in a loss of 99.57o of lactate dehydrogenase activity but 
only 477o of heart homogenate activity was destroyed under 
these conditions. They suggested measurement of the 
heat-stable lactate dehydrogenase in serum as a diagnostic 
index of myocardial infarction. In patients with congestive 
heart failure, hepatitis and after surgical operation the 
'heat-stable lactate dehydrogenase activity was -the same as 
in normal sera and this was confirmed and expanded in a 
later report (Strandjord, Clayson and Freier, 1963). 
In the interval Van Der Helm, Zondag, Hartog and Van 
Der Kooi (1962) demonstrated that following heating for 
thirty minutes at 560C, LD113, LDH4 and LD115 were no longer 
demonstrable by electrophoresis and the scheme of Wro"blewski 
and Gregory (1961) was simplified by Bell (1963) and Latner 
and Skillen (1963) to heating at 60 0C for one hour. The 
latter workers found that the "heat stability index", that 
is, the ratio of activities of the heated and unheated samples, 
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was greater than 0.5 in myocardial infarction, consistently 
less than this in other diseases and in health was less 
than 0.3. This last figure is difficult to reconcile with 
the known isoenzyme composition of normal sera and was not 
confirmed personally (King, 1966). 
Even the simplified procedures have not enjoyed a wide- 
spread use in routine clinical practice mainly because of 
the lengthy periods of denaturation. Employment of a 
sub-optimal concentration of 2-oxobutyrate in the assay of 
"alpha-hydroxybutyrate dehycrogenase" (Rosalki and 
Wilkinson, 1960) has proved more acceptable, albeit 
possibly with less vindication of its diagnostic value 
(Ellis and Goldberg, ý971; King, 1972). 
The relative stabilities to heat displayed by tho 
isoenzymes of lactate dehydrogenase are almost mirrored 
by their cold stability. Zondag (1963) demonstrated that 
tile LD114 and LDI15 of liver extract in barbital buffer of 
p1l 7.9 were destroyed overnight at -20 
0 C. Thin occurred 
in the buffered extract only, was not evident in the tissue 
alone at -20 
0C and could be prevented In the buffered 
homogenate by addition of NAD. This addition also appeared 
to increase the speed of anodal migration of LDIII and LD112. 
The lability at low temperatures of the slower-moving 
fractions was confirmed by Kreutzer and Ferris (1964) who 
reported however that LD114 was less stable than LD115 under 
these conditions. 
Differences in the heat-sensitivity of alkaline 
phosphatases were first reported by Moss and King (1962), 
who recorded, without further discussion, that at 55 0C and 
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pH 7.0, the times required to reduce the activities of 
bone, kidney, intestine and liver isoenzymes to half the 
initial level were 8,12j 15 and 18 minutes respectively. 
The remarkable stability to heat of placental alkaline 
phosphatase was later demonstrated by Neale, Clubb, Hotchkis 
and Posen (1965). The activity of this isoenzyme, which 
predominates in serum in the third trimester of pregnancy 
(McMaster, Tennant, Clubb, Neale and Posen, 1964) is not 
altered by heating for 30 minutes at 70 
0C in the presence 
of 10- 
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magnesium ions. The presence of the metal ion 
activator was not necessary with fresh placental homogenate 
or with serum enriched with placental enzyme. 
The studies of Posen, Neale and, Clubb (1965) to 
determine the source of origin by the heat lability of the 
alkaline phosphatase indicated that the heat sensitivity 
of each isoenzyme remained characteristic and independent 
of the influence of others in the mixture. They were able, 
by means of heating for 30 minutes at 560C, to distinguish 
between "osteoblastic" and "hepatic" sera and to conclude 
that normal serum behaved like a mixture containing 50 to 
759o' of the skeletal isoenzyme. Further, on the observed 
differences between bile and liver isoenzymes they concluded 
that the serum alkaline phosphatase from patients with 
hepatic disorders behaves like a mixture, predominantly of 
the bile enzyme. Fishman and Ghosh (1967) confirmed most 
of this work but found that since the heat inactivation of 
the intestinal enzyme (50 - 657o) was similar to that of the 
liver (50 - 75'io)*it was not possible to determine the 
tissue source of the serum alkaline phosphatase by heat 
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sensitivity alone. An indication of the aimount of intestinal 
enzyme present by means of L-phenylalanine inhibition was 
also deemed necessary. 
In all of these studies it was the permanent irrevers- 
ible effect of heat on the enzyme protein which had been 
examined, and while this was followed over a wide range of 
temperatures in some, it was only the total loss of activity 
by one species following prolonged incubation that was 
sought. Indeed the progressive effect of heat upon enzyme 
activity in the presence of substrate, apart from establishing 
temperature correction factors had apparently not been 
studied in clinical enzymology. Certainly it had not been 
examined with a view to possible usefulness in differentiating 
enzyme species. 
Interest in this field was first awakened by the need 
to determine temperature correction factors for a numbor 
of serum enzymes (King, 1965). This work revealed that the 
temperature-activity curves showed no abrupt point of 
denaturation and while one temperature might denature one 
enzyme and not another, this was only a particular facet 
of an individual, characteristic temperature-activity 
relationship. It was obvious that where there were differences 
in the so-called "optimum temperature", that beyond which 
inactivation played a major role, then there were equally 
discernible differences at lower temperatures. Thus it 
was found that the ratios of activities at 37 0C and 25 
0C 
were 2.78 for caeruloplasmin, 2.13 for aspartate transaminase 
and 1.88 for cholinesterase. It could be argued that these 
represent different categories of enzymes but this is not 
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a valid point. As it is even in the same class, say the 
oxido-reductases, differences as wide were found with values 
of 2.78 for isocitrate dehydrogenase; 2.5 for malate 
dehydrogenase; and 1.89 for 6-phosphogluconate dehydrogenase. 
Early studies on heat denaturation at 60 0C with 
lactate dehydrogenase and malate dehydrogenase in the sera 
of patients suffering from a wide range of diseases had 
indicated that clinically useful information could be 
derived from the differing isoenzyme responses to heat 
(King, 1966). On the practical side however the delays 
during the pre-assay denaturation process militated against its 
employment in routine clinical laboratories. A study of 
the temperature-activity relationship-of lactate dehydrogenase 
in human serum was then undertaken and while distinct 
differences were noted depending upon the isoenzyme. compo- 
sition there was invariably present in varying proportions 
at least four of the five isoenzymes as revealed by agar-gel 
electrophoresis (Wieme, 1959). The same applied to tissue 
extracts and facilities for isolating the isoenzymos of 
human lactate dehydrogenase were not available at that time. 
The same impediments applied to the "tissue-specific" 
isoonzymes of alkaline phosphatase. The obvious solution 
to this was the study of an enzyme, the molecular species 
of which were already completely separated in human sera, 
and in this respect the genetically-determined isoenzymes 
of cholinesterase appeared to be a perfect example. In 
homozygous individuals only one enzyme variant is present. 
Further cholinesterase is clinically labelled as -a "serum- 
specific" enzyme and as such evinces a relatively high 
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activity precluding the need for preliminary purification. 
1. (d) Aims of the study. 
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(d) Aims of the study 
The scheme of work envisaged was an investigation into 
methods of differentiating the human serum cholinesterase 
variants and an examination of these as a means of assessing 
molecular differences. An emphasis was to be placed on the 
effect of heat on the enzyme kinetics. 
It was considered that studies with various inhibitors 
and substrates might reveal further phenotypes and possibly 
give some indication of the structural differences. On a 
more practical plane it was hoped to elaborate simple 
screening procedures for suxamethonium-sensitive individuals 
and to gain enlightenment on the anomalies between biochem- 
ical parameters and physiological observations. 
2. Benzoylcholine Hydrolysis. 
(a) TemperatUre studies. 
sq, 
Benzoylcholine has certain recommendations as a substrate 
for studies on cholinesterase. First, it has the advantage 
of specificity (Mendel and Rudney, 1943) and therefore 
although it was proposed only to examine human serum, even 
a degree of haemolysis would not invalidate results. 
Secondly, benzoylcholine has an absorption maximum at 
232 nm much greater than its hydrolysis products which 
absorb. maximally at 224 nm. The rate of hydrolysis can 
therefore be readily monitored in an ultraviolet spectro- 
photometer. The validity of an initial reaction rate assay 
compared to other types of enzyme activity determination 
is well established. Finally, benzoylcholine has proved 
to be a particularly useful substrate in studying the 
allelic variants of human cholinesterase (Kalow and Staron, 
1957; Harris and 11.1hittaker, 1962). Indeed it was with this 
substrate in the assay procedure of Kalow and Lindsay 
(1955) that the means of identifying these variants was 
discovered by dibucaine inhibition (Kalow and Genest, 1957). 
Almost as a matter'of custom since then, the same assay 
procedure has been employed in investigations with other 
inhibitors in differentiating the human cholinesterase 
allelic isoenzymes. 
Kalow and Lindsay (1955) did not follow the substrate 
hydrolysis at 232 nm but at 240 nm. The difference in 
absoxýptions between benzoylcholine and its hydrolysis 
products, mainly benzoate, is greatest at 235 nm but this 
is reduced by less than 10% at 240 nm. At the lower 
wavelength the dilute serum itself has an absorption of 
1.2 but at 240 nm this is reduced to 0.5. This latter 
1 40 
wavelength was obviously chosen as giving an acceptable 
initial absorption while retaining adequate sensitivity 
in following the hydrolysis of benzoyleholine. A 50 vM 
concentration of benzoylcholine in the final reaction 
M 
mixture was employed at PH 7.4 given by a -f-5 Sbrensen 
phosphate buffer. These workers'were obviously aware that 
these conditions did not give maximal activities but, as 
with the choice of wavelength, were optimal compromises. 
This knowledge was explicit in later reports which gave 
a ratio of 5.5 between the Ifichaelis-Menten constants for 
the atypical and usual enzymes and of 0.5 for the Vmax 
ratio (Davies, Marton and Kalow, 1960) thereby indicating 
that the substrate concentration for maximal activity 
varied with the cholinesterase phenotype. 
Preliminary experiments with the limited phenotype 
sera available at the beginning of this project indicatod 
that a 50 lilt benzoylcholine concentration was indeed 
optimal for the usual enzyme at 25 
0 C. The atypical enzyme 
required a substrate concentration of about 125 Of for 
saturation. However since inhibition by excess substrate 
was found with all variants tested and most acutely with 
the usual enzyme, it was obvious that unless the substrate 
concentration were to be varied for each phenotype then 
that optimal for the usual enzyme was the best compromise. 
Tentative investigations into the effect of pll on 
benzoylcholine hydrolysis were generally in agreement with 
the findings of Kalow (1964). The oPtimum p1l varies with 
the type and ionic strength of the buffer, with the substrate 
concentration and also with the enzyme variant. With a 
If 
M 50 VM benzoylcholine concentration and 1-5 Sbrenson phosphate 15 
buffer the usual enzyme has an optimu m pH about 9.0, the 
atypical about 8.5. At a 100 pM substrate concentration 
the atypical pH optimum was slightly increased towards that 
of the usual enzyme at its optimal substrate concentration. 
At these hydrogen ion concentrations however the spontaneous 
hydrolysis'of the substrate was no longer neglibible and 
certainly not at higher temperatures. This factor 
presumably had made for the original choice of pH 7.4. 
As it was, the proposed scheme of study did not 
envisage elaborating new assay conditions if those already 
available and well-tested were adequate. Obviously the 
kinetics of cholinesterase are very complex and any now 
sot of assay conditions would be difficult to justify as 
superior to those originally set out by Kalow and Lindsay 
(1955). Even if this could have been done the knowledge 
with regard to phenotyping accumulated over the intervening 
years would be void, and it would be an empty exercise to 
repeat this with the new-assay conditions. Accordingly 
the assay procedure of Kalow and Lindsay (1955) which had 
been found to give remarkably reproducible results was 
adopted without modification for temperature studies. 
The negligible variation with temperature in the difference 
in molar absorptivities of benzoylcholine and benzoate at 
pH 7.4 was a bonus since this meant that the rate of change 
in absorption (AA) was directly and constantly related to 
enzyme activity at all temperatures studied. 
ilt 2- 
Instrumentation, Methods and Materials 
Initially, estimations were carried out on a Unicam 
SP 800 recording spectrophotometer with scale expansion to 
a Servoscribe recorder. Temperature control was obtained 
by circulating water from a Shandon water-bath through the 
jacketed cuvette-holder. Cooling was obtained by adding 
ice chips to the water-bath. Later, a Unicam SP 8000 
recording spectrophotometer with Unicam AR 25 linear 
recorder and with temperature control given by a Tecam 
water-bath and Grant Instruments dip-cooler was employed. 
In the final stages, studies were performed on a Unicam 
SP 1800 recording spectrophotometer with Unicam AR 25 
linear recorder, constant temperature-being assured by a 
circulating Heto water-bath and Grant Instruments dip- 
cooler. This last group of instrumentation was provided 
by the Medical Research Council under grant G971/343/C 
and acknowledgment of this generous support is gratefully 
recorded. 
With all these instruments the temperatures of the 
water-bath and of the cuvette contents were correlated 
over the temperature range 15 
0C to 600C by means of a 
standardised mercury thermometer and Wayne Kerr contact 
thermometer respectively. The difference between the bath 
and cuvette temperatures increased with temperature 
deviation from the ambient as did the time required for 
equilibration. Temperature control was improved by the 
use of Techne polypropylene spheres floating in the 
water-bath. 
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Figure 2. Phenotype ranges of inhibitor numbers. 
These inhibitor numbers or percentage inhibitions refer 
to the assay procedure of Kalow and Lindsay (1955) with 
a 50 IAI benzoylcholinc substrate in phosphate buffer at 
p1l 7.4. 
The ranges refer to 25 
0C from earlier personal experience 
and to 26.50C from Whittaker (1968b) and Lehmann and 
Liddell (1969). 
40" 
all volumes less than 2 millilitres. 
Serum cholinesterase activity was estimated by the 
procedure of Kalow and Lindsay (1955), modified by King 
(1965) and results were expressed in nanomoles of benzoyl- 
choline hydrolysed per minute by one millitre of serum, . 
that is., mU/ml (International Union of Biochemistry, 1961; 
1965). Normal values obtained by this method range from 
620 to 1370 mU/ml at 259C (King, 1965). For cholinesterase 
phenotyping, activity was simultaneously and separately assayed 
in the presence of 10 pM dibucaine (Kalow and Genest, 
1957), 50 vM sodium fluoride (Harris and Whittaker, 1961) 
and 500 mM sodium chloride (Whittaker, 1968b). All pheno- 
typing assays were performed at 250C. - 
Figure 2 indicates ' 
the ranges of inhibition by dibucaine, fluoride and chloride, 
culled from the literature and personal experience and 
which were used to phenotype serum specimens. 
Reagents 
Benzoylcholine, sodium fluoride, sodium chloride and 
orthophosphate salts were obtained from BDII Chemicals Ltd. 
and the cinchocaine hydrochloride (dibucaine hydrochloride) 
from Ciba. 
67 m1l. Sbrensen phosphate buffer, pH 7.4. Dissolve 
19.19 g disodium hydrogen phosphate dihydrate 
(Na 2 11 PO 4' 211 2 0) and 3.48 g potassium dihydrogen 
phosphate (KII 2 PO 4) in Nvater and make to 2 litres. 
200 jill substrate solution. Dissolve 48.8 mg 
benzoylcholine chloride in I litre of water. 
40 pM dibucaine solution. Dissolve 15.2 mg 
cinchocaine hydrochloride in 1 litre of water. 
(iv) 200 p1l sodium fluoride solution. Dissolve 8.4 mg 
sodium fluoride (AR) in I litre of water. 
(v) 2M sodium chloride solution. Dissolve 117 g 
sodium chloride (AR) in water and make to I litre. 
Procedure 
A1 in 200 dilution of serum in buffer was prepared 
and placed in the blank euvettes. A further 100 V1 of 
serum was diluted to 10 ml with phosphate buffer and 2 ml 
of this dilution added to each of the four test euvottes. 
To the first euvette, that giving the cholinesterase 
activity, was added 1 ml of water and to the other three 
euvettes I ml of the respective inhibitor solution. Time 
was allowed for temperature equilibration, then I ml of 
substrate solution was added to each cuvotte, the contents 
thoroughly mixed with a plastic paddle and the reaction 
rates recorded at 240 nm for a minimum of five minutes. 
From this the decrease in absorption per minuto (AA) was 
obtained. 
Using the micromolar extinction coefficient for 
benzoylcholine of 6.6 at 240 nm (Kalow and Lindsay, 1955) 
then in a4 ml reaction volume with a light path of 10 Dim 
activity is given by: - 
4 AA V moles benzoylcholine hydrolysed per min 6.6 per 20 V1 serum 
4 1000 1000 AA =n moles/min/ml 6.6 20 
or 30300 AA = mU/ml 
It is not necessary to calculate the activities in 




(percentage inhibition) were calculated as: - 
100 change 
in absorbance of inhibited assay 
change in absorbance of uninhibited assay) 
In all of these studies the substrate solution and 
pipette tips were always maintained at the bath temperature 
which, below ambient was lower, and above ambient higher 
than the euvette contents. Opening the cuvette*compartment 
causes a slight change in the cell-housing temperature in 
an opposite direction so that the two effects have a 
tendency to cancel each other. Certainly after 30-60 
seconds no consistent, significant variation in the reaction 
rates with time was evident within the limits imposed by 
substrate saturation. 
It was also established that the activity and the 
response to inhibitors of serum diluted in phosphate buffer 
did not alter significantly during eight hours at bench 
temperatures. All temperature variation experiments, 
usually from 15 0C to 60 
0C in steps of 0C wore undertaken 
in one run which usually took from six to eight hours. For 
these temperature studies therefore 1 ml of serum was 
diluted to 100 ml with phosphate buffer. This was then 
employed throughout the experiment and reduced errors due 
to preparing fresh dilutions for each temperature. 
The enzyme source for these studies was sera from 
normal, healthy volunteers, from hospital patients with a 
wide variety of pathologies, from patients who had exhibited 
prolonged apnoeic responses to suxamethonium and from their 
relatives. A service was instituted at the Department of 
Biochemistry, Royal Infirmary, Glasgow which offered to 
phenotype any serum spec. imen referred and also offered 
il 
cholinesterase phenotyping to close relatives of those 
confirmed as sensitive by inhibition studies. Sensitivity 
cards (Telfer, McDonald and Dinwoodic, 1964) are issued to 
all individuals of the four phenotypes invariably at risk, 
that is, Ea 1 Ea 1 Ea 1 Ef 1 EfEf and 11 EsEs 11 
As a, result of the widespread use whicli has been made 
of this service, an adequate suPPly of material has becn 
available and individuals of all the ten generally-recognised 
genotypes have been discovered, some the first recorded in 
Scotland. Table I indicates the generally-accepted geno- 
types at the first locus, the nomenclature employed 
(Motulsky, 1964) and the frequency of occurrence in the 




Usual/ Fluoride-resistant ficterozygote 
Usual/Atypical Heterozygote 
F1 uorido- resistant Homozygote 
I 
Atypica I/Fluoride- resistant Heterozygote 
GENOTYPE FREQUENCY 
-U E. u E. 95 in 100 
e, E, ' 11.190 
Eý E! I in 280 
I in 26 
f E! EI 1 In 300.000 
ý Eý lin20Q000 
a Ef I in 29.000 
0.1 in 2,800 Atypicol Homozygote 
E5, I in 20,000 
Silent Homozygote E, I in 140,000 
Table 1. Frequency of occurrence of the cholinesterase phenotypes. 
47 
Experimental Results 
As indicated earlier (page 35) differentiation of 
isoenzymes by heat had only been attempted where there 
were differences in the irreversible denaturation of the 
molecular species. To determine whether such differences 
exist between the cholinesterase variants, serum specimens 
of the three usual/atypical genotypes were incubated for 
various periods at temperatures from 25 
0C to 60 0 C. The 
samples were then assayed at 25 
0C for cholinesterase 
activity. Below 50 
0C there was no evidence of denaturation 
in any sample for incubation periods up to one hour. 
Table 2 shows some typical results obtained from this series 
of experiments which indicated that there was no substantial 
difference in the irreversible thermal denaturation of the 
cholinesterase variants studied. That the change was 
irreversible was confirmed by re-assay of the specimens 
four to six hours after original removal of the heated 
aliquot and dilution in buffer (Table 2). 
These denaturation experiments were carried out at the 
50 VII benzoylcholine concentration of Kalow an6 Lindsay 
(1955) which preliminary studies bad indicated was substrate- 
saturating at 250C for usual homozygote sera. The prelim- 
inary studies had also confirmed the findings of Davies, 
Marton and Kalow (1960) that heterozygotes had higher optimal 
substrate concentrations. Obviously these. optimal concen- 
trations would increase with temperature but no cognisance 
of this or of change in the optimal p1l with temperature was 
taken in the next series of experiments. In this study 
sera from patients who had undergone prolonged paralysis 
9P r'll 
ýtq 
following suxamethonium administration and from members 
of their families were assayed at increasing temperatures 
as indicated under Methods. Preliminary studies (King, 1967) 
had shown striking differences in the effect of heat on 
the enzyme reaction rate and these are confirmed and 
extended in the following family studies (King and Dixon, 
1969; King, McQueen and Morgan, 1971). 
Table 2. 
Heat Denaturation of Serum Cholinesterase 
uuu 'a aa Temperature (minutes) El El (J. B. ) El El (M. G. ) El El (j. L. ) 




C 30 93% 96.5% 91ck 
60 75.57o 79.57o 73% 
0 585 mU/ml 560 mU/ml 176 m. U/ml 
0C 
5 657o Mo 76'/o 
30 12.57o I% 297o 
60 1.57o 1.57o 3.576 
0 606 mU/n-a 565 mU/ml 179 mU/ml 
600C 
5 37o 3.57o im 
30 1.570 1.970 6.5"'10 
60 1.57o 1.57o 3.9jo 
Repeat assays after 4 to 6 liours 
0 615 niU/n-a 575 mU/ml 173 mU/nil 
5CPC 
5 957o 957o 96.5%, 
30 847o 9070 88% 
60 707o 76'lo '12k 
0 615 mU/na 585 mU/ml 186 rnU/ml 
0C 
5 687o 727o 77.57o 
30 177o 19% 297o 
60 3.57o - 1070 
4,11 
Case 1 
The patient (A) exhibited Prolonged apnoea after 
suxamethonium was given during an obstetric procedure prior 
to delivery. Assay of her serum yielded values of 
395 mU/ml for cholinesterase activity, 21 for dibucaine 
number (DN) and 17 for fluoride number (FN). She was 
aa accordingly classified as phenotype E, El, homozygous for 
the atypical enzyme. Later figures for the son (B) were; 
serum cholinesterase 700 mU/ml, DN = 58, FN = 46 indicating 
a genotype EuEa while the father (C) was a usual homozygote, 
EuEu with cholinesterase activity of 920 mU/ml, DN = 78 11 
and FN = 66. Cord blood serum from a second child, a 
daughter (D) permitted classification-as an atypical 
heterozygote with cholinesterase activity 470 mU/ml, DN = 61 
and FN = 50. 
The cholinesterase temperature/activity relationship 
of this family are shown in Figure 3. 
Cas e 
The brother (E) of a suxamethonium-sensitive patient 
was found to have a serum cholinesterase activity of 
475 mU/ml, dibucaine number 51, fluoride number 46 and was 
u it therefore classed as an atypical heterozygote, EI r" 1. Of 
his two sons, one (F) was apparently a usual homozygote 
with DN = 77 and FN = 62 but with a low serum cholinesterase 
activity of 370 mU/ml while the other (G) exhibited an even 
lower activity of 220 mU/ml with DN = 29 and FN = 27. 
These latter figures suggested an atypical homozygote but 
investigation of the mother's serum gave values of 555 mU/ml 
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Figure 3. Cholinesterase teniperature/nctivity curves of desiCnated 
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Reoction Temperaturc (OC) 
Figure 4. Cholinesterase temperature/activity curves of desIgnated 
family members of Case 2 (pages 49,50). 
nk 
dibucaine and fluoride inhibition respectively. The 
presence of a silent gene in the mother (11) was therefore 
evident, assumed in the son (F) and both Nvere classified 
as genotype, EU Es. The second'son was obviously an 11 
atypical/silent heterozygote, EaES 1V 
The variation of serum cholinesterase activity with 
temperature in this family is illustrated in Figure 4. 
Case 3 
Following suxamethonium injection during dental 
anaesthesia patient (J) was apnoeic for 35 minutes. Serum 
assays indicated that he was heterozygous for both 
dibucaine - and fluoride-resistant genes, EaEf with 11 
cholinesterase activity of 305 mU/ml, DN = 42 and FN = 34. 
Both his daughter (K) and a grand-daughter (L) were 
classified as atypical heterozygotes, Eu E CIL 1 1, with cholin- 
esterase activities of 640 mU/ml and 685 MU/ml, dibucaine 
numbers of 65 and 67 and fluoride numbers of 55 and 52 
respectively. Figure 5 illustrates the temperature/activity 
curves for serum cholinesterase in the three generations 
of this family. 
Case 4 
The patient (M) suffered prolonged paralysis following 
suxamethoniuri administration prior to external cdphalic 
version of her second child. Assay of her serum at this 
time yielded anomalous figures (page 124) but later results 
indicated a phenotype of EfEf with cholinesterase activity 11 
of 480 mU/ml and dibucaine, fluoride and chloride numbers 
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Figure 5. Cholinesterase temperature/activity curves of OesiCnated 
family members of Case 3 (page 50). 
20 30 40 
Reaction Temperature 
51 
be genotype E 
U. Ef as was the elder boy (0) whose serum 
cholinesterase activity was 1010 MU/ml with DN = 70, 
FN = 47 and C1 N= 19. Assay of the husband's serum (N) 
gave results for cholinesterase activity of 695 mU/ml 
and DN = 79, FN = 59 and C1 N= 10, a usual phenotype 
although the rather low activity in a healthy young adult 
might suggest the presence of a silent gene. Equally, 
of course, it was realised that the patient's phenotypic 
behaviour might mask a silent gene. 
The patient's mother was deceased but her father (P) 
with dibucaine) fluoride and chloride numbers of 74,52 
and IS respectively was classified as a usual/fluoride- 
resistant hoterozygote, Eu Ef as was-. paternal aunt. 11 
On examining the sera of the maternal. uncle and aunt it 
was found that they were homozygous for the usual and 
fluoride-resistant genes respectively. The aunt (Q) had 
a sertim cholinesterase activity of 78 mU/ml, DN = 67, 
FN = 39 and C1 N= 26, a second fluoride-resistant homozygote 
in the same family but in an earlier generation. This 
evidence for the presence of a fluoride-resistant gene in 
the maternal family made it unnecessary to postulate the 
presence of a silent gene and the cholinesterase activity 
of 1400 mU/ml in the maternal uncle made it unlikely. The 
temperature-activity relationships of the members of this 
family given letters in the text are shown in Figure 6. 
Details of the serum assays on all members studied are 
given in Table 3 and the cholinesterase phenotyping is 




Reaction Temperature ('C) 
Figure 6. Cholinesterase temperature/activity curves of designated 
family members of Case 4 (pages 50,51). 
Table 3 
Assay values for thefamily of Case 4 
Scr= cholinesterase 







.. NuiTbcr Phenotype, 
Patient (11) 480 64 36 28 EfEf 
Son (0) 1010 70 47 19 EUEf 11 
Daughter 580 72 55 18 E u. Ef 
Husband (N) 695 79 59 10 it u EIE 
rather (P) 645 74 52 18 E"ýý Fý f 1 
Paternal Uncle 1.070 82 64 13 EUEu 11 
Paternal Aunt 880 77 48 20 F, -ý. E, 
f 
11 
Maternal Uncle 1400 81'-- 59 IG EU 11, U 
Maternal Aunt 780 67 39 26 f r" 
Figure 7. Phenotype relationship of Case 4 family (pages 50,51). 
52 
Case 5 
The patient (R) was a month-old baby boy. Serum assay 
gave a cholinesterase activity of 530 mU/ml, dibucaine 
number 52, fluoride number 29 and chloride number 39 
af consistent with a genotype E1E1 Cholinesterase pheno- 
typing of the parents indicated that the father (S) was an 
atypical heterozygote with cholinesterase activity of 
585 mU/ml, DN = 60, FN = 48 and Cl N= 23 while the mother 
(T) had a serum cholinesterase of 210 mU/ml with dibucaine, 
fluoride and chloride numbers of 62,33 and 28 respectively. 
The inhibitor numbers suggested that she was a fluoride- 
resistant homozygote, EfEf but assay of her parents' 
sera revealed that she was in fact a fluoride-resistant/ 
silent heterozygote since her father (U) was genotype 
Eu Ef and her mother (V) apparently a usual homozygote but 11 
obviously heterozygous for the silent gone. The paternal 
grandmother was deceased and both the paternal grandfather 
(W) and paternal uncle were found to be usual homozygotes. 
The cholinesterase temperature activity curves of the 
indicated members of this family are shown in Figure 8, 
the assay figures in Table 4 and the cholinesterase phono- 
type relationship in Figure 9. 
Case 6 
The patient (X) underwent orthopaedic surgery in 
Bridge of Earn Hospital, Perthshire. The parents were 
somewhat disquieted by reports of untoward reactions which 
they felt might have been a cardiac arrest. Professor 
II. G. Morgan thought that the episode could have been a 





Peoction Tomparoture (OC) 
Figure S. Cholinesterase temperature/activity curves of designated 
family members of Case 5 (page 52). 
Table 4. 
Assay Figures for th6 Family of Case 5 
Serm 
Cholinesteý&! e Dibucaine Fluoride ailoride 
(mU/ml at 25 Q Number Number Nunbor Phenotyr 
Patient (R) 530 52 29 39 EaEf 11 
F ather (S) 585 60 48. 23 ,u ra El jjI 
Mother (T) 210 62 33 28 Ef 11 I 
Yaternal Grandfather (U) -1080 74 53 23 E, Ef 
Maternal Grandmther (V) 390 79 62 15 jj 1 J. 
Paternal Grandfather (W) 740 80 65 13 EuEu 
Paternal Wele 920 so 58 15 11 u 1! " 1, ý 
. 1. 
FiCure 9. Phenotype relationship of Case 5 family (page 52). 
r" 
her father (Y), mother (Z) and younger sister. Analysis 
of the sera indicated that. the patient had cholinesterase 
activity less than 30 mU/ml and that the father, mother 
and sister were of the usual phenotype with serum activities 
of 385., 280 and 465 mU/ml at 25 
0C respectively. The patient 
was accordingly classified as homozygous for the silent 
gene, phenotype EsEs and the parents as hcterozygotes 11 
Eu Es. The sister is probably also a usual/silent heterozy- 11 
gote. 
The temperature activity curves for this famil. y. are 
shown in Figure 10. 
Another family of which at least two were silent gene 
homozygotes was referred by Professor--Richterich of Berne. 
However due to the untimely death of this renowned clinical 
biochemist most of the serum specimens and all the details 
of relationship and clinical data were not received. 
From the curves of the foregoing cases which include 
all ten generally-acknowledged genotypes and from studies 
on other sera totalling 21 samples of EuE 
11 
,6 of EuE, 
f 
Uaffaf11 111 Ift 
I JP 
11 of E1 Elp 3 of E1EI, 5 of E1E1 and 9 of E. 1 E, mean 
values were calculated relative to unit activity at " C, 050 
30 0C and 370C. These temperature-activity relationships 
are illustrated in Figures 11,12 and 13. Table 5 contains 
the Q10 values for all six phenotypes throughout the range 
of temperatures studied. Also derived from these studies, 
the temperature correction factors for the three homozygous 
phenotypes, EUEupEfEf and EaEa are given in Tables 6, 111111 
7 and 8 respectively. 
The cholinesterase activities at 25 
0C and 37 0C of a 
Figure 10. Cholinesteraso temperature/activity curves of do. -Aguated 
family members of Case 6 (pages 52,53). 
The rate of benzoyleholine hydrolysis by the propositus 
X was minimal and of the same order as the spontaneous 
hydrolysis. Despite this and the knowledge that at such 0 
levels of activity laree proportional errors can result 
there was in several experiments a tendency for increase 
in the rate of hydrolysis with temperature exhibiting a 
maximum about 450C. 
20 30 , 40 50 
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Reaction Tomparatute (OC) 
Figure 11. Temperature/activity relationships of serum cholinesterase 
phenotypes referred to unity at 250C. Assay procedure 
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Figure 12. Twnperature/activity relationships of serum cholinestorase 
phenotypes referred to unity at 300C. Assay procedure 
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phenotypes referred to unity at 370C. 




Temperature Coefficients of Serum Cholinesterase Variants 
uufuaffafaa QIO E1E11 El Eý ]Ej El El El El El El 
150 - 25 
0C 1.89 1.96 1.76 1.70 1.70 1.72 
20 0- 300C 1.94 1.77 1.71 1.50 1.45 1.37 
250 - 350C 1.76 1.67 1.60 1.30 1.23 1.14 
30 0- 40()C 1.60 1.58 1.45 1.14 1.01 0.93 
350 - 45 
0C 1.47 1.42 1.29 0.93 0.80 0.75 
400 - 50()C 1.26 1.19 1.11 0.65 0.58 0.59 
450 - 55 
0C 0.97 0.8.0 0.85 0.35- 0.30 0.39 
Table 6. 
Teffperature correction factors for sermn cholinesteras"henotype Oý F'ý 1--Lll 
Reaction Standard Tcrnperature Temperature 
(0c) 2EPC 309C 37 0C 
15 1.89 2.58 3.62 
16 1.80 2.45 3.44 
17 1.70 2.32 3.25 
18 1.61 2.19 3.08 
19 1.52 2.08 2.92 
20 1.42 1.94 2.72 
21 1.33 1.81 2.54 
22 1.24 1.69 2.37 
23 1.15 1.57 2.21 
24 1.07 1.47 2.06 
25 1.00 1.37 1.92 
26 0.94 1.28 1.80 
27 0.88 1.20 1.68 
28 0.62 1.13 1.58 
29 0.78 1.06 1.49 
30 0.73 1.00 1.41 
31 0.69 0.95 1.33 
32 0.66 0.90 1.26 
33 0.63 0.86 1.20 
34 0.60 0.82 1.14 
35 0.57 0.78 1.09 
36 0.54 0.74 1.04 
37 0.52 0.71 1.00 
38 0.50 0.68 0.96 
39 0.48- 0,65 0.92 
40 0.46 0.63 0.88 
Table 7. 
Tapperature correction factors for serwn cholinesterase phenotype EfRf ='-l-" 1 
Reaction Standard Temperature 
Temperature 
OC 30'C 37 0C 
15 1.70 2.00 2.26 
16 1.60 1.89 2.13 
17 1.50 1.77 2.00 
18 1.42 1.67 1.89 
19 1.35 1.59 1.80 
20 1.28 -1.51 1.71 
21 1.22 1.43 1.62 
22 1.16 1.36 1.54 
23 1.10 1.30 1.46 
24 1.05 1.24 1.39 
25 1.00 1.18 1.33 
26 0.96 1.14 1.28 
27 0.93 1.10 1.24 
28 0.90 1.06 1.20 
29 0.87 1.03 1.16 
30 0.85 1.00 1.13 
31 0.83 0.97 1.10 
32 0.81 0.95 1.08 
33 0.79 0.93 1.06 
34 0.78 0.92 1.04 
35 0.77 0.91 1.02 
36 0.76 0.90 1.01 
37 0.75 0.89 1.00 
38 0.75 0.89 1.00 
39 0.75 0.88 1.00 
40 0.75 0.88 1.00 
Table S. 
Temperature correction factors for serum cholinesterase pjicnotype aa 
Reaction Standard Temperature 
Tenperature 
2ýOC 30'C 370C 
15 1.75 1.96 1.95 
16 1.61 1.80 1.80 
17 1.50 1.67 1.67 
18 1.39 1.56 1.65 
19 1.30 1.46 1.45 
20 1.23 1.38 1.37 
21 1.17 1.31 1.30 
22 1.12 1.25 1.24 
23 1.07 1.20 1.19 
24 1.03 1.16 1.15 
25 1.00 1.12 1.11 
'26 0.97 1.09 1.08 
27 0.95 1.06 1.05 
28 0.93 1.03 1.03 
29 0.91 1.01 1.01 
30 0.89 1.00 1.00 
31 0.88 0.99 0.98 
32 0.87 0.98 0.97 
33 0.87 0.97 0.97 
34 0.87 0.98 0.97 
35 0.88 0.98 0.98 
36 0.89 0.99 0.99 
37 0.90 1.00 1.00 
38 0.91 1.02 1.02 
39 0.93 1.05 1.04 
40 0.96 1.08 1.07 
wider selection of sera comprising 178 usual homozygotes,, 
24 usual/fluoride-resistant. heterozygotes, 60 usual/atypical 
heterozygotes, 3 fluoride-resistant homozygotes, 11 atypical/ 
fluoride-resistant heterozygotes and 20 atypical homozygotes 
are shown in Figures 14 and 15. 
m' (Ilý j Z> 
Discussion 
Not all prolonged responses to suxamethonium can be 
attributed to enzymic anomalies and indeed may not be 
attributable to suxamethonium alone but may be caused by 
a complex situation'dependent upon anaesthctic premedication 
or simple reduction in cholinesterase activity in conjunction 
with electrolyte imbalance (Kalow, 1959a). That there exist 
routes of inactivation or removal of suxamethonium apart 
from hydrolysis by serum cholinesterase is shown by the 
recovery from suxamethonium apnoea, albeit slow, of 
individuals homozygous for the silent gene and therefore 
devoid of the enzyme (Hart and Mitchell, 1962; Liddell, 
Lehmann and Silk, 1962). It may well be a failure of these 
supporting or alternative mechanisms which results in 
prolonged paralysis in individuals for whom no genetic 
anomaly can be demonstrated (Telfer, McDonald and Dinwoodie, 
1964). 
However, a low serum cholinesterase leval alone is 
rarely a cause for concern in the use of suxamethonium 
while the mass of evidence accumulated over the last decade 
or so concerning the inherited variants of serum cholinest- 
erase has indicated that individuals homozygous for one 
ssaaff 
of the variant species (E 1 Ell El Ell El E, ) or heterozygous 
sasfaf for two (El Ell El Ell El El) show undue sensitivity to 
suxamethonium. Individuals homozygous or heterozygous for 
the usual enzyme (E uEu or E 11 EspEUEf)EuEa) do not 
usually exhibit prolonged response (Kalow, 1959; Lehmann, 
Liddell, Blackwell, O'Connor and Daws, 1963). The rate of 
occurrence of suxamethonium apnoea among the different 
5 CA 
phenotypes has been summarised by Lehmann and Liddell 
(1969). 
Kalow (1959) demonstrated that compared to the usual 
enzyme, the atypical or dibucaine-resistant enzyme had a 
reduced affinity for succiny1dicholine and calculated that 
at in vivo concentrations the drug would not combine with 
the atypical esterase. This last postulate took no 
account of the relatively increased concentration, at 
least one-hundred fold., of enzyme in vivo compared to the 
in vitro experiments but certainly a reduced efficiency in 
hydrolysing suxamethonium was demonstrated for the atypical 
enzyme. Where apnoea is connected with an inherited 
cholinesterase variant it has therefore been assumed that 
the sole cause is the reduced affinity for suxamethonium 
and this was summed up by Wylie and Churchill-Davidson (1966) 
as follows: "The only difference between these two enzymes 
is one of degree. Both are capable of hydrolysing 
suxamethonium in vitro but only the normal enzyme can do 
it in clinical conditions where the concentration of 
suxamethonium is low. Thus if a patient with the atypical 
enzyme receives a dose of suxamethonium, the dilution 
caused by the blood volume rapidly causes a drop in its 
concentration below the effective level for the atypical 
esterase. In these circumstances the patient remains 
paralysed for a long period of time". 
The results of the present study indicate however 
that the reduced enzyme-suxamethonium. affinity is not the 
sole factor causing the increased time of paralysis through 
decreased hydrolysis of the drug. There is also the 
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inactivation at body temperature of the enzyme variants 
present in the serum of scoline-sensitive subjects which 
reduces the rate of hydrolysis. At least this has been 
conclusively shown in the foregoing studies with benzoyl- 
choline and was so reported (King and Dixon, 1969). It 
was realised that this might not be the case with other 
substrates, in particular with succ inyldicholine and 
therefore this was examined and is discussed later, 
I 
(page 103 et seq. ) 
These studies also show that the presence of a silent 
gene does not affect the temperature-activity characteristics 
of the allele present in heterozygotes. In this respect 
tile characteristics of the usual/silent heterozygote Ell ES 
shown in loci F and 11 (Figure 4) and V (Figure 8) are 
identical with the usual homozygote curves, C (Piguro 
N (Figure 6) and W (Figure 8). Similarly the curvo of tho 
It 
, ttypical/silent lieterozygote EIs IE1 of G (Figuro 4) is 
identical with curve A (Figure 3) given by an atypic,, 1.1 
homozygote. Curve T (Figure 8) that of genotype Ef ES has 11 
the same temperature-activity characteristics as those of 
M and Q (Figure 6) given by the fluoride-resistant homozygotes. I 
This was to be expected, has already been noted in inhibition 
studies and was confirmed by the investigation of the only 
silent homozygote to be discovered in this study; curve X 
(Figure 10). This does not deny that there may in some 
cases be minor but probably undetectable variations due to 
the silent variant since this has been shown conclusively 
to be a heterogeneous group (Goedde and Altland, 1968; 
Rubinstein, Dietz, Hodges, Lubrano and Czebotor, 1970). 
1; c. 
Harris, Lehman and Silk (1960) reported that there 
was "a significant correlation between the dibucaine numbers 
and cholinesterase levels within the 'intermediate' phenotype". 
This has been generally confirmed in the present study 
with the outstanding exception of individual D of Case 1. 
However, the cholinesterase activity of cord blood serum 
is generally lower than adult normal (Lehmann, Cook and 
Ryan, 1957; King, 1965) and this probably accounts for the 
low activity found in that case (Figure 3). Dibucaine and 
fluoride numbers were readily determined on this specimen 
which also yielded a curve similar to those found in the 
adult phenotype. It is perhaps noteworthy that at 250C at 
which activity was measured this neonate's serum cholin" 
esterase activity was only a little higher than that of the 
mother A (Figure 2) while at 370C, the functional tempera- 
turo of the enzymo, the cord serum activity was nearly twice 
as high and this alone indicates some reduction of risk in 
the use of suxamethonium. 
This single examplc of the. general findings reported 
above also helps to resolve some anomalies noted in the 
literature. Bush (1961) for instance found "a 
scatter of cholinesterase levels imthe heterozygote and 
abnormal homozygote groups" than that observed by Lehmann, 
Patston and Ryan (1958) and later by Harris, Lehmann and 
Silk (1960). All these workers used acetylcholine as 
substrate, but Bush (1961) employed the procedure of Biggs, 
Carey and Morrison (1958) in which the pH change is measured 
during 30 minutes at 25 0 C, while Lehmann and colleagues 
recorded the volume of carbon dioxide liberated in a 
Distribution of Cholinesterose AdiAtias by Phenofypo (250C) 
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Figure 14. Serum cholinesterase activities by phenotype assayed 
at 250C by the procedure of Kalow and Lindsay (1959). 
The vertical broken line indicates the lower limit of 
normal activity (King, 1965). 
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Figure 15. Serum cholinesterase activities by phenotype assayed 
at 370C by the procedure of Kalow and Lindsay (1955). 
The vertical broken line indicates the lower limit of 
normal activity (King, 1965). 
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Warburg micromanometer at 37 0 C. From the results of these 
present studies it is obvious why the latter workers 
obtained at 37 0Ca better separation of the phenotypes by 
assay alone and indeed emphasises the fact that a true 
index of serum cholinesterase activity can only be obtaiDed 
if the estimation is conducted at the functioning tempera- 
ture of the enzyme, that is, 37 0 C. This is reinforced by 
the values shown in Figures 14 and 15 of activities on 
the same specimens by assay at 250C and 37 0C respectively. 
The usual homozygote group illustrated in these figures 
is by no means representative of a normal population and 
contains at least six, presumptive but almost certain, 
usual/silent heterozygotes and a number of hospital pntients, 
some suffering from diseases in which low cholJnestera; --; o 
levels are to be expected. Despite this it it., readily soon 
that there is a wide overlap of activities from all pliono- 
types at 250C (Figure 14) and that a number of suxamothonium. - 
sensitive individuals have serum cholinesterase activities 
which can only be classed as normal. While with activities 
at 370C (Figure 15) the distribution of the usual homozy. - 
gotes does not alter significantly, a larger proportion of 
the usual/atypical heterozygote group have activities 
which fall below the lower limit of normal. Most conclus- 
ively however is the change in distribution of the three 
scoline-sensitive phenotypes where all activities are seen 
to be abnormally low. This is one of the facts used by 
King (1972) in recommending the adoption of 370C as the 
standard temperature for enzyme assays. 
Certainly if cholinesterase estimations are carried 
out at any other temperature then for valid results tliese 
must be corrected to 37 0 C. This would involve determining 
the phenotype and then employing the appropriate set of 
temperature correction factors. King and Morgan (1970) 
suggested that for routine purposes this could be simplified 
without incurring a gross error by considering two groups 
only. In support of this it was noted that the phenotypes 
EUEUtEuEf and EuEa have respectively Q (250 - 35 
0 C) 
II1111 10 
of 1.76,1.67 and 1.61 and correction factors from 25 
0C to 
37 0C of 1.92,1.82 and 1.72. This represents a maximum 
divergence of about 117o in the range 25 0- 370C. Again 
the variants EaEa and EaEf have Q (250 - 350C) -f 1.14 1111 10 
and 1.23 and 25 0C to 37 0C conversion factors of 1.11 and 
1.22 respectively, a divergence of less than 10%. Later 
(King and Morgan, 1971) it was noted that for the Ef I 
phenotype the Q 10 (250 - 350C) was 1.30 and the correction 
factor from 25 0C to 37 0C was 1.33, a divergence of nearly 
20% from the atypical homozygote values and more t,.. I, i . 3070 
from the normal homozygote figures. This suggested a third 
set of temperature correction factors were required. Such 
figures to convert activities to 25 0 C, 30 
0C and 37( the 
temperatures recommended (International Union of Biochemistry, 
1961; 1965) or commonly used as standard temperatLres, for 
the usual enzyme, the fluoride-resistant variant and the 
atypical cholinesterase are given in Tables 6,7 and 8 
respectively. 
It is realised thatIthese figures only apply to a 
benzoylcholine substrate and in fact only to a 50 VM 
benzoylcholine concentration under the assay conditions 
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used in these studies. These are relevant facts which 
dispute the validity of using temperature correction 
factors and reinforce the arguments for international 
adoption of a standard assay temperature in clinical 
enzymology (King, 1972). 
From these studies the ratio of activities at 37 
0C 
and 26 0C is 1.78 and the temperature coefficient (Q 10 ) in 
the range 15 0C- 25 0C is 1.90 for the usual enzyme. These 
figures are in excellent agreement with the values given 
by Kalow and Lindsay (1955). The literature does not 
contain comparable thermal characteristics for the other 
serum cholinesterase variants. 
Reports that the. magnitude-and duration of suxameth- 
onium paralysis are increased by hypothermia (Zaimis, 
Cannard and Price, 1958; Cannard and Zaimis, 1959) are in 
keeping with the facts presented here (Figure 12) although 
it is doubtful if this phenomenon can be attributed solely 
to the decrease in serum cholinesterase activity with 
reduction in body temperature. In fact this effect should 
be less in suxamethonium-sensitive individuals and indeed 
it is interesting to speculate that whatever the function 
of serum cholinesterase (Clitherow, Mitchard and Harper, 
1963) those individuals of phenotypes EaEaIEaEf and 1111 
EfEf will be less affected by a reduction in body tempera- 11 
ture than will normal individuals. 
-ions employed in these studies, Under the assay condit 
the temperatures at which maximal activities are obtained 
is 50 - 510C for the usual enzyme, about 48 
0C for the usual 
heterozygotes EuEf and EuEa$ 40 0C for the fluoride- 1111 
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resistant homozygote, about 36 0C for genotype EaEf and 11 
32 - 33 
0C for the atypical homozygote. The results of the. 
denaturation experiments (Table 2) would therefore indicate 
that only in the case of the usual enzyme is the optimal 
temperature dictated by an irreversible process and that 
the temperature of maximal activity for the other variants 
is set by a progressive, reversible inactivation. This 
constitutes a previously undescribed phenomenon of isoenzyme 
differentiation and indeed would appear to contradict 
Harris (1970), who, referring to the usual and atypical 
enzymes, stated "However it should be noted that in a number 
of properties, for example thermostability and clectro- 
phoretic mobility the two forms of the enzyme do not 
apparently differ". This contradiction results from the 
earlier approaches to thermal differentiation which had 
relied, as in Table 2 experiments, upon the irreversible 
effect of heat on the protein itself rather than on its 
catalytic activity. 
It is possible, if not to differentiate each pheno- 
type, at least to segregate, suxamethonium-sensitive 
individuals from those at no predictable risk, by means 
of assays at two temperatures. The two most feasible 
temperatures in the light of present discussions on standard 
temperature would appear to be 25 
0C and 370C or 30 0C and 
37 0 C. This would provide a method of differentiating the 
usual homozygote and heterozygotes from the EaEa and EaEf 1111 
variants, that is, those most at risk to succiny1dicholine. 
The latter group havO 370/25 0 and 37 0 /300 ratios of less 
than 1.3 and less than 1.1. respectively while for the 
a 
U. 
former group these temperature ratios are 1.7 to 2.0 and 
1.3 to 1.5. It is not possible to differentiate further 
within these'two groups with certainty and King and Morgan 
(1970) further predicted that the phenotype EfEf would be 11 
found to occupy a position intermediate to the two groups. 
In fact the fluoride-resistant homozygote was found to be 
closer to the other suxamethonium-sensitive phenotypes 
than expected with 37 0 /25 0 and 37 0 /300 activity ratios of 
about 1.35 and 1.15 (King and Morgan, 1971). This makes 
segregation less certain using 30 0C and 370C as the assay 
temperatures but the difference between the sensitive and 
non-predictable groups is adequate when 25 0C and 37 0C are 
the temperatures employed. Differentiation would obviously 
be improved with greater divergence in the two temperatures. 
One hesitates to employ 500C which is close to the tempera- 
ture of denaturation but assays at 250C and 45 0C would give 
ratios of activities 
EaEa and a Ef respi 1111 
resistant homozygote 
phenotypes EuEa, Eu I11 
f orm the basis f or a 
about 0.85 and 1.0 for the phenotypes 
actively, about 1.2 for the fliioride- 
and from 2.0 through 2.35 to 2.65 for 
fuu E1 and E1E1 This could readily 
simple screening test of surgical 
patients for suxamethonium-sensitivity. 
However at this time there was no means of recording 
reaction rates at 240 nm with such temperature differentials 
which could be mechanised to give through-put rates 
compatible with screening procedures. The Unicam AC 60/1800 
system was the only available instrumentation which seemed 
I to have the capability. In co-operation with Mrs. Christine 
Witchell of the Applications Dcpartment of Pye-Unicam, 
L 
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Cambridge a study involving the use of inhibitors (Witchell, 
1971) and of different assay temperatures was carried out. 
The temperature change proved cumbersome and time-consuming 
and even reducing the scan-time to two minutes only permitted 
processing ten to fifteen specimens perhour. In addition, 
the instrumentation embodied no automatic range selection 
and permanent attendance at the spectrophotometer was 
essential. In later models of this spectrophotometer, 
Unicam have improved the sensitivity and introduced 
automatic adjustment of the absorption range so that 
screening for suxamethonium-sensitivity may now be a 
feasible proposition with this instrument. 
Continuous-flow mechanisation,. as in the Auto-Analyser 
systems is not capable of yielding valid enzyme reaction 
rate assays nor apparently even valid two-point determina- 
tions. In enzyme estimations the time of the reaction must 
be precisely known and the reaction temperature must be 
constant throughout the reaction. While it would seem 
possible to arrange these conditions, the writer is not 
aware of any fixed-time enzyme assay by continuous flow 
technology which does. Again the simple filter colori- 
meters employed in Auto-Analyser systems do not permit of 
recording absorptions at 240 nm. However, if a ratio of 
activities, as opposed to an absolute activity is all that 
is required then assays by continuous-flow mechanisation 
are permissible. The hydrolysis of thiocholine esters may 
be followed at 405 nm using Ellman's reagent and this removes 
the problem of recording absorptions in the ultra-violet 
range with a benzoylcholine substrate. This seemed an 
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eminently practical procedure and Dr. E. D. Lash of 
, Technicon Instruments Corporation, Tarrytown, 
New York 
expressed interest and was given the temperature-activity 
data and different phenotype samples. By an ingenious 
arrangement of splitting the sample-reactant stream into 
water baths at 37 0C and 55 
0C and by arranging for the 
signals from both colorimeters to be simultaneously drawn 
on the same recorder with peak heights made equal with 
usualýhomozygote sera, the presence of a suxamethonium- 
sensitive phenotype could be detected by a simple scrutiny 
of the chart (Lash, Ponzio, Rush and Garry, 1972). 
Further experiments and stu . dies in the field of mass 
screening are more fully and appropriately described 
later (page 103 et seq. ). 
As recorded earlier (page 10 et seq. ) variations in 
cholinesterase activity occur in certain disease states 
and in pregnancy (page 123) and some such specimens are 
included in Figures 14 and 15. Apart from this even in 
a normal healthy population the scatter of serum cholin- 
esterase activities is regarded as wide and contradictory 
reports and speculations abound to account for this. 
There would certainly appear to be a positive cor- 
relation between body weight and cholinesterase activity 
(Thompson and Trouce, 1956; Kalow and Gunn, 1959) and this 
factor may in turn be the major influence in the higher 
activities reported in males (Reinhold, Tourigny and 
Yonan, 1953; Breuer and Schbnfelder, 1961) or with age 
(Kalow and Gunn, 1959). In infancy, after the first 
week of life (Lehmann, Cook and Ryan, 1957) and in children 
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(King, 1965) significantly higher activities are reported-. 
These influences have either not been observed by other 
workers or positively refuted (lVetstone, Honeyman and 
McComb, 1965). 
These last workers from a study of twins, parents and 
sibs concluded on statistical evidence that there was a 
major genetic control of quantitative levels of cholin- 
esterase activity. On the other hand, Simpson and Kalow 
(1963) from a similar examination of monozygotic twins, 
like- and unlike-sexed dizygotic twins, sibs and parents 
concluded that the observed variation in cholinesterase 
activities was largely environmentally determined and found 
no evidence for any important homogenic or multigenic' 
control. 
With regard to the wide range of cholinesterase 
activity and its quantitative control it has not been 
i 
clearly stated that this. may be due to two possible causes. 
The first is an alteration in the rate of synthesis and 
could be caused either by a mutation in, or other influence 
on, a regulator gene, or by a similar effect in an unrelated 
gene resulting in a change of some inducer or repressor 
substance. This would involve a change in the actual 
number of enzyme molecules produced. The second cause could 
be the synthesis of an altered enzyme protein with consequent 
changes in either catalytic efficiency or structural 
stability. This does not envisage a change in the number 
of enzyme molecules produced, but a quantitative change in 
activity or in vivo stability secondary to a qualitative 
change in the enzyme. 
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The reduced catalytic activity of the unusual variants 
is readily appreciated (Figure 15) but of these only the 
genotypes EUEf and Eu Ea occur in a significant proportion 1111 
of the population, 0.4% and 47o respectively (Lehmann and 
Liddell, 1969). These therefore contribute to the observed 
scatter of serum cholinesterase activities. However this 
was appreciated by the protagonists of the genetic control 
of quantitative enzyme activity who accordingly selected 
their cases from the "usual" phenotype. Although they did 
not specify the mode of control it is therefore evident 
that they meant factors influencing the rate of synthesis 
as outlined above. About 951, o of the population are pheno- 
type EUEu and about 0,57o are probably genotype EUEs The 
latter certainly have reduced cholinesterase activity. The 
C5 variant E+ which confers additional cholinesterase 21 
activity occurs in about 10% of the population (Harris, 
Hopkinson and Robson, 1962). Already therefore in a 
selected phenotype, that regarded as normal, there are 
two inherited factors contributing to an extension at both 
ends of the "normal" range of activities. If these 
influences are eliminated from the population to be 
investigated it can be reasoned that the range of serum 
cholinesterase activities will be much reduced. Only then 
would the population also be free from the second cause of 
genetic quantitative control previously outlined. 
As it is the range of serum cholinesterase activities 
is not wide compared to other enzymes; the upper limit of 
normal is only twice the lower limit. For the normal 
ranges of aspartate transaminase and alanine transaminase 
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activities in serum the upper limits are four to five times 
the lower limits (King, 1973). The normal serum range for 
creatine kinase activities is 0 to 100 mU/ml, and this is 
doubtless environmentally and to a lesser extent hormonally 
controlled. The higher numerical values attached to serum 
cholinesterase activities are merely a reflection of its 
"serum specificity" (page 11). 
2. (b) Arrhenius Relationships. 
Rl 
Preliminary studies had indicated that the 50 jill 
benzoyl-choline employed in these studies although optimal 
for the usual enzyme at 25 0C was grossly suboptimal for 
the other allelic isoenzymes. At 25 0C the atypical enzyme 
exhibited maximal velocity with 100 pM benzoyleholine and 
this was the concentration required for substrate saturation 
of the usual enýyme at 37 0 C. It was realised that the 
activities recorded in the previous experiments did not, 
for the most part, represent maximum velocities and that 
the differences in thermal inactivation might be due to 
differences in substrate concentration requirements rather 
than true reversible alterations in protein structure. 
Specimens of the threp homozygous sera were therefore 
assayed through the temperature range at both 50 IiM and 
100 IN benzoylcholine concentrations. The results shown 
in Figure 16 would appear to indicate that the temperaturo 
of maximum activity, or more precisely, the temperature of 
zero activation energy is a reflection of the protein 
structure and relatively independent of the substrate 
concentration, altbough some substrate protection may be 
afforded at the temperature of irreversible denaturation. 
Arrhenius plots (Figure 17) taken from the data of 
Figure 11 reveal that the customary linear relationship 
can only be said to exist for the usual homozygote and 
heterozygotes and that over a very limited temperature 
range below 300C. While Figure 18 would appear to indicate 
that linearity of the relationship is extended by the use 
of 100 VII benzoylcholine this is probably fallacious since 
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r-igure 16. Temperature/activity relationships of the three 
cholinesterase homozygotes with 50-10.1 and 100 IiM 
benzoylcholine substrate in phosphate buffer, p1l 7.4. 
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Figure 17. Arrhenius relationships of serum cholinesterase 
phenotypes. These plots are taken from data of 
Figure 12 in which activities were referred to 
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Figure 18. Arrhenius relationships of the usual cholincsteraso 
enzyme at benzoylcholine concentrations of 50 IN 
and 100 VM. 
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at temperatures below 30 
0C (Figure 16) and this doubtless 
contributes to the extended linearity of the locus. This 
extended linearity with 100 pM benzoylcholine is therefore 
spurious and emphasises that a valid temperature-activity 
relationship can only be established by use of reaction 
conditions which are optimal at each temperature. 
As it is these studies were not only conducted at a 
fixed substrate concentration but also at a fixed hydrogen 
ion concentration. While the pII of a phosphate buffer 
does not change dramatically with temperature it must at 
the same time be conceded that the p1l 7.4 buffer employed 
by Kalow and Lindsay (1955) does not permit measurement 
of maximum activity. Except at the lower temperatures 
therefore and then only for the usual homozygote and 
possibly the usual/fluoride-resistant heterozygote were 
the conditions employed optimal, yielding maximal velocities. 
There was therefore evidence that the substrate concentration 
necessary for enzyme saturation, and lience the Michaelis- 
Ifenten constant, the Km, varied with temperature. Use 
could therefore be made of the Van't Hoff equation which 
relates the variation with temperature of the reaction 
0 
equilibrium with the standard enthalpy (A Hf) for the 
reaction. 
A Ho RT 
2d loge Keq 
f dT 
This however would only be valid if the Michaelis-Menten 
constant represented a true equilibrium constant. Since 
it is generally accepted that the reaction catalysed by 






+3 EH + Al. Ac. (Ell-Al. Ac. Alcohol + E. Ac. H0) EII + acid T: 1 2 
This complicates calculations based on a simple reversible 
chemical reaction. 
However the effect of temperature on the rate constant 
of a reaction is given by the Arrhenius equation 
E RT 2d loge k 2.303 X 1.98 T2 _d 
logr 
a dT dT 
where E. is the Arrhenius activation energy. 
The similarity of the precise thermodynamic Van't Hoff 
equation to the empirical Arrhenius equation can be recon- 
ciled by appeal to the theory of absolute reaction rates 
which postulates that the rate of a reaction is proportional 
to the concentration of an activated complex which is in 
equilibrium with the reactants and thus governed by the 
usual laws of thermodynamics. It can be shown that 
E, AT-I* + RT 
Where AII4- is the enthalpy difference between the actJ. vated 
complex and the reactants, that is, the enthalpy of 
activation which is related to the other thermodynamic 
functions, the standard free energy (AF*) and the standard 
entropy (AS*) of activation by the equation 
AFt = All* - TAS* 
The energy of activation is readily calculated from 
the differentiated Arrhenius equation 
4.56 T, T2 E -- 2 
10 9 T, 
ý 
T2 - Tj 
k2 
Where k is the ratio of recorded activities, proportional 
to the rate-limiting constant, at the temperatures T2 and T,., 
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that is, the Q 10 values if T2 and T, are 100 C apart. Table 9 
shows the activation energi. es so calculated from Q10 and Q5 
values for all six genotypes over the temperature range 
studied. 
The Arrhenius equation. 
d loge k Ea 
dT -ýfý2 becomes on integration 
E 
loge k loge A-a RT 
Ea 
Or -T -4.56 log k+4.56 log A 
Where A can be considered a constant provided the temperature 
range is narrow. Certainly over the range 20-30 0C linearity 
of the slopes can be accepted and A therefore considered 
to be a constant. Figure 19 shows the loci of variation 
of activation energy with temperature for all six genotypes 
over the temperature range examined. The slopos of the 
loci are then -4.56 log k, that is proportional to the 
logarithm of the rate-limiting rate constant. 
From this diagram it can be seen that the reaction 
catalysed by the three enzyme variants, the usual, fluoride- 
resistant and atypical cholinesterases have zero activation 
energies at 49.5 0 Cj 39.5 
0C and 33 0C respectively. Above 
these temperatures the reactions become exothermic. In 
addition to these points, previously recorded in earlier 
sections as temperatures of maximum activity, Figure 19 
would indicate that transitions in the rate-limiting steps 
occur for the usual enzyme at 46 0 C, the fluoride-resistant 
variant. at 40.5 0C and the atypical isoenzyme at 41 0 C. 
The latter two transitions occur in the exothermic phase 
















a , -L 
E 
15-20 9310 12000 9560 9310 10800 11500 
20-25 12400 10900 9310 8550 7730 6890 
25-30 11000 9550 9390 5930 5320 4600 
30-35 9440 9440 7650 3630 2155 730 
35-40 7830 7600 6320 1150 -1890 -3645 
40-45 6200 5870 3770 -4120 -10680 -7860 
45-50 2765 808 197 -13300 -14900 -13750 
50-55 -4380 -10800 -6950 -30600 -. 35900 -25800 
15-25 11650 11500 9620 9050 9050 9240 
20-30 11650 10050 9,150 7150 6550 5400 
25-35 10600 9550 8600 4790 3780 2390 
30140 8870 8630 7100 2470 187 -1450 
35-45 7480 6810 4940 -1495 -4490 -5680 
40-50 4620 3490 2095 -8650 -10880 -10680 
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Figure 19. Variation of activation energies with temperature 




of the reaction. Other transitional stages would appear 
to be indicated by change in slope of the loci at lower 
temperatures but there is no consistent pattern to these 
and it must also be conceded that at these temperatures 
the activities measured are comparatively low and hence 
least precise and reliable. 
It has been assumed earlier that at the temperature 
of zero activation energy, reversible alterations in the 
protein structure occur and it is tempting to speculate 
that further configuration changes occur in the enzyme 
molecule at the transitional points but there is no basis 
for this in the data from which these facts were obtained. 
It is however valid to suggest that at different tempera- 
tures short of protein denaturation, changes do occur in 
the rate-limiting steps which are-characteristic of the 
human serum cholinesterase variants. 
Because of the limitations outlined earlier it is 
not possible to derive, nor were the experiments designed 
to give, any absolute thermodynamic data regarding the 
enzymic activation. Indeed as far as these are concerned 
Dixon and Webb (1958) stated 
"In fact it must be admitted that 
remarkably little is known about 
any of these quantities and that 
such values as are given in the 
literature have meanings which 
are doubtful 
Certainly in biological work the symbol p is used instead 
of Ea to signify that the quantity measured may not be as 
rigorously defined as the energy of activation. That aside 
however the data recorded in this study would indicate 
that under the specific experimental conditions employed 
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there are temperature-dependent changes in the efficiencies 
with which the enzymes catalyse the hydrolysis of benzoyl- 
choline. In addition, at any specific temperature these 
efficiencies, as exemplified by the rate-limiting constant, 
of which the recorded activity is an index, also differ. 
Further, solely and specifically under the assay conditions 
employed the energies of activation at any on e temperature 
are an index of the relative catalytic efficiencies of the 
variants. While these values have no absolute significance 
they do have a valid relative meaning and this validity is 
most acceptable at temperatures where activities are most 
accurately measured and the response to change in tempera- 
ture most linear. 
These last stipulations inexorably suggest the range 
25-30 0C and between these values the energies of activation 
were calculated as 11.0 Kcals for the usual homozygote, 
9.55 Kcals for the usual/fluoride-resistant heterozygote, 
9.39 Kcals for the usual/atypical heterozygote, 5.93 Kcals 
I for the fluoride-resistant homozygote, 5.32 Kcals for the 
atypical/fluoridc-resistant heterozygote and 4.6 Kcals for 
the atypical homozygote. These represent mean values for 
the sera studied as illustrated in Figures 12 and 17. 
A study of these activation energies indicates that 
af with the possible exception of the E, E, phenotype the 
activation energies of the heterozygous sera are obviously 
not derived from a 50: 50 proportional activity of the 
two variants. If then X is taken as the fractional 
activity of the usual enzyme and Y that of the fluoride- 
resistant variant in the heterozygote, EUEf 11 
75 
11.0 X+5.93 Y=9.5 where X+Y=1 
or 5.93 X+5.93 Y=5.93 
Subtracting 5.07 X=3.57 
or X= . 704 
and X= . 296 
Similarly for the usual/atypical heterozygote 
11.0 X+4.6 Y=9.39 and 4.6 X+4.6 Y=4.6 
Subtracting 6.4 X=4.78 
or X= . 748 
and Y= . 252 
For the atypical/fluoride-resistant heterozygote 
5.93 X+4.6 Y=5.32 and 4.6 X+4.6 Y=4.6 
Subtracting 1.33 X=0.72 
or X= . 54 
and Y= . 46 
The proportions of activity due to the atypical and fluoride- 
af 
resistant enzymes in the E, E, phenotype are in excellent 
agreement with their relaýive proportions in the respective 
usual heterozygotes. 
As an independent check on the validity of these 
calculated proportions of activity in heterozygous sera 
the inhibition of the cholinesterase variants may be 
considered. The usuall fluoride-resistant and atypical 
enzymes have mean inhibitions of 80%, 65% and 207o respect- 
ively (Figures 2 and 29) in the presence of 10- 
5 11 dibucaine 
under the assay conditions employed. 
Uf Considering then the E1E, phenotype every 100 units 
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of activity comprises 
70 units Eu inhibited 807o = 14 units 1 
and 30 units Ef inhibited 657o = 10.5 units. 
therefore inhibited activity 24.5 = 75.5% inhibition. uninhibited lactivity 100 
Similarly for the EY Eal phenotype every 100 units of 
activity comprises 
75 units EU inhibited 807a = 15 units 1 
and 25 units Ea inhibited 207o = 20 units. 1 
therefore inhibited activity 35 657o inhibition. 
uninhibited activity 100 
af For the El E, phenotype every 100 units, of activity 
comprises 
It 46 units Et inhibited 20% = 37 units I 
and 54 units Ef inhibited 65% = 19 units I 
therefore inhibited activity 44% inhibition 
uninhibited activity 100 
These calculated inhibitions or dibucaine numbers are in 
excellent agreement with the mean values found for the 
heterozygous phenotypes (Figures 2 and 29). 
By the same procedure using mean fluoride inhibitions 
of 607o, 377o and 247o for phenotypes EuEu, EfEf and Ea Ea 111111 
respectively the calculated mean inhibitions for the hetero- 
zygotes EuEfpEuEa and EaEf are 537o, 51% and 317o, figures I11111 
which are in good agreement with the values determined 
experimentally. The same agreement is found between the 
calculated and experimentally determined figures for 
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It is a matter of common observation that the inhibitor 
numbers of heterozygous sera do not occupy a medial 
position between the homozygous phenotypes. For instance 
the mean dibucaine numbers for the usual and atypical 
enzymes are 80 and 20 respectively while that of the 
heterozygote is about 62. As discussed in greater detail 
later (page 86 et seq. ) in the heterozygote this could be 
due to an unequal rate of synthesis of the two variant 
enzymes, to unequal enzymic efficiences or a combination 
of both. However the foregoing data is independent of the 
absolute activity, that is, the quantity of enzyme, but 
solely reflects the catalytic efficiency of the enzyme in 
the same way that the turnover number-does. The foregoing 
calculations in equating enzymic efficiencies (V values) 
does not rule out the possibility of unequal rates of 
synthesis of the variants, but only show that in the 
heterozygote the activities due to to the enzymic species 
are not equal. 
However if one assumes equal molecular proportions 
of the usual and fluoride-resistant enzymes in the betero- 
zygote the percentage activity due to the usual variant 
would be 
100 x 11.0 1100 657o 
11.0 + 5.93 16.93 
By similar arithmetic it can be shown that on an equimolecular 
basis, the proportions of activity in the Eua and Ea Ef II11 
heterozygotes are 71: 29 and 44: 56 respectively. The inhibi- 
tions calculated from these proportions are shown in Table 10 
and if anything are closer to the exp6rimentally determined 
means than those calculated from equating the p values. 
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The difference between the two sets of calculated 
proportional activities in the heterozygotes are obviously 
not significant and can readily'be appreciated when it is 
considered that all the values involved are mean figures 
and there are cogent reasons to believe that the currently 
accepted variants are not homogeneous (p. go et seq. ). 
Certainly the foregoing indicates that there is no need to 
postulate a quantitative difference in the rates of 
synthesis of the enzyme variants in the hetcrozygous state; 
all the observed experimental facts are entirely resolved 
on qualitative differences. 
Confirmation of some of the experimental and derived 
data obtained in this study is to be found in the literature. 
Thus Kalow and Lindsay reported an activation energy of tho 
usual homozygote to be 11.2 Kcals/degrec/mole wiliell is ill 
good agreement with that recorded herein. Tile literature 
does not appear to contain values for the activation 
energies of the other cholinesterase variants. In the 
classical studies of Liddell, Lehman, Davies and Sharih 
(1962) the usual and atypical enzymes in heterozygous sera 
were separated by chromatography on diethyl amino-ethyl 
cel 
. 
lulose columns and by paper electrophoresis at P11 9.7. 
Determination of the cholinesterase activity in the chromato- 
graphy eluate fractions gave a usual to atypical ratio of 
69: 31 and from paper strip elution of 71: 29. These values 
are in excellent agreement with those obtained on an 
equimolecular basis in this study. No other such ratios 
appear to have been determined and Lehmann and co-workers 
did not seek confirmation of their activity ratios by 
79) 
calculating the inhibitions of the hetcrozygote from those 
of the homozygotes. 
2. (c) Inhibition of Benzoyleholine Hydrolysis. 
so 
Inhibition' of Denzoylcholine Hydrolysis 
In routine analysis of specimens referred from 
"suxamethonium apnoeas" and in preliminary studies, the 
inhibitions by 10 VII dibucaine (Kalow and Genest, 1957) 
and 50 Q sodium fluoride (Harris and Whittaker, 19G1) 
of the hydrolysis of a 50 pM benzoylcholine substrate in 
phosphate buffer, pH 7.4 and at 25 0C (Kalow and Lindsay, 
1955) have been found necessary and sufficient for precise 
phenotype identification. At an early stage in these 
investigations the inhibition by 500 nill sodium chloride 
(Whittaker, 1968b) was also included in the hope that 
correlations of the three inhibitors might yield further 
evidence to substantiate the claim (Whittaker 1968c) that 
its use revealed now phenotypes. 
It seemed reasonable that, in the specific clinical 
setting under investigation, that of suxamethonium apnoca, 
use of the causative agent, succiny1dicholine, as a differ- 
entiating substrate or inhibitor woul(I have potential 
advantages. The investigation of succiny1dicholine and its 
sulphur analogue as substrates is detailed later (p. 103et seq. ). 
In the light of modern theories of neuro-muscular-trans- 
mission, the classification of muscle-relaxant drugs becomes 
increasingly complex. In the classic picture which satisfied 
elementary stereochemical, pharmacological and physiological 
precepts, such drugs were separated into two categories, 
depolarising and non-depolarising. The former were long, 
thin molecules which achieved their effect by depolarising 
the motor end plate in the same way as acetylcholine. Indeed 
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Figure 20. Structural formulae of some substrates and inhibitors 
of cholinesterase. Other exnmples are'il2ustrated in 
Figure 1 indicating the affinity of cholinesterase 
for compounds containing a positively charged nitrogen 
atom particularly when linked to methyl or ethyl groups. 
ol 
through this so do the anti-acetyleholinesterases. These 
are therefore classed as depolarising agents. The non- 
depolarising relaxants were bulky molecules which acted 
post-synaptically by occupying the receptor sites for acetyl- 
choline. Succiny1dicholine and tubocurarine are the typical 
examples of depolarising and non-depolarising muscle 
relaxants respectively and their structural formulae are 
shown in Figure 20. 
Pancuronium, bromide (Pavulon) is a recently-introduced 
non-depolarising muscle relaxant. The structural formula 
(Figure 20) shows it to be steroidal with two methyl pyridine 
and two acetyl residues attached. It is interesting to 
note that in both instances the ester oxygens are separated 
by two carbon atoms from the quaternary nitrogens. Pharma- 
cologically the neuromuscular block produced by p-ancuronium 
is of curariformtype and stereochemically the molecule is 
typically non-depola-rising. However the presence of the 
methylated quaternary nitrogens and acetyl groups suggested 
possible anticholinesterase potential and this latter aspect 
was accordingly investigated. 
Instrtimentation, 'Metliods and Materials 
Instrumentatlon and methods were as described in the 
previous section (page 42). All assays were carried out 
at 25 0C unless otherwise stated. 
In addition to the reagents previously employed 
(page 43) succiny1dicholine chloride dihydrate was obtained 
from BDH Chemicals, Pancuronium bromide (Pavulon) from 
Organon Laboratories, tubocurarine chloride (Tubarine) 
from Burroughs Wellcome and gallamine triethiodide (Plaxedil) 
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from May and Baker Ltd. Aqueous solutions of these inhibitors 
were made up to different concentrations and 1 ml aliquots. 
employed as inhibitors in the assay scheme detailed earlier 
(page 44 ). 
Sera from six phenotypes, 100 usual homozygotes EUEu 1 11 
25 usual/fluoride-resistant heterozygotes EuEf, 61 usual/ 11 
atypical heterozygotes EuEa, 3 fluoride-resistant homozy- 11 
gotes EfEf 12 atypical/fluoride-resistant heterozygotes 1 11 
EaEf and 20 atypical homozygotes EaEa were used in defining 1111 
the phenotype ranges and in comparing inhibitor numbers. 
Experimental Results 
At a benzoylcholine concentration of 50 pM the 
succiny1dicholine concentration in the reaction mixture was 
varied from 5 11H to 100 mM. The inhibition curves obtained 
for the six commonly-recognised phenotypes are shown in 
Figure 21. These follow the typical sigmoid pattern. It 
was evident that maximum differentiation between the pheno- 
types was obtained at a1 mll concentration of succinyldi- 
choline in the reaction mixture. Preincubation of the 
reaction mixture without benzoylcholine, that is, buffered 
dilute serum in the presence of 1 mAl succiny1dicholine for 
periods up to one hour did not alter the percentage inhibition 
significantly. 
By employing a4 WvI aqueous solution of succinyl- 
dicholine (397 mg succiny1dicholine chloride dihydrate per 
litre) in the assay scheme outlined earlier the percentage 
inhibition (Scoline Number) was determined simultaneously 
with dibucaine, fluoride and chloride numbers on the sera 
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Figure 21. Inhibition of seruin cholinesterase activities by 
succiny1dicholine in the assay procedure of Halow 
and Lindsay (1955) at 250C. Theoretical concen- 
trations in the blood plasma following injection 
of 100 mg succinyldicholine are shown initially 


















Eu Eu Eu E Eu Ef E! E9 E! If Eý , , , , , 
Figure 22. Cholinesterase phenotype inhibitions by mM 
succinyldielioline in the presence of 50 VM 
benzoylcholine in phosphate buffer, p1l 7.4 
at 250C. 
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for succiny1dicholine inhibition in this survey over a 
period of two years are shown in Figure 22. In this illus- 
tration, the closed circles for the usual phenotype each 
represent three sera, the open circles, one specimen. 
Three anomalous values obtained from serum samples of two 
sisters were assigned to the atypical homozygote group 
where they are shown as open circles. 
Figures 23,24 and 25 illustrate the correlations 
between the distribution of Scoline numbers and dibucaine, 
fluoride and chloride numbers respectively. The remaining 
correlations are also illustrated between dibucaine and 
fluoride numbers in Figure 26, between dibucaine and chloride 
numbers in Figure 27 and between fluoride and chloride numbers 
in Figure 28. A point in the centre of a symbol in these 
diagrams indicates two sera with identical numbers. 
The phenotype ranges for all four inhibitors derived 
from this study are shown in Figure 29, (King, 1974). It 
should perhaps be emphasised that in this study whore a 
result was doubtful or of a controversial nature it was 
confirmed by repeated estimations. 
Pavulon is a solution of 2 mg pancuronium dibromide 
per ml that is 2.63 X 10-3 M. A dilution therefore of 1 ml 
Pavulon and 2.29 ml of water gives a solution 8X 10- 
4M 
with respect to the drug and 1 ml of this solution in a 
final assay mixture of 4 ml gives a reaction concentration 
of 2X 10-4 M. Dilutions to give reaction concentrations 
down to 2X 10-8 M were prepared and the inhibition of 
benzoylcholine hydrolysis by a variety of phenotype sera 
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Figure 25. Correlation of Scoline Numbers and Chloride Numbers 
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Figure 26. Correlation of Dibucaine Numbers and Fluoride Numbers 
for the cholinesterase ph-enotypes. 
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Fif: ure 27. Correlation ol Dibucaine 'Numbers and Chloride Numbers 
for the cholinesterase phenotypes. 
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rigure 29. Phenotype ranges of inhibitor numbers (percontage 
inhibition) by 10 1AI dibucaine, 50 Vt. %I sodium fluoride, 
500 al sodium chloride, mIM succinyldicholine in the 
presence of 50 11M benzoy1cholinc in phosphate buffer 
p1l 7.4 and at 250C. 
8117.1. 
Figure 30. 
Similarly for tubocurarine and gallamine, concentrations 
of the drugs to give reaction concentrations from 10- 
3M to 
-5 10 M were prepared and the inhibitions recorded. These 
are shown in Figure 31. 
Discussion 
Kalow and Genest (1957) made the observation that the 
dibucaine number of an individual remains remarkably 
constant even when the serum cholinesterase activity changes. 
This fact implies a constant proportion of the two enzyme 
variants in any particular heterozygote. Furthermore Kalow 
and Staron (1957) reported that even when the cholinesterase 
activity of a serum sample decreased upon storage, the dibu- 
caine number remained unaltered for as long as it could be 
determined. rnlis fact implies an equal in vitro stability 
of the cholinesternse variants. These observations of 
Kalow-and co-workers only applied to dibucaine inhibition 
and only knowingly to the usual and atypical variants but 
the in vivo constancy of percentage inhibition for all 
phenotypes and inhibitors. studied has been confirmed in 
the present study except in one set of circumstances (page 123 
While it has been noted that the usual and atypical 
isoenzymes-are apparently equally stable to storage the 
fluoride-resistant variant would appear to be somewhat less 
so under these conditions. 
The finding that preincubation of dilute serum with 
mll succiny1dicholine for one hour did not alter the 
percentage inhibition is in agreement with Kalow (1959a) 
who showed that the usual and atypical enzymes at this 
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concentration of succiny1dicholine hydrolysed about 80 jimol 
and less than 5 pmol per minute per litre respectively at 
30 0 C. This is equivalent to hydrolysis of 96 nmol and less 
than 6 nmol per hour by 20 ul of serum which from Figure 21 
would not result in any significant change in inhibition. 
The figures given by Goedde, Held and Altland (1968) for 
the spontaneous hydrolysis of succiny1dicholine are of the 
same order as that for the atypical enzyme. These workers 
studied the inhibition by succiny1dicholine of benzoyl- 
choline hydrolysis by the usual and atypical enzymes-and 
the curves they obtained are almost identical with those 
reported here (Figure 21). The literature does not appear 
to contain any similar. study relating to the other cholin- 
esterase phenotypes. 
The technical advantages to tho use of suecinyldicholiDe 
in differentiating the serum ChOliDCStorase variants are 
limite 
. 
d. Less skill is required in preparing the reingent. 
For a litre of solution an error of a few milligrams in the 
required 397 mg of succiny1dicholine chloride dihydrate 
will not significantly alter the results, whereas with 
dibucaine and sodium fluoride, 13.7 mg and 8.4 mg respectively 
must'be accurately weighed for one litre of solution. This 
robustness of the reagent does not extend to storage however 
where it was found to be no more stable than the dibucaine 
solution and, not unexpectedly, much less than the fluoride 
and chloride reagents. 
Lehmann and Liddell (1969) indicated that about one 
in 3,200 of the usual homozygote population is found to be 
moderately sensitive to suxamethonium and that this accounted 
nc 
for 371, lo of suxamethonium apnoeas. It had been hoped, 
rather than confidently expected, that employing the, actual 
causative agent as inhibitor might demonstrate a new pheno- 
type and permit differentiation of sensitive usual homozygotes. 
Eleven such individuals were tested during this survey and 
did not exhibit any difference to succiny1dicholine inhibition 
from the other usual homozygotes. 
There is nevertheless an undoubted advantage in inter- 
preting results from succiny1dicholine inhibition in that 
the difference between the means of the usual homozygotes 
(907o) and the atypical homozygotes (187o) is greater than 
that obtained with dibucaine. Figure 23 however indicates 
that there is a close correlation between the two inhibitor 
numbers. 
It is only a comparison of Figures 24 and 26 which 
shows any divergence of interpretation. Three of the 
specimens classified as EaEf by Scoline and fluoride number 11 
combination (Figure 24) would probably be classed as EuEa 11 
by dibucaine and fluoride numbers (Figure 26). It is not 
possible by family studies to decide this matter, although 
in one case involved in an apnoeic episode, it may be 
possible at a later date if there are any children. The 
wide range of inhibitor numbers which is found particularly 
in heterozygotes, has been the cause of much speculation 
and some experimental work. 
Apart from experimental error, there would appear to 
be two possible causes, either the synthesis of enzyme due 
to each gene is separately controlled, that is, the 
proportions of variants in heterozygous sera varies, or 
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there are numerous cholinesterase variants with different 
enzymic properties, mainly turnover number, but also possibly, 
relative stabilities. 
With regard to the experimental error, the assay of 
cholinesterase activity in these studies has an error of 
2.47o and replicate estimates of dibucaine number around 
20 and 80 have maximum variations of ±3 and ±1 respectively. 
The scatter of results due to experimental error can be 
readily calculated. Assuming a higher, rounded figure of 
37o for the coefficient of variation the ratio is independent 
of the actual level of cholinesterase activity which again 
for ease may be taken as the rounded figure of 1000 mU/ml- 
Then for the usual homozygote with 80% inhibition by 
dibucaine the outside limits of error are: 
2070 activity ±C. V. 206 to 194 -1 OT01/0 7, ýC-' tivityT. C-V- 970 1030 
that is, 79 to 81 
For the atypical homozygote inhibited 207 the limits of 
dibucaine number are: 
80% activity ±C. V. 824 to 776 100% a tivity TC. V. 970 1030 
that is, 15 to 25 
The fluoride-resistant homozygote with 65% inhibition by 
dibucaine will have limits: 
1 
3579 activity ±C. V. 360.5 to 339.5 1007o activity : TC. V. 970 1030 
that is 63 to 67 
The theoretical limits of dibucaine number due to experi- 
mental error so calculated and the actual ranges encountered 
(Figure 29) are shown in Table 11. The conclusion to be 
Table 11 
Dibucaine Numbers 
Phenotype Theoretical Range Experimental Range 
Eu Eu 80 ±1 77 - 83 1 1 
Eu 1 Ef 1 
75 ± 1.5 70 - 80 
Eu Ea 60 ± 2.5 54 - 69 1 1 
Ef 1 Ef 1 
65 ±2 64 - 67 
Ea Ef 50 ±3 41 - 56 
E Ea 1 
20 ±5 15 28 
8413 
derived from this is that, apart from the fluoride-resistant 
homozygote where only three values have been obtained to 
establish the actual range, the ranges of inhibitor numbers 
are real and not a result of lack of precision in the assay. 
Accuracy of activity measurement does not enter into these 
calculations since the inhibitor number is independent of 
the absolute level of activity. Accordingly the scatter 
of results due to experimental error in other inhibitor 
numbers follows the same pattern, being least (±l) at 
highest percentage inhibitions (80%) and greatest (±5) at 
lowest inhibitions (20'/0) with intermediate gradations. 
That different amounts of enzyme are synthesised 
through each gene was. postulated by Kalow and Staroll (1957) 
and Kalow (1959a). These workers noted that the distrIbIlLion 
curve of dibucaine numbers in what they termod the inter- 
mediate group was negatively skewed, th; tt is, the tall 
extended towards the lower numbers, and also that the 
position was asymmetric between the atypical and utsmal 
homozygote distributions. This observation has been amply 
confirmed in the present study (Figure 29). Kalow and 
Staron (1957) then mixed equal volumes of usual homozygous 
and atypical homozygous sera and both by calculation from 
means and by experiment found the dibucaine number to be 
61.5. When the mixture contained two parts of usual serum 
to one part of atypical serum the percentage dibucaine 
inhibition was 68.8. By this means they considered it 
possible to translate each dibucaine number of the inter- 
mediate group into a "percentage of atypical esterase" and 
found the mean to be 50.2 with a standard deviation of 9.0. 
The distribution curve obtained from these calculations was 
superimposed on the numbers determined experimentally but 
I 
it was found that "the fit of the data to this curve is 
imperfect". This is not surprising since from the data 
presented by Kalow and Staron (1957) and enlarged later 
Kalow (1959b) the series contained sera from atypical/ 
fluoride-resistant heterozygotes, the existence of which 
was not known at that time (Lehmann, Silk, Harris and 
Whittaker, 1960) and the existence of which they were 
endeavouring to disprove. 
The basic argument is unsupportable since in mixing 
equal parts of the two sera they assumed that they were 
mixing equal amounts of the two enzymes. In other words 
the argument was based on the premise that the genes in 
the atypical homozygote brought about the synthesis of enzyme 
molecules at the same rate as the genes in the usual 
homozygote and this was then used to prove that the genes 
in each individual mediated different rates of synthesis. 
On the contrary if the fact that the mean value obtained 
from their calculations of 50.2 is accepted as proof that 
the original assumption was correct (and the concordance 
with the values obtained in this study from thermodynamic 
data lends confirmation) then this in turn provides evidence 
that there is no genetic control of the number of enzyme 
molecules only of the type of enzyme molecule. 
Despite this apparently unappreciated argument in 
favour of genetic control of qualitative but not quantitative 
enzyme synthesis, Kalow (1959a) presented interpretation 
of some of the data of Kalow and Staron (1957) "assuming 
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genetical control of type and activity of cholinesterase" 
but concluded "while it is necessary to postulate a control 
of activity, the observed values do not conform rigidly". 
A study of the presentation reveals that even with an 
unexplained juggling of supposed proportions of activity 
due to each gene any semblance of conformity is only achieved 
in two members of the second generation and none at all in 
the third generation. 
Kalow (1959b) concluded his discussion: 
"However the total blood of a person 
contains nearly a kilogram of haema- 
globin and perhaps 20 mg of serum 
cholinesterase: the assumption is 
inescapable that the levels of 
proteins are under genetical control". 
This argument could readily be reworded to the alternative 
proposition and say that in the blood of adult humans there 
occur more than 100 variants of haemoglobin and to date only 
four of serum cholinesterase: the assumption is inescapable 
that numberous cholinesterase variants are as yet unidentified. 
I 
Certainly among the "silent gene" homozygotes hetero- 
geneity has been conclusively demonstrated (Goedde and 
Altland, 1968; Rubinstein, Dietz, Hodges, Lubrano and 
Czebotor, 1970) and either explicitly or implicitly the 
presence of subtypes has been suggested by chloride inhibition 
(Whittaker, 1968b; King and Dixon, 1970) by the effect of 
n-butyl alcohol (Whittaker, 1968a) or by substrate affinities 
(Irwin and Hein, 1966). 
The three sera of controversial phenotype (Figures 24 
and 26) can readily be explained on either premise but the 
concept that there may be numerous subtypes of cholinesterase 
gains support from the three anomalous results from two 
sisters who were classified as atypical homozygotes despite 
the unusually high inhibition values (Figure 22). This 
in turn could suggest that there is not a single entity 
at present classed as "usual", "atypical" or "fluoride- 
resistant" enzyme but that each of these designations 
embraces a heterogeneous population. There may well be 
therefore a continuous range of cholinesterases within 
that which is presently termed a phenotype and characterised 
by the enzymic properties of the molecular species. 
Unlike succinyldicholine, pancuronium is reputedly 
not hydrolysed by cholinesterase and its molecular structure 
would tend to support this. Under these circumstances any 
inhibition observed with pancuronium would not be an index 
of its rate of enzymic hydrolysis but of a simple blocking 
of the active site. From Figure 30 it can be soon that the 
effect of pancuronium on benzoylcholine hydrolysis is In 
general very similar to that of succinyldl. clioline. 
Pancuronium could therefore readily be employed for differ- 
entiating the allelic variants but for the lack of contrast 
in effect between the usual and fluoridc-resistant enzymes. 
The plasma levels of most injected substances show a 
biphasic, reduction, the first rapid followed by a more 
gradual decline. The half-life of the first phase is 
generally of the order 4-7 minutes. Five circulation times 
or about 7J minutes is usually accepted as necessary for 
even distribution of injected substances throughout the 
plasma and therefore it is inferred that the first rapid 
phase represents a transfer from the plasma to the inter- 





Figure 30. Inhibition of serum cbolinesteraso activities by 
pancuro-nium in the assay procedure of Nalow nnd 
Lindsay (1955) at 251C. Theoretical concentrations 
in the blood plasma following injection of -4 mg 
pancuronium are shown initially at A and after 
20-30 minutes at B. 
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Figure 31. Comparative inhibitions of serum cholinesternse 
activities by some depolarisinG and non-ftpolarising 
muscle relaxants. 
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as 5% of body weight and extraccllular fluid as 20-25% or 
3.5 litres and 14-18 litres. respectively in a 70 Kg person 
it can generally be assumed that 20-30 minutes after 
injection only 207b Of the calculated initial concentration 
will remain in the plasma. 
This highlights another difference between the inhibitions 
by succiny1dicholine and pancuronium. The maximal dose of 
100 mg succiny1dicholine assuming immediate even distribution 
would give a plasma level of 100 vM and after 20-30 minutes, 
assuming no hydrolysis, the concentration would be 20 1A. A. 
Neither assumption of course is justified but even at these 
maximal possible levels of 10 -4 M and 2X 10- 
5M (A and B in 
Figure 21) barely come into the range-of concentrations at 
which succinyldielioline inhibits benzoylcholine hydrolysis 
in vitro. On the other hand a full dose of pancuronium of 
7 mg would result in an initial plasma level of about 2.5 till 
and after 20-30 minutes 0.5 VM. Both of those levels (A and 
B respectively, Figure 30) are well within the effoctive 
range of in vitro Pavulon inhibition of benzoylcllolJ. ne 
hydrolysis, the initial level representing near maximum 
inhibition of the usual homozygote. 
As far as the writer is aware this is the first 
recording of anticholinesterase activity in a non-depolarising 
muscle relaxant at in vivo concentrations. Neither gallamine 
nor tubocurarine exhibit inhibition at such concentration 
(Figure 31). A dose of 15 mg of Tubarine gives an initial 
plasma concentration of 5 vM and 120 mg of gallamine about 
40 pM. 
2. (d) Effect of Temperature on Inhibition. 
fl') 
Introduction 
That the inhibitory action of. some compounds on serum 
cholinesterase activity alters with temperature has been 
known for some time. Thus King (1965) reported that the 
phenotype ranges of fluoride numbers which lie presented 
were only valid if the assays were performed in the 
neighbourhood of 25 
0 C. Heilbronn (1965) also recorded an 
increased inhibition by fluoride with decrease in reaction 
temperature as did McComb, La Motta and Wetstone (1965) 
who found the dibucaine and succiny1dicholine inhibition 
of o-nitrophenylbutyrate hydrolysis to be less affected. 
In making a plea for the adoption of a standard temperature, 
King (1967) illustrated the variation with temperature of 
dibucainc and fluoride inhibition which showed that these 
alterations were also dependent upon the enzyme variant. 
These early observations are confirmed and extended in the 
present studies (King and Dixon, 1970; King, McQtieen and 
Morgaiý, 1971). 
Instrumentation, Methods and Materials 
These were the same as described in the previous 
section except that a fourth inhibitor solution, 4 mM 
succiny1dicholine (King and Griffin, 1973) was included 
in some of the later experiments. 
The studies on the effect of heat on the inhibition 
of benzoylcholine hydrolysis followed the same protocol 
as previously in, that no allowance was made for change in 
optimum substrate or hydrogen ion concentrations with 
temperature, but the same concentrations of reactants and 
inhibitors were employed over the temperature range studied, 
94 
15 0C to 550C. 
Serum specimens from seven usual homozygotes, three 
usual/fluoride-resistant heterozygotes, seven usual/atypical 
heterozygotes, two fluoride-resistant homozygotes,.. three 
atypical/fluoride-resistant heterozygotes and seven atypical 
homozygotes were studied. 
Experimental Results 
The variation with reaction temperature of the per- 
centage inhibition (inhibitor number) of dibucaine, fluoride, 
chloride and Scoline (succinyldicholine) are shown for each 
phenotype in Figures 32 to 37. Although in some cases, 
because of paucity of numbers, the mean values are barely 
meaningful, these were calculated and are also shown in 
these diagrams. The phenotype mean inhibitor numbers were 
Collected for each inhibitor and these are illustrated in 
Figures 38 to 41. The ranges of inhibitor numbers 
established in this study for 25 0C (Fig. 29) are also 
shown in these latter diagrams as are also the expected 
ranges at 37 0 C. 
. The mean variations in the four inhibitor numbers 
for each 50C temperature range are listed according to 
cholinesterase phenotype in Tables 12 to 15. 
Discussion 
Although in the description of their assay procedure 
Kalow and Lindsay (1955) corrected activities to 26 0C and 
'reported them at this temperature, for the determination 
of dibucaine numbers., Kalow and Genest (1957) used a 
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Figure 35. Variation with temperature of tile inhibitor numbers 
of sera of cholinesterase phenotype Ef Bf. Each 11 
symbol represents one specimen and the lines, the 
mean values. 

























Figure 36. Variation with temperature of the inhibitor numbers 
of sera of cholincsterase phenotype Ea Ef. r 11 ach 
symbol represents one specimen and the lines, the 
mean values. 
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The brackets represent the phenotype ranges encountered 
at 250C and 370C. 
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between 210 and 250. Only if there was a difference in 
reaction temperature between the inhibited and uninhibited 
assays were the reaction rates corrected to 26 0 C. This 
obviously would not correct for any variation in inhibition 
with temperature and the earlier figures at least for 
dibucaine numbers given by Kalow and co-workers are suspect 
on these grounds. However, Kalow and Genest did state that 
"the influence of temperature on the intensity of inhibition 
was negligible within the narrow range from 21-25 ocit ) 
indicating that they were aware of the phenomenon. On the 
other hand, Harris and Whittaker (1961) in introducing the 
fluoride number did not mention any reaction temperature 
merely stating that it. was determined "in exactly the same 
way as dibucaine number determination". It was assumed 
therefore by some workers (Lee and Robinson, 1967) that 
the phenotype ranges of fluoride number were determined 
0 .0 at 2 -25 C, as they well may have been although Whittaker 
(19G4,1967) did stipulate a reaction ternperaturo of 
26.5 OC. This was also the temperature at which she deter- 
mined chloride numbers (Whittakor, 1968a, b) while King arid 
Griffin (1973) estimated succinyldicholine inhibition at 250C. 
In general, in the temperature range studied, all 
inhibitions were highest at the lower temperatures, except 
for the anomalous chloride inhibition of the family reported 
by King and Dixon (1970) as having low or zero chloride 
0 numbers at 25 C. These individuals were classified as 
either usual homozygotes or usual/fluoride-resistant 
heterozygotes and the loci of chloride numbers are shown 
in Figures 32 and 33 respectively. It was noted in these 
inhibition experiments, as in the previous benzoylcholine 
hydrolysis studies, that the presence of a silent gone 
did not alter phenotype behaviour. I 
Chloride inhibition was the least affected by change 
in reaction temperature and showed a similar pattern for 
all variants. As the temperature increases there is a 
small decrease in inhibition reaching minima about 35 
0C 
for the usual enzyme, 20 0- 300C for ihe fluoride-resistant 
variant and 400-45 0C for the atypical isoenzyme after 
which the inhibitor numbers increase. It is interesting 
to note that the heterozygous sera demonstrate intermediate 
minima and although it would be foolhardy to draw any 
conclusions from two experiments, the-erratic behaviour of 
the chloride number with the atypical/fluoride-resistant 
sera could possibly be construed as mirroring the widely- 
divergent minima of th6 two constituent variants (Figure 40). 
Variation with temperature of chloride inhibition of 
cholinesterase activity does not appear to be recorded in 
the literature. 
For all phenotypes, dibucaine and succinyldicholine 
inhibitions follow fairly similar patterns (Figures 32 to 
37). There is, in general, except for the fluoride-resistant 
enzyme a tendency to show a maximum about 200C, followed 
by a moderate decline in number to about 35 0- 40 0C and then, 
except for the atypical variant which shows an increase, 
a more rapid decrease in inhibition. It is difficult to 
explain the anomalous behaviour of the succiny1dicholine 
inhibition of the usual/atypical heterozygous sera except 
that these three specimens came from siblings and may not 
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be representative of the general atypical hetcrozygote 
population. 
Between 25 0C and 37 0C the dibucaine number falls by 
11 in the usual homozygote, by 15 for phenotype EfEf and 11 
by 7 for the atypical homozygote with generally intermediate 
values for heterozygotes (Figure 24 and Table 10). Between 
20 0C and 40 0C the average dibucaine inhibition of the usual 
enzyme decreases from 817o to 66% or a fall of 0.75 per 
degree in the dibucaine number. Over the same temperature 
range, Lee and Robinson (1967) reported a reasonably similar 
figure of 0.6 for what they termed the AD, 
'. Except for At 
this study (King and Dixon, 1970) the literature does not 
appear to record any information regarding the variation 
with temperature of dibucaine inhibition of cholinestorase 
activity for any of the other genetic variants. 
Over the range 25 0 to 37QC the mean scoline number 
decreases by 4 for the usual homozygote, by 11 for the 
fluoride resistant homozygote and by 6 for the atypical 
homozygote, values which are less than, but follow a 
similar trend to., the dibucaine number (Figure 41 and 
Table 15). For the usual homozygote-the change in scoline 
number is less than 0.3 per degree between 20 0C and 40 0 C. 
The picture for fluoride inhibition differs from the 
others, qualitatively in that there are no maxima or minima 
and, quantitatively in that there are greater changes 
amounting to reductions in the mean fluoride number of 25, 
21 and 15 for the phenotypes EuEu, EfEf and E a. Ea 111111 
respectively between 25 0 and 37 0 C. The heterozygotes show 
the appropriate intermediate changes (Figure 39 and Table 1.3)). 
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For the usual homozygote over the temperature range 200-40 0C 
there is a change of 2.2 in the fluoride number per degree. 
This is the identical value given by Lee and Robinson (1967) 
but is less than the 3.1 found by McComb, La Motta and 
Wetstone (1965). The latter authors employed o-nitrophenyl- 
butyrate as substrate however and the values are therefore 
not truly comparable. 
The values given in the. preceding paragraphs, 
particularly those referring to the fluoride number, tend 
to give the superficial impression that the inhibition of 
the atypical enzyme is least affected by temperature change. 
This results from the fact that, except for chloride, the 
inhibition of the atypical enzyme is much lower than tho 
other variants at 200-25 0 C. Perhaps the most valid index 
of sensitivity by phenotype is to take the inhibition at 
250C as standard and record the increase in tomporaturo 
necessary to reduce the inhibition by half. Expressed in 
this manner, fluoride inhibition is reduced to 50% at 34 0 CS 
350C and 390C for the phenotypes EaEa$EfEf and Ell E"' 
respectively (Figure 39). By the same procedure the 
dibucaine number at 25 0C of the fluoride-resistant homozy- 
gote is reduced by half at 460C but this does not occur 
with any other phenotype at less than 500C (Figure 38). 
Harris, Lehmann and Silk (1960) reported that there 
was "significant correlation between the dibucaine numbers 
and cholinesterase levels within the 'intermediate' group", 
that is the atypical heterozygote group, and indeed there 
is in general a correlation between the dibucaine number 
and the cholinesterase activity between the groups. The 
(Z)o I 
phenotypes with lowest dibucaine numbers tend to have 
lowest serum activities (Figures 14 and 15) and there is 
a distinct correlation between dibucaine number and 
suxamethonium sensitivity (Figures 2 and 29) with duration 
of apnoea under standardised conditions. This general 
precept only fails in the case of the fluoride-resistant 
homozygote with which dibucaine inhibition is similar to 
that of the atypical heterozygote, although the EfEf 11 
phenotype is invariably sensitive but EuEa individuals 11 
are rarely and unpredictably so. Again however this anomaly 
is resolved by a study of Figure 38 where it is seen that 
the dibucaine inhibition of the fluoride-resistant homozy- 
gote is more severely affected by increase in temperature 
than any other phenotype and at 370C the dibucaine number 
is sensibly that of the Ea Ef genotype which is invariably 
suxamethonium sensitive. The same applies to the other 
inhibitors, fluoride (Figure 39), chloride (Figure 40) and 
scoline (Figure 41) and Tables 12-15. 
Once more therefore this study has indicated the 
inadequacy of measurements at lower reaction temperatures 
to predict that which will happen at the functional 
temperature of the enzyme, 37 0 C, and for a true comparability 
between inhibitor number and sensitivity to suxamethonium 
the inhibition assays should be performed at 370C. 
In the absence of a thermostatically controlled 
spectrophotometer it is the ambient temperature which 
dictates the reaction temperature of cholinesterase assays. 
Schneider and Willis (1958) and Henry, Chiamori, Golub and 
Berkman (1960) found the temperature in the cell compartment 
Table 12 Variation of Percentage Inhibition with Temperature 
DIBUCAINE NUMBER 
Temperature 
Range 0 C) 
uu E1E uf E1E1 u EIE1 ff EIEI af EIE1 a a. E1E 
15 20 +2.5 -1.5 +1.5 -3.0 0 -3.5 
20 25 -1.0 -1.5 -0.5 -4.0 -0.5 -3.5 
25 30 -4.0 -1.0 -2.0 -6.0 -0.5 -3.0 
30 35 -4.0 -4.0 -1.0 16.5 -2.0 -3.5 
35 40 -6.5 -6.0 -0.. 5 -7.0 -7.0 -0.5 
40 45 -7.0 -7.5 -4.0 -9.5 -3.0 -0.5 
45 50 -7. o -7.5 -3.5 -11.5 -6.0 +2.0 
50 55 -12.5 -6.5 -8.0 -8.5 -7.0 +6.0 
Table 13 Variation of Percentage Inhibition with Temperature 
FLUORIDE NUMBER 
Temperature 
Range 0 C) 
uu E1E1. uf EIE1 ua E1E1 ff EIEI f E1E1 E1E1 
15 20 -9.0 -11.5 -8.5 -13.5 -9.0 -13.0 
20 25 - 10.5 -10.5 -6.0 -12.5 -9.0 -11.5 
25 30 -10.0 -7.0 -9.0 -10.5 -7.5 -6.5 
30 35 -10.5 -12.0 -9.0 -7.5 -10.0 -7.0 
35 40 -12.5 -9.0 -9.5 -6.0 -6.0 -4.0 
40 45 -8.0 -8.5 -7.0 -5.0 -0.5 -3.0 
45 50 - 7.0 -6.0 -6.0 -4.5 -2.5 -0.5 
50 55 -6.5 -4.0 -5.5 -1.0 0 -0.5 




Uu E1E1 uf EIE1 ua EIE1 ff E1EI af E1E1 aa EIE1 
15 - 20 -4.0 -2.0 -1.0 -3.0 +1.1 -1.5 
20 - 25 - 3.0 -2.0 -3.5 +0.5 -4.0 0 
25 - 30 -1.5 -2.0 -2.5 -0.5 +1.0 +0.5 
30 - 35 -0.5 -0.5 -1.5 +2.0 0 +0.5 
35 - 40 +1.0 +0.5 -1.5 +1.0 -3.0 -0.5 
40 - 45 +1.5 +0.5 -0.5 +1.0 +1.5 +0.5 
45 - 50 +3.0 +1.0 +1.5 -0.5 -1.0, +2.5 
50 - 55 +2.0 +1.5 +0.5 -2.0 0 -2.0 
Table 15 Variation of Percentage Inhibition with Temperature 
SCOLINE NUMBER 
Temperature 
Range (0 C) 
uu E1E1 uf EIEI ua EIEI ,ff E1E1 af EIE1 aa EjE I 
15 - 20 -0.5 -2.0 - -3.0 - -1.5 
20 - 25 +1.0 -1.5 +2.0 -4.0 -2.5 0 
25 - 30 -2.0 -3.0 +1.5 -4.5 -3.0 +0.5 
30 - 35 -1.0 -3.5 +1.5 -5.0 -5.0 +0.5 
35 - 40 -2.5 -3.5 +0.5 -5.5 -5.5 0 
40 - 45 -3.5 -4.0 +1.0 -G. 0 -5.5 0 
45 - 50 -5.0 -5.0 -2.5 -7.0 -5.5 +2.5 
50 - 55 -6.5 -6.0 -5.0 -8.5 -7.5 -2.0 
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of their spectrophotometers to be 50 to 70C above the 
ambient room temperature. In these laboratories in 
Glasgow Royal Infirmary, the bench temperature, out of 
direct sunlight, has been found to fluctuate between 18 0C 
and 32 0C during the year. This is probably a general range 
in these islands but is probably wider elsewhere. It was 
doubtless an appreciation of such high ambient temperatures 
which prompted the International Union of Biochemistry 
(1965) to reject the earlier advocacy of 250C by its Commission 
on Enzymes (I. U. B. 1961) and to recommend that 300C be 
used as the standard temperature. In many parts of the 
world however, even in these northern latitudes in summer- 
time, to maintain a euvette temperature of 30 0C requires 
thermostatic cooling of the instrument. This difficulty, 
the fact that a valid index of some enzymes is only obtained 
by assay at their physiological temperature (King and Dixon, 
1969; King and Morgan, 1970) and the desirability of 
exploiting the increased activity, and honce better precislon, 
at higher temperatures in the automation of enzyme assays, 
compellingly suggest the universal adoption of 370C as tho 
standard temperature for enzyme assays at least in clinical 
biochemistry (King, 1972). 
The variation with temperature in the inhibition of 
the allelic serum cholinesterase isoenzymes would appear 
to be a counter-argument to this proposal. This only 
applies to fluoride however under the assay conditions 
employed in this study since Figures 38,40 and 41 show 
that dibucaine, chloride and succiny1dicholine respectively 
can still provide a means of differentiating the cholin- 
esterase phenotypes at 37 0 C. With fluoride on the other 
I ol 
hand (Figure 39) the inhibition is extremely sensitive to. 
temperature change so that even at 30 0 C, far less 37 0C it 
cannot provide a reliable means of distinguishing the 
cholinesterase variants. 
As it is, even with current practices, the revelation 
that between 180C and 32 0 C, the ambient temperature range 
in these laboratories, the fluoride number alters by 1.4 
to 2.2 per degree change in reaction temperature, emphasises 
the need for strict temperature control of the reaction. 
From Figure 39 it can readily be seen that an alteration 
in reaction temperature of 2 0- 40C suffices to change the 
fluoride number from one phenotype range to that of the 
next. It has been recorded (King, McQueen and Morgan, 1971) 
that if the assays were performed at 20 0 C, the fluoride- 
resistant homozygote would give values for inhibitor 
numbers except scoline, which could lead to a classification 
uauf of E1EI or even E1E It was even speculated that the 
ff 
rarity of the phenotype El El (Lehmann and Liddell, 1969) 
might in part be due to a general failure to appreciate 
the necessity for strict temperature control. 
Kalow and Davies (1958) postulated that the structural 
difference between the usual and atypical enzymes involved 
an alteration in the so-called "anionic site" at which the 
positively charged grouping of some substrates and inhibitors 
(Figures 1 and 20) finds attachment. To check this hypothesis 
Bamford and Harris (1964) used the 'neutral' substrate 
a-naphthyl acetate with which it was argued that the anionic 
state would play little part while the postulated esteratic 
site would be the same for both enzymes. These later 
ioi 
workers found that with the Positively-charged inhibitors, 
dibucaine and R02-0683 (Kalow and Davies, 1958), at 
appropriate concentrations, differential inhibitions were 
obtained with a-naphthyl acetate similar to those with 
benzoylcholine. However they found the differential 
inhibition of the enzymes, with fluoride was minimal with 
a-naphthyl acetate in contrast to that obtained with a 
benzoylcholine substrate and concluded 
"However, some difference in the degree of 
inhibition of the two enzymes by fluoride 
does appear to be present even when naph- 
thyl acetate is used as substrate, and 
when therefore neither substrate not 
inhibitor is positively charged. This 
observation is not readily explained by 
the hypothesis in its simplest form, and 
it will clearly be difficult to assess its 
significance until more is known about the 
mode of action of the F- ion on the enzyme". 
Bamford and Harris (1964) followed the hydrolysis of the 
a-naphthyl acetate substrate at 37 
0C and the reduction in 
the obsorved differential inhibition by fluoride was 
probably entirely due to the reaction temperature and little 
influenced by the substrate. 
3. Thiocholine Ester Hydrolysis, 
, 7"", 
Thiocholine' Ester Ilydr'olysis 
Koelle (1957) used acetylthioclioline as a substrate 
for histochemical localisation of cholinesterase. The 
sulphur analogues of aliphatic choline esters have also 
been widely used in cholinesterase assays employing various 
indicator reactions to follow the liberation of thiocholine 
(Page 8). The most successful of these has been the reaction 
(Ellman, 1959) with 5,51-dithiobis-(2-nitrobenzoic) in which 
the liberation of the yellow anion of 5-thio-2-nitrobonzoic 
acid (Figure 42) is used to follow the enzymic hydrolysis 
at wavelengths 405-420 nm. Ellman, Courtney, Andres and 
Featherstone (1961) were the first to employ this principle 
for assay of acetyleholinesterase and Garry and Routh (1965) 
for human serum cholinesterase. Since then numorous modifi- 
cations (Augustinsson, 1971) havo appeared, all employing 
acetylthiocholine or butyrylthiocholino as substrate, except 
for the recently published Selected Method of the American 
Association of Clinical Chemists which uses prop Iony 1 thio- 
choline (Dietz, Rubinstein and Lubrano, 1973). 
The validity of using thiocholine esters as substrates 
has been established therefore and the kinetics of the 
reactions apparently well investigated, certainly for the 
acetyl and butyryl esters. Augustinsson (1971) concluded 
that "the principle described by Ellman and his co-workers 
represents one of the most straightforward methods developed 
for___cholinesterase experiments". Only one disadvantage can 
be attributed to the principle. Unlike benzoyleholine for 
which Kalow, Genest and Staron (1956) estimated a half-life 
at bench temperature of 21 years, the thiocholine ester 
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Figure 42. The reactions involved in estimating thiocholine 
aster hydrolysis. 
solutions are not very stable and non-enzymic hydrolysis 
cannot be ignored. 
Initially it had been thought that succiny1dicholine 
would be an excellent substrate for differentiating the 
suxamethonium sensitive individuals by cholinesterase activity 
alone. However preliminary experiments in following the 
change in pII by means of the Astrup micro-equipment (Johnson 
and Whitehead, 1965) revealed this to be too insensitive. 
This did lead to the studies of succiny1dicholine as a 
differential inhibitor however (p. 80 et seq. ) and the search 
for a commercial source of succinyldithiocholine. This 
substrate has only recently become commercially available 
(Boehringer Corporation) following the studies of Gibson 
and Brown (1972). 
Instrumentation, Methods and Materials 
Initially, studies with thiocholine esters were 
carried out at 410 nm on a Unicam SP800 recording spectro- 
photometer with scale expansion to a Servoscribe recorder 
and temperature control given by a Shandon circulating 
heater and waterbath. The major part of the work herein 
reported however was carried out on an LKB 8600 Reaction 
Rate Analyzer with 410 nm filter system. This is a fixed- 
temperature instrument, operating at 37 0C and therefore not 
capable of accomodating temperature studies. It was modified 
however by Mr. J. Gilchrist, the LKB Scottish Region Engineer 
to have a variable temperature control (Figure 43) between*20 
0C 
and 500C in steps of 50C (King and Ritchie, 1974). At first, for 
temperatures below ambient, this instrument was operated in 
the cold room, but was more conveniently employed in con- 
Figure 43. Temperature modification to the LKB 8600 Reaction 
Rate Analyzer. 
Figure 44. Complete instrumentation for reaction rate analysis 
of thiocholine ester hydrolysis comprising modified 
LKB 8600 analyzer, LKB 8610 cooling stage, LKB 6500 
flat bed recorder, LKB 8200 calculator and Data 
Dynamics 390 ASR teletype. 
01. I 
r- 
junction with an LKB 8610 Cooling Stage for which the generous 
support of the New Medical Developments Committee of the 
Scottish Home and Health Department is gratefully acknowledged. 
This last apparatus holds the reaction temperature at 
25 0C against an ambient temperature of 32.5 0 C, the highest 
experienced during its period of operation. As a cooling 
device it is very slow however, taking 2 hours to cool the 
reaction tunnel of the analyzer from 450C to 250C at ambient 
temperatures around 30 0 C. It was found that keeping the 
cuvette racks in the deep freeze (-20 
0 C) and processing 
these through the tunnel reduced the temperature in a matter 
of minutes. The same result was obtained more conveniently 
by a solid brass block of identical dimensions to the euvette 
rack which was manufactured to order by Watson-Balgray 
Engineering of Glasgow. Latterly, the instrumentation was 
largely automated by the addition of an LKB 8200 Calculator 
and Data Dynamics 390 ASR teletype (Figure 44). The LKB 
8600 Reaction Rate Analyzer was further modified in that the 
timing-cam was cut for a 30-second differential. For the 
, experiments 
described it was found that a 30-second scan was 
sufficient for precise, accurate results and the reduced 
pre-incubation time of 71 minutes was just sufficient for 
the rack, cuvette and contents to reach the selected reaction 
temperature (King, 1973). Initially temperature control 
was checked by means of a Wayne Kerr contact thermometer and 
latterly by a Light Laboratories 3GID Temperature 11onitor 
with an IRM probe. 
In addition to the reagents previously employed (p. 43 
and p. 82) acetylthiocholine iodide was obtained from 
106 
Boehringer Corporation (London) and DDII Chemicals, propionyl- 
thiocholine iodide from Sigma Chemical Corporation, butyryl- 
thiocholine iodide from BDH Chemicals, succiny1dithiocholine 
iodide from Boehringer Corporation (London) and Ellman's 
reagent, 5,5'-dithio-bis(2-nitrobenzoic acid) from Boehringer 
Corporation (London) and BDII Chemicals. 'No significant 
difference was found between reagents from alternative sources. 
For these studies the following solutions were 
prepared: 
(i) 50 mg DTNB (5,51-dithiobis-(2-nitrobenzoic acid) 
dissolved in 50 ml 67 mM Sbrensen phosphate 
buffer, pH 7.4. 
(ii) 160 mg acetylthiocholine iodide dissolved in 
10 ml of reagent (i). 
165 mg propionylthiocholine iodide dissolved 
in 10 ml of reagent (1). 
(iv) 105 mg butyryltliioelioline iodide dissolved In 
10 ml of reagnet (i). 
(v) 60 mg succinyldithiocholine iodide dissolved 
in 10 ml of reagent (i). 
Addition of 100 Q of these substrate-DTNB solutions to give 
a reaction volume of 1.1 ml produced final substrate concen- 
trations of 5W acetylthiocholine, 5 mM propionylthyocholine, 
3 0.1 butyrylthiocholine and I mM succiny1dithiocholine. 
The enzyme sources for these studies were human sera, 
the phenotypes of which had been determined as detailed in 
the preceding sections. For assay of cholinesterase activity 
on the LKB 8600,20 pl of the reqiiired serum was diluted 
with 20 ml of 67 mM phosphate buf 'r, pH 7.4. One millilitre 
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of this diluted serum was then placed in a euvetto and the 
reaction started by the automatic priming with 100 V1 of 
substrate-DTNB solution. For the inhibition studios, 20 P1 
of serum was diluted with 10 ml of buffer; 0.5 ml of this 
dilution and 0.5 ml of inhibitor in buffer were then placed 
in the euvette and the assay continued as above. 
For the acety1cholinesterase experimcnts human erythro- 
cytes were twice washed in 0.9% saline and then haemolysed 
by adding 100 vl of packed cells to 10 ml of distilled water. 
After centrifugation this preparation was employed as the 
source of human acetylcholinestorase. To 1 ml of buffer 
containing varying concentrations of inhibitor, 200 pl of 
haemolysate was added and the reaction started as indicated 
above by priming with 100 V1 of ace-tylthiocholine. F or 
these experiments the acetylthiocholine-DTNB (roagent (ii), 
p. 1OG ) was diluted I in 10 with phosphate buffer to Vivo 
a final substrate concentration of 0.5 mM, optimal for 
acetyleliolinesterase. 
Although the level of non-enzymic hydrolysis was 
constant for each series of experiments a blank to monitor 
this was included in each raci-ý of ton cuvettes. 
Experimental Results 
Preliminary experiments to establish optimal assay 
conditions by investigating the variation of enzyme activity 
with substrate concentration, buffer and pH, confirmed the 
lability of the thiocholine esters. The non-enzymic or 
spontaneous hydrolysis obviously increased in the order 
butyryl-, propionyl-, acetyl-, succinyl-, and while the 
percentage rate of hydrolysis remained sensibly constant 
10 20 
the absolute amount of product obviously increased with 
substrate concentration (Figure 65). The spontaneous 
hydrolysis also increased with p1l (Figure 45). An 
observation from standard cysteine curves prepared at dif- 
ferent pH values appeared to indicate that the absorption 
at 410 nm of the 5-thio-2-nitrobenzoate anion I increased 
with pH. To check this 0.5 ml each of aqueous cysteine 
solution and DTNB solution were added to 3 ml of different 
buffers of varying pH values. Blanks with water substituted 
for cysteine solution were also prepared. Absorptions were 
recorded at different temperatures and at various time 
intervals. Typical results are illustrated in Figure 46. 
These results confirmed the original observation and 
indicated that tile increase in spontaneous hydrolysis with 
p1l was in part due to the increased absorption of tile. 
indicator ion with p1l. This also meant that the obsei, ved 
variation in enzyme activity with hydrogen ion concentration 
was similarly affected. ' This latter phenomenon and the iioli- 
enzymic hydrolysis of the thiocholine esters were largely 
the determinants in deciding to retain tile buffer msed in 
previous experiments, that is, 67 mll Sbrensen phosphate 
buffer, p1l 7.4 and substrate concentrations of 5 mM, 5 mM 
and 3 mAl for acetyl, propionyl- and butyrylthiocholine 
respectively at 37 0 C. ese were the standard assay con- 
ditions employed in all later experiments. The correctness 
of this decision gained Support from the work of Szasz (1968a) 
who, at 250C, used 50 mM tris buffer and 2 mIT butyrylthiocholine. 
This worker also recorded that the optimum for acetylthio- 
















Figure 45. Variation of non-enzymic hydrolysis of butyryl- 
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Figure 46. * VariatJon in the absorption at 410 nui of the 
S-thio-2-nitrobenzoate anion (Figure 42) with 
p1j, typo of buffer and temperature. 
U 
at least 5 n2M. This increase in 
concentration does however raise 
conside'rably the autolysis of the 
substrate". 
Consequently Szasz used a2 mM concentration of acetyl- 
thiocholine at 25 0 C, thereby indicating similar experiences 
to those described above. 
Experiments with succiny1dithiocholine were disap- 
pointing due to the spontaneous hydrolysis at 37 0C (Figure 
65). In many cases particularly with sera from suxamethonium- 
sensitive phenotypes or with low normal activities, 907o or 
more of the recorded change in absorption was due to non- 
enzymic factors. Studies with succiny ldithiocholine were 
not continued because of this lack of sensitivity in the 
assay. 
Inhibition of the cholinesterase hydrolysis of the 
thiocholine esters was only examined with % view to establish- 
ing that the characteristics of the variants exhibited with 
. benzoyleholine were also shown with these substrates. 
Figures 47,48 and 49 illustrate the effects of increasing 
dibucaine concentration of the hydrolysis at 37 0C of 5 mAl 
acetylthiocholine. 5 mM propionylthiocholine and 3 mll 
butyrylthiocholine respectively by the six cholinesterase 
phenotypes studied. Similar curves were obtained using 
succiny1dicholine, chloride and with certain anomalies, 
fluoride as shown in Figures 50 to 58. 
To complete studies reported earlier (p. 83 et seq. ) 
the inhibition of erythrocyte acetylcholinesterase hydrolysis 
of acetylthiocholine was also examined and the results with 
pancuronium and tubocurarine are shown in Figures 59 and 60 
respectively. Gallamine inhibition was also attempted in 
ilo 
these acety1cholinesterase experiments but addition of the 
substrate-DTNB solution produced such an intense yellow 
colour that recording of reaction rates was not possible. 
Although the May and Baker leaflet on Flaxedil gave no 
indication as to the possible cause of this phenomenon the 
British Pharmacopoeia (p. 334) indicates, that for injection, 
gallamine triethiodide is dissolved in 0.27o w/v sodium 
sulphite. 
It was evident at an early stage of preliminary 
studies that the relative rates of hydrolysis of the different 
substrates varied with the serum phenotype. This had also 
been observed with a wide range of choline esters (Davies, 
Marton and Kalow, 1960) with acetylcholine and benzoylcholine 
(Rubinstein and Dietz, 1963) and with acetylcholine, benzoyl- 
cholinc, procaine and tetracaine (Smith and Foldes, 1972). 
At most these studies only compared the usual and atypical 
homozygotes and the heterozygote. To extend these observations 
sera from 34 usual homozygotcs, 5 usual/fluoride-resistant 
heterozygotes, 21 usual/atypical heterozygotes, 2 fluoride- 
resistant homozygotes, 4 atypical/fluoride-resistant heterozy- 
gotes-and 11 atypical homozygotes were assayed under the 
prescribed conditions at 37 0 C. The best differentiation was 
obtained with acetylthiocholine and butyrylthiocholine and 
is shown in Figure 61. 
The results of the temperature studies with t'he three 
thiocholine ester substrates and six phenotypes are 
illustrated in Figures 62,63 and 64. In these figures the 
spontaneous hydrolysis (Figure 65) is allowed for but no 
account is taken of the increase in absorption with tempera- 
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Figure 47. Dibucaine inhibition of aectylthiocholine hydrolysis 
by cholinesterase phenotypes at 370C, with a reaction 
concentration of 5 mIJ acetylthiocholine in 67 idl 
Sbrensen phosphate buffer p1l 7.4. 
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Figure 48. Dibucaine inhibition of propionylthiocholino 
hydrolysis by cholinesterase phenotypes at 37CIC 
with a reaction concentration of 5 mM propionyl- 
thiocholine in 67 mM Sdrensen phosphate buffer, 
p1l 7.4. 
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rUgurc 49. Dibucaine inhibition of butyrylthiocholine hydrolysis 
by cholinesterase phenotypes at 370C with a reaction 
concentration of 3 mM butyrylthiocholine in 67 ml-I 
St3rensen phosphate buffer, pll 7.4. 
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Figure 50. Succinyldicholine inhibition of acetylthiocholine 
hydrolysis by cholinesterase phenotypes at 370C 
with a reaction concentration of 5 mM acetylthiocholine 
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Figure 51. ocuccinyldicholine inhibition of propionylthlocholine 
hydrolysis by cholinesterase phenotypes at 370C with 
a reaction concentration of 5 mM propionylthiocholine 
in 67 mV S13rensen phosphate buffer, p1l 7.4. 
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Figure 52. Succinyldicholine inhibition of butyrylthiocholine 
hydrolysis by cholinesterase pheiiotypes at 370C with 
a reaction concentration of 3 WA butyrylthiocholine 
in 67 WA Sbrensen phosphate buffer, p1l 7.4. 
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Figure 53. Sodium chloride inhibition of acetylthiocholine 
hydrolysis by cholinesterase phenotypes at 370C 
with a reaction concentration of 5 mlil acetyl- 
thiocholine in 67 mAI S8rensen phosphate buffer, 
p1l 7.4. 
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FIBU - re 54. Sodium chloride inhibition of propionylthiocholine 
hydrolysis by cholinesterase phenotypos at 370C 
with a reaction concentration of 5 WA propionyl- 
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Figure 55. Sodium chloride inhibition of butyrylthiocholine 
hydrolysis by cholinesterase phenotypes at 37oC 
with a reaction concentration of 3 mM butyryl- 
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Figure 56. Fluoride inhibition of acetylthiocholino hydrolysis 
by cholinesterase phenotypes at 370C with a reaction 
c, oncentration of 5 mM acetylthiocholine in G7 mM 
SUrensen phosphate buffer, pill 7.4. The curves for 
the other phenotypes lie between those extremes 
shown and are omitted for clarity of presentation. 
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Figure 57. Fluoride inhibition of propionylthiocholine hydrolysis 
by cholinesterase phenotypes at 370C with a reaction 
concentration of 5 mM propionylthiocholine in 67 el 
SUrensen phosphate buffer, pli 7.4. 
Butyrylihiocholine 












20-- / o" 
10 
-log MoVI Sod; u,, % rivoride 
Figure - 58. Fluoride inhibition of butyrylthiocholine hydrolysis 
by cholinesterase phenotypes at 370C with a reaction 
concentration of 3 mM butyrylthiocboline in 67 Al 
SUrensen phosphate buffer, pH 7.4. 
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Figure 59. Pancuronium inhibition of acetylthiocholino hydrolysin 
by serum cholinesterases and erythrocyte acetyl- 
cholinesterase at 370C. For the cholinesterase assays 
a reaction concentration of 5 mlla acetylthiocholine and 
for the acetylcholinesterase studies of 500 1AI 
acetylthiocholine in 67 mAl Sbrensen phosphate buffer, 
p1l 7.4 were employed. 
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Figure 60. Tubocurarine inhibition of acetylthiocholine hydrolynis 
by serum cholinesterases and erytbrocyto neutyl- 
thiocholinesterase at 370C. For the cholinesteraso 
assays a reaction concentration of 5 mM acetylthlocholine 
and for the acety1cholinesterase estimations of 500 VIA 
acetylthiocholine in 67 M Sbrensen phosphate buffer, 
pH 7.4 were employed.. 










Figure 61. Ratios of activities at 370C with 3 mM butyrylthiocholine 
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Figure 62. Temperature/activity curves of serum cholinesteraso 
pbenotypes with a5 mM acetylthiocholine substrate 
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Figure 63. Temperature/activity curves of serum cholinosterase 
phenotypes with a5 mM propionylthiocholine substrate 
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Figure 64. Temperature/activity curves of serum cholinestorase 
phenotypes with a3 iyM butyrylthiocholino substrate 
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Figure 65. Variation of the non-enzymic hydrolysis of 
thiocholine esters with reaction temperature. 
om 
ture of the indicator ion (Figure 46). 
Discussion 
The non-enzymic hydrolysis of the thiocholine esters 
varies with the hydrogen ion concentration (Figure 45), 
substrate concentration and reaction temperature (Figure 65) 
and even the absorption of the indicator ion, 5-thio-2- 
nitrobenzoate, varies with pH and temperature (Figure 46). 
These facts, some apparently unappreciated by other workers, 
make this assay less ideal and reliable than that based on 
benzoylcholine hydrolysis. 
Interpretation of results from benzoyleholine hydrolysis 
however must always be viewed from the background knowledge 
that this ester is hardly acceptable as- a physiological 
substrate. Nonetheless if similar behaviour is exhibited 
by other substrates with close chemical affinity to naturally 
occurring esters then it may be concluded that these inter- 
pretations are real and valid. Therefore despite the doubts 
engendered by the preliminary investigations into the assay 
principle, the study was continued albeit bearing in mind 
that all that was sought or expected was generally confirm- 
atory evidence. As a consequence no absolute values were 
recorded in these studies, only relative figures such as 
percentages and ratios. 
The inhibition studies with dibucaine., succinyl- 
dicholine and chloride amply provided the confirmation that 
these substances reacted with the enzyme protein. For 
dibucaine the concentration giving optimal differentiation 
between the phenotypes was 10- 
4 if with all three substrates. 
For acetylthiocholine and propionylthiocholine this gave 
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inhibitions about 657o, 307o and >10,, ýo' for the homozygous 
phenotypes EuEu*EfEf and EaEa respectively (Figures 47 111111 
and 48. With butyrylthiocholine (Figure 49) these values 
become 757o, 407o and 107o. The difference in these inhibitions 
does not necessarily betoken a contrast in the handling of 
the substrates but is probably related to their concentrations, 
5 mM for the acetyl and propionyl esters, 3 mM for butyryl- 
thiocholine. When the dibucaine concentration is reduced 
proportionally to 6X 10- 
5 1.1 the inhibitions obtained with 
butyrylthiocholine are identical to those obtained at 10- 
4 hi 
with the other two substrates. This is the expected 
behaviour of a simple competitive inhibitor. 
The improved differentiation of-'the fluoride-resistant 
homozygote from other phenotypes is probably not a reflection 
of its behaviour in the presence of thiocholine ester 
substrates but rather of the reaction*temperature, 37 0 C. it 
was noted earlier (Figure 35) that the inhibitions of the - 
fluoride-resistant homozygote were more sensitive to tempera- 
ture change than the other phenotypes and at 37 0C yielded 
inhibitions more consistent with its known suxamethonium 
sensitivity (p. 99). 
Succiny1dicholine is also a competitive inhibitor 
and its bohaviour is therefore unexpected. The inhibitor 
concentration giving maximum differentiation is 10 mM at 
which the atypical homozygote is inhibited 107o irrespective 
of substrate. Under the same conditions the usual homozygote 
is inhibited 70', 10 with acetylthiocholine, 557o with propionyl- 
thiocholine and 657o with butyrylthiocholine. Proportional 
adjustment of succiny1dicholine concentration to 6 rrM reduces 
11 
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the butyrylthiocholine inhibition to 551, lo. It is interesting 
to note that the optimal differentiating concentrations for 
both dibucaine and succinyldicholine are tenfold greater 
than those employed with benzoylcholine. Although not 
directly comparable because of the different substrate 
concentrations employed and the use of tris buffer of pIl 7.2 
similar results to those described here for dibucaine and 
succinyldicholinc were reported by Garry (1971). 
With sodium chloride the differential inhibition of 
phenotypes is much reduced and is fairly constant between 
0.01 and 1.5M. Again the loci for the propionyl and 
butyryl esters are very similar with acetylthiocholine 
giving a slightly different picture and better segregation. 
Nonetheless at 0.01 sodium chloride the usual homozygote is 
inhibited about 207o and the atypical homozygote about 45% 
with all three substrates. 
With sodium fluoride the most bizarre results are 
obtained with distinct progressive variations depending upon 
the substrate. The degree of inhibition for all phenotypes 
increases with substrate chain length. At lower inhibitor 
concentrations the relative phenotype inhibitions are the 
reverse of that found with a benzoylcholine substrate but 
with increasing concentration of fluoride this becomes 
inverted. The first part of these curves with the atypical 
variant more inhibited than the usual enzyme is illustrated 
by Garry (1971) using a butyrylthiocholine substrate. This 
worker did not continue the fluoride concentration beyond 
5X 10- 4M at which he was obtaining almost complete 
inhibition of all phenotypes. The effect of other inhibitors 
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were examined by Garry at 37 0C but strangely the fluoride 
experiments were conducted at 25 0 C. Heilbronn (1965) had 
already noted that fluoride inhibition of butyryleholine 
hydrolysis increased with lowering of temperature as noted 
in this study with a benzoylcholine substrate (Figure 39). 
Garry (1971) did employ higher concentrations of 
4 
fluoride up to 10- 
2 14 but in these experiments in tris buffer. 
At these higher concentrations the usual enzyme was inhibited 
to a greater extent than the atypical variant, the inversion 
to the situation found with benzoylcholine substrate. This 
inversion was attributed to the effect of the change in 
buffe r from phosphate to tris. Certainly in tris buffer the 
inhibitory effect of fluoride is much reduced as well as 
the relative phenotype inhibitions inverted to that found 
in phosphate buffer. This phenomenon is made use of by 
Garry, Owen and Lubin (1972) to differentiate the fluoride- 
resistant variants by duplicate assays at 215 0C in phosphate 
and tris buffer, with and without addition of fluoride. 
Obviously from the results obtained in this study (Figure 58) 
the same differentiation could be obtained at 37 0C in 
phosphate buffer alone at two fluoride concentrations, say 
10- 4 11 and 10- 
2M 
with a butyrylthiocholino substrate. 
In the Selected Method of the American Association of 
Clinical Chemists (Dietz, Rubinstein and Lubrano, 1973) a 
2 mM propionylthiocholine substrate, with 4 mll sodium 
fluoride, phosphate buffer, )? H 7.6 and reaction temperature 
of 37 0C is recommended. These conditions yield highest 
percentage inhibitions with overlapping ranges for the usual 
(78-81%) and atypical homozygotes (82-867o) and the heterozyLgote 
115 
(78-827o), lowest values of 54 and 657o for the fluoride- 
resistant homozygote and 67-697o for the atypical/fluorido- 
resistant heterozygote. Obviously the conditions chosen 
are close to the point of inhibition inversion and incredibly 
in an official Selected Method this would appear not to 
have been appreciated. 
In unrecorded experiments on benzoylcholine hydrolysis 
it was found that at the inhibitor concentrations routinely 
employed (page 43) increasing the substrate concentration 
from 50 vII to 100 vM reduced the inhibition by the competitive 
inhibitors, dibucaine and succiny1dicholine by about 10%, 
but increased the fluoride number by about 10. The complexity 
of fluoride. inhibition had been appreciated therefore before 
these thiocholine ester studies. The increase in inhibition 
with increase in substrate concentration had given rise to 
the idea that fluoride acted by forming a complex with the 
substrate. That this complex might be thermolabile would 
be in accord with the pronounced decrease in inhibition with 
increase in reaction temperature (Figure 39). This simple 
hypothesis might also be in keeping with the difference in 
degree of inhibition experienced with the different thiocholine 
substrates (Figures 56,57,58). This last phenomenon had 
already been reported by Heilbronn (1965) who noted that 
sensitivity to fluoride inhibition decreased in the order, 
benzoylcholine, butyrylcholine, acetylcholine. Cimasoni 
(1966) also recorded that 'human serum pseudocholinesterasel 
was less readily inhibited by fluoride with an acetylthio-7 
choline substrate than with butyrylthiocholine. 
Inhibition by fluoride is reversible both by dilution 
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and by dialysis against 0.97o sodium chloride (Heilbronn, 
1965) and phosphate buffer (Cimasoni, 1966). Garry (1971) 
explained the differences in inhibition in tris and 
phosphate buffers by postulating that in the former the 
inhibitor was the fluoride ion and in the latter the. 
fluorophosphate ion. However Cimasoni (1966) obtained 
comparable inhibitions of thiocholino ester hydrolysis in 
phosphate and veronal buffers. He concluded that the 
inhibition 
"does not take place through the 
formation of complexes of fluoride 
with magnesium, phosphate or calcium; 
nor does the substrate play a role in 
the mechanism of inhibition. It can 
therefore be postulated that the 
enzyme molecules themselves-are directly 
affected by the halide ions. " 
The statement that the substrate does not play a role 
is difficult to understand since the only experiments under- 
taken on this point did show different inhibitions with 
different substrates. Heilbronn (1965) considered many 
possible mechanisms including the hypothesis that trans- 
acylation occurred to fluoride rather than the hydroxyl 
ion and that the acyl fluoride was then the inhibitor. 
This could account for the more potent inhibitions found 
with the longer (butyryl) and bulkier (benzoyl) esters'. 
She also considered inhibition of acylation due to a reaction 
of the inhibitor with the enzyme-substrate complex but 
finally recorded that an "interaction with a group in the 
active site, necessary for the acylation of the enzyme, 
seems indicated. " 
None of these postulated mechanisms however would 
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appear to account for the inversion of the phenotypic 
inhibitions. This occurs with all three substrates examined 
in this study at roughly the sane fluoride concentration 
between 5X 10- 4 and 10- 
3 
and is due to inhibition of the 
atypical variant reaching a plateau about this concentration. 
A possible explanation could be the presence of two 
inhibitory species, one a readily-formed fluoride complex 
and the other free fluoride ions, both equally inhibitory 
to the usual enzyme but only one a potent inhibitor of the 
atypical variant. 
Speculations regarding these inhibitions far less their 
mechanisms must be tempered by the recent report (Brownson 
and Watts, 1973) that. 5,5'-dithiobis-(2-nitrobenzoic acid) 
has an activating effect on cholinesteraso. This activation 
is abolished at saturating concentrations of acetylthio- 
choline although it is still found with butyrylthiocholine 
under such conditions. Indeed it is even possible that this 
activation may be phenotype-dependent but this was not 
recorded. 
This complication and that concerning the variation 
in absorpt. ion of the indicator ion with temperature were 
not taken into account in the'temperature studies with the 
thiocholine esters. Only the non-enzymic hydrolysis of the 
substrate was allowed for in these experiments by including 
a control for each substrate at each temperature. The 
uncompensated complexities of this assay make calculation 
of temperature-activity constants a meaningless exercise. 
I 
Even expressed as ratios referred to unity at 250C as in 
Figures 62 to 64 probably yields erroneously high values 
"I I ý131 
at the higher temperatures. However even without the 
I 
necessary compensatory adjustments the temperature-activity 
relationships found for all three thiocholine ester substrates 
is sufficient to confirm that the phenotypic thermal responses 
found with a benzoylcholine substrate result from character- 
istic molecuiar alterations in the allelic cholinesterase 
isoenzymes. 
Apart from this general confirmatory evidence any 
meaningfulness to be attached to these experiments can only 
be considered approximations, and that under the specific 
conditions employed. This does not invalidate these results 
from being used for screening purposes however (King and 
Ritchie, 1974). It would be quite valid by assays at 25 
0C 
0 and 45 C to infer that ratios of activity less than 1.5 
with 5 mM acetylthiocholine (Figure 62), less than 1.55 
with 5 mM propionylthiocholine (Figure 63) and less than 
1.7 with 3 W1 butyrylthiocholino (Figure 64) indicate a 
suxamethonium-sensitive phenotype. With the modified 
LKB 8600 Reaction Rate AnalYser used in those studies, 100 
cholinestorase assays can be performed in one hour. A 
realistic figure might be 600 assays per day, say 300 at 
25 0C in the morning then repeated at 450C in the afternoon. 
This number of specimens could be processed readily using 
the LKB 2071 or the Hook and Tucker K40 sample-diluters and 
processing the teletype tape through a modest computer to 
obtain the ratios. The recently introduced Vitatron AKES 
which has a variable temperature control, a sampling- 
dispensing system and produces a print-out of results can 
increase the number of specimens screened to 400 per day 
00-1 00 
(McQueen and King, 1974). 
The action of inhibitors may be used also to screen 
for suxamethonium-sensitive phenotypes. With 10 -4 it 
dibucaine an inhibition of less than 4079,3876 or 507o with 
acetylthiocholine (Figure 47), propionylthiocholine 
(Figure 48) or butyrylehiocholine (Figure 49) respectively 
would indicate a sensitive phenotype. Less reliably, 
succiny1dicholine at 10- 
2M 
sensitive phenotypes would give 
inhibitions less than 60%, 34cilo or 45/10 with acetyl- (Figure 
50), propionyl- (Figure 51) or butyrylthiocholine (Figure 
52) respectively. Chloride and fluoride do not provide 
sufficient differentiation to be of use even for screening. 
Yet again the ratio of hydrolysis rates with two sub- 
strates may be employed although here the differentiation 
is less precise. However with 3 mM butyrylthiOChOlIDO Und 
5 mM acetylthiocholine an activity ratio of less than 1.65 
(Figure 61) would suggest the need for further investigatton 
of the specimen. 
The experiments into the effect of the non-depolarising 
relaxants on the hydrolysis of acetylthiocholine by usual 
and atypical homozygous sera confirm the inhibitory action 
of pancuronium and tubocurarine noted earlier with a 
benzoylcholine substrate (page 92). There is however a 
relative difference in that an initial plasma level of 
2.5 1 pancuronium is too low to have any effect on either 
variant (Figure 59) while an initial plasma level of 5 vM 
tubocurarine would slightly inhibit the usual enzyme 
(Figure 60). 
0 
Particularly interesting is the inhibition of erythrocyte 
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acetyleholinesterase which with both pancuronium and tubo- 
curarine closely resembles the behaviour of the atypical 
cholinesterase. Although both non-depolarising relaxants 
have an anti-acetylcholinesterase action this does not 
occur at concentrations achieved in the blood. 
4. Population Surveys 
12 1) 
During the course of the biochemical investigations 
reported herein, two extensive population studies were made, 
the first on a family or geographical basis, the second in 
a selected clinical setting. 
Scalpay Survey 
A patient admitted to the Lewis Hospital, Stornoway, 
suffered a "suxamethonium apnoeall and assay of his serum 
indicated cholinesterase activity of 260 mU/ml at 25 
0 C, 
dibucaine number 19, fluoride number 22, chloride number 
57 and scoline number 17. Ile was accordingly classified 
as phenotype EaEa 11 although in view of the low activity 
the presence of a silent gene was possible. 
Family studies were suggested but this was difficult 
since the patient resided on a small, fairly remote island, 
Scalpay, off the Island of Lewis. His father was the 
"Elder" of the island which was the home of most members 
of his family. However, Dr. J. H. Burton, Surgical House 
Officer at the Lewis Hospital and Dr. J. W. Robertson, the 
local General. Medical Practitioner took blood samples from 
109 members of the family. As a result one brother and 
two sisters of the propositus were also classified as 
atypical homozygotes, two brothers as heterozygotes and one 
brother a usual homozygote. One further brother was at sea 
and no specimen was obtained and one sister was dead. The 
mother was also dead but the father was identified as a 
usual/atypical heterozygote. 
Two neices of the propositus, daughters of a heterozygote 
brother, were classified phenotype EaEf although in the 11 




phenotype must remain in some doubt (p. 86 and Figures 24 
and 26). A second-cousin was found to be phenotype EuEu 11 
with a serum cholinesterase of 280 mU/ml which in a healthy 
individual again raises the possibility of the presence of 
a silent gene although there was no evidence for this in 
the immediate family and indeed the usual homozygote brother 
had serum cholinesterase activity of 1000 mU/ml. The 
phenotype relationship of the immediate family is shown in 
Figure 66. 
- Outside the immediate family of the propositus the 
relationship data received was somewhat less than satisfactory 
but a possible maternal aunt, a usual homozygote had serum 
ebolinesterase activity of 2100 W/ml, and twenty of the 
sera assayed had activities greater than the normal range 
of 600 to 1350 mU/ml. This might suggest segregation within 
the family of the A variant but no attempt was made to 
confirm this. Although deriving from a second cholinestorase 
locus it has been shown that the A variant apparently adopts 
the same inhibition characteristics as the variants at the 
first locus (Harris, 1970). 
Despite the possible presence of these other variants 
in the population studied, in which incidentally there was 
no evidence of consanguineous matings, it had been hoped 
that in such an extensive family study the scatter of 
inhibitor numbers would be less than in the general population. 
Such a finding would lend support to the thesis (p. 86 et seq. ) 
. 
that the atypical gene, as currently accepted, is not a 
single entity but embraces several mutations. However the 
figures obtained and summarised in Table 16 were disappointing 
1..,,.., 
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Figure 66. Phenotype relationship of the immediate family of 
the Scalpay propositus. 
Table 16 
Summary of Results from Scalpay Survey 
Phenotype Number Cholinesterase 
Dibucaine Fluoride Chloride Scoline 
Number Number Number Number 
(280 - 2100) 
EuEu 73 520 - 1740 79 - 83 56 - 66 .9- 19 88 - 
93 
11 
EuEa 28 340 - 1320 54 - 69 45 - 52 21 - 30 63 - 70 11 
aEa4 260 - 395 15 - 22 19 - 24 48 - 57 14 - 17 11 
The values in parenthesis for cholinesterase activity of the usual 
homozygotes represent the true limits found. When these two values are 
deleted the narrower unbracketted range is obtained. 
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in this respect. The inhibitor numbers for the atypical 
homozygotes certainly show less scatter than the general 
population but this was from only four individuals. 
Pregnancy Survey 
The first patient suffered a "Scoline apnoeall at 
term in Glasgow Royal Maternity Hospital and a blood sample 
was sent for analysis. The results of cholinesterase 
130 mU/ml, dibucaine number 29, fluroide number 31 and 
chloride number 40 did not fit with any phenotype (Figures 2 
and 29). The sample was haemolysed and although it was 
known that this did not invalidate the results a repeat 
specimen was requested. Analysis of this second specimen 
gave results for serum cholinesterase 105 mU/ml, dibucaine 
nijmber 33, fluoride number 31 and chloride numbe-r 42. TIio 
second values were still anomalous but a provisional pheno- 
type of EEa Nvas given. A third blood sample Nvas received 
five weeks later when the results of sentin cholincsternso 
435 mU/ml, DN =-- 44, FN = 35 and Cl N= 30 were obtained and 
1.1 f ater indicated that the patient's phenotype was El E1L, 
assays confirmed this phenotype just as, repeated assays of 
the first two specimens yielded the original anomalous 
results. The change in inhibitor numbers was paralleled 
by alterations in the temperature-activity relationships 
(Figure 67). 
The second case originated in identical circumstances 
and the first determinations gave serum cholinesterase 
175 mU/ml, DN = 30, FN = 34 and Cl N= 39 figures which 
did not correlate with any phenotype but most closely 
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Figure 67. Temperature/activitY curves for the serum cholinesterase 
of the first pregnancy case (page 123) at different 
times. The specimen dated 5.3.69 was taken on the day 
of delivery. 
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indicated a phenotype EaEf with cholinesterase activity 11 
375 mU/ml, DN = 45, FN = 37, Cl N= 31 and Scoline number 50. 
Chloroform had been part of the anaesthetic regime in 
the first case and without any real conviction had been 
postulated as the cause of the anomalous inhibitor numbers. 
Chloroform was not employed with the second patient and 
the anomalous inhibitions were attributed generally to term 
pregnancy. 
It was this background which gave rise to the comment 
(King, McQueen and Morgan, 1971) when the third case 
(patient M of Case 4, page 49) was presented that "assay 
of her serum at this time yielded the usual anomalous 
results associated with late pregnancy". These restilts 
were serum cholinesterase 365 mU/ml, DN = 54, FN = 32 and 
C1 N= 27 which corresponded most closely to phenotype 
Ea Ef. However later, post-partum figures for cholinesterase 11 
activity of 480 mU/ml and dibucaine, fluoride and chloride 
numbers of 64,36 and 28 respectively indicated that she 
was in fact a fluoride-resistant homozygote, Ef Ef 1 1* 
It was recalled (King, 1965) that the activity of 
oxytocinase, an aminopeptidase, increased in the blood 
plasma in pregnancy, reaching very high levels in the last 
trimester. It is the presence of this enzyme, which has 
overlapping substrate specificities with leucine amino- 
peptidase, which results in high activities of the latter 
enzyme'being measured in blood serum in pregnancy (Green, 
Tsou, Bressler and Seligman, 1955; Bressler and Forsyth, 
1959; Miller and Worsley, 1960). 
It seemed possible that the aminopeptidase action 
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might be modifying the molecular structure of cholincsterase 
resulting in the anomalous inhibitions. Dr. L. Murray of 
the Glasgow Royal Maternity Hospital was therefore approached 
with the project of obtaining blood samples at various times 
during pregnancy for assay of leucine aminopeptidase activity, 
cholinesterase activity and inhibitor number to determine 
whether and at what point these last altered during pregnancy. 
Four hundred and fifteen blood samples from 148 patients 
were obtained over a period of fourteen months . Many of the 
specimens were single samples and from other patients only 
two blood specimens were received. However from 26 patients, 
five or more blood samples were obtained during pregnancy 
and in 13 cases post-partum specimens were also obtained. 
While analysis of the sera confirmed the pronounced increase 
in aminopeptidase activity already mentioned and the more 
modest decrease in cholinesterase activity (Friedman, Lapan 
and Taylor, 1961; Schnider, 1965; Robertson, 1966) in 
pregnancy, no change in inhibitor numbers was found. This 
was in agreement with the report by Hazel and Monier (1971) 
published about this time. 
. During this survey however a fourth term pregnancy 
apnoea with anomalous results was referred from Stobhill 
Hospital. The serum cholinesterase was 395 mU/ml, DN = 65, 
FN = 50, C1 N= 24 and SN = 78 which suggested a phenotype 
uaff of EIEI or less likely EIE1 Arrangements were made to 
phenotype close relatives and on this occasion the patient's 
sera gave values for cholinesterase of 570 mU/ml and of 76, 
54,21 and 86 for dibucaine, fluoride, chloride and scoline 
numbers respectively which indicated a usual/fluoride- 
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resistant heterozygote EIE1 This Phenotype agreed with 
those of parents and siblings. 
It then became clear that the anomalies occurred in 
individuals possessing the fluoride-resistant gene. This 
accounted for the negative findings in the pregnancy survey 
in which only the usual and atypical variants had been 
encountered. 
Attempts were later made with sera containing the 
fluoride-resistant cholinesterase to simulate the proposed 
mechanism in vitro by adding crystalline leucine amino- 
peptidase (Boehringer Corporation, leucine arylamidase). 
It was found however that addition of the enzyme caused an 
immediate alteration in all inhibitor numbers which did not 
further change significantly on prolonged incubation. The 
crystalline enzyme is supplied as a suspension in 3.2 1.1 
ammonium sulphate and it was found that addition of a simple 
3.2 M ammonium sulphate solution resulted in the observed 
change in inhibitions. 
Dialysis or ultrafiltration of the crystalline enzyme 
and subsequent solution in say 50% glycerol may remove this 
last effect but obviously a purification of cholinesterase 
as achieved by Das and Liddell (1970) would also seem indicated. 
Then, if changes in inhibitor numbers were noted on incubation 
with aminopeptidase or other proteolytic enzyme, an amino- 
acid analysis of the reaction mixture might give some insight 
into the alteration in the molecular structure of cholinestcr- 
ase which brought about this change in kinetic behaviour. 
5. Discussion. Conclusions and ProspectS. 
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Discussion, Conclusicins and Prospects 
The studies undertaken in this project have produccd 
results with applications and meaningfulness in the diverse 
but connected spheres of technology, biochemistry, physiology, 
pharmacology and genetics. 
Technical and Clinical 
For precise identification of sensitive cholinesterase 
phenotypes the assay method of Kalow and Lindsay (1955) 
employing a 50 VM benzoyleholine substrate with inhibition 
by 10 VII dibucaine (Kalow and Genest, 1957) and 50 pM sodium 
fluoride (Harris and Whittaker, 1961) at 25 0C has been shown 
to be adequate and indeed apparently essential. As King and 
Griffin (1974) have pointed out retention of this technJque 
is certainly not on the grounds of case or speed. The rate 
of hydrolysis is monitored at 240 nm which requires a fairly 
sophisticated ultraviolet recording spectrophotometer with 
temperature control, while the procedure is somewhat time- 
consuming and, by routine clinical biochemistry standards, 
demands more than the usual technical ability. However the 
studies on the variation of benzoylcholinesterase activity 
and the studies with other substrates have not revealed an 
alternative procedure capable of yielding precise categorisation 
of the phenKype. Nevertheless these investigations have 
disclosed means of screening for individuals at risk to the 
muscle-relaxant, suxamethonium. 
By the use of thiocholine esters and the LKB 8600 
Reaction Rate Analyzer it has been shown to be possible to 
screen 300 patients per day using the relative hydrolysis 
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rates of two. substrates, dibucaine inhibition, or the ratio 
of hydrolysis rates at two temperatures. The first two of 
these techniques do not require the ability to alter the 
reaction temperature and can be achieved by the standard 
instrumentation, automated to a degree and performed quickly, 
simply and cheaply. These are the requirements for population 
screening. 
The modifications carried out on the LKB instrumentation 
serve to underline the concept that the limits of endeavour 
in laboratory medicine must never be circumscribed by 
manufacturers. Only the laboratory worker knows what is 
required of him and only he knows what he must have to carry 
this out. The fact that the manufacturers of this instrument, 
following publicity attached to our modificatlons, now offer 
a variable temperature device as an optional extra, emphasises, 
this point of view. As it is, recently introduced alte-rnativo 
analysers such as the Vitatron AKES system, the Union- 
Carbide Centrifichem and Aminco Rotachem, which have variable 
temperature capabilities, can be employed for chollnesterase 
screening using procedures based on any of the three principles 
outlined above. 
However it is too easy to be blinded by dedication to 
a single goal. The ability to carry out population screening 
for cýolinesterase variants would appear to be possible as 
a result of these studies. The question to be considered 
now and which should have been posed at the outset, is 
whether screening for suxamethonium sensitivity is desirable 
and worthwhile. Obviously it is desirable to have information 
concerning the sensitivity of a patient to a drug. At 
12S. 
present biochemical investigations are only undertaken after 
the apnoeic episode has occurred and in a few laboratories 
such as these, close relatives are subsequently offered 
phenotyping. This is a very limited screening. As it is, 
the ability to screen 300 patients per day would cover all 
surgical patients in the Glasgow Royal Infirmary group of 
hospitals. Indeed it can be estimated that if screening 
were to be limited to patients receiving suxamethonium, 
300 per day would provide such discriminatory cover to the 
whole West of Scotland Region, embracing a population of 
some three million. Since about one in three thousand of 
the population is of a predictably sensitive phenotype 
(Lehmann and Liddell, 1969) then on the average the proposed 
screening programme would reveal one such patient every 
ten days of operation. During this same period however one 
other pationt would suffer a suxamethonium apnoca which in 
our present state of biochemical knowledge and anaesthetic 
practice could not have been predicted (Lehmann and Liddell, 
1969). At its very best then a fifty per cent success rate 
is all that can be expected from a screening programme 
for 8uxamethonium sensitive individuals. Were the apnoeic 
episodes to carry a similar percentage of fatal outcomes, 
indeed any significant percentage of fatalities, then the 
answer to whether screening is worthwhile would never have 
to be given for the question would not be asked. However 
today the phenomenon is well understood by all practising 
anaesthetists and while it is the cause of some inconvenience 
and even prolonged, intensive attention it does not con- 
stitute a serious major problem either to patient or 
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anaesthetist.. Under these circumstances it is debatable 
whether mass screening is more desirable and worthwhile 
than the limited selective screening currently undertaken 
in these laboýatories. 
It has been amply shown above that in the clinical 
setting under discussion, that of suxamethonium apnoca, 
the standard procedure for identifying the serum cholinest- 
erase variants has little to recommend it to the analyst. 
That it does precisely define the cholinesterase phenotype 
is the sole reason for its retention because the results 
obtained are not always readily correlated by the anaesthetist 
with the degree of sensitivity. Generally it can be accepted 
that the lower the cholinesterase activity and the lower 
the dibucaine and fluoride numbers the longer will be the 
period of paralysis. However, oven excluding the 507o of 
all apnocas which occur in the usual homozygote or heterozy- 
gotes and hence are not predictable, as was seen from 
Figure 14 the serum activity of many suxamethonium-sensitive 
individuals is in the normal range of this standard 
procedure at 25 
0 C. The studies herein recorded have 
indicated that a false impression is obtained of the 
activities of the most sensitive phenotypes by assay at 
25 0C and a true index is only obtained at 37 0C as shown in 
Figure 15. 
The second lack of correlation between enzymic para- 
meters and apnoeic response occurs with the fluoride- 
ff 
resistant homozygote, E1E1 This sensitive phenotype is 
categorised by a dibucaine number, and also chloride and 
scoline numbers, of the same order as the non-sensitive 
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ua usual/atypical heterozygote, E, E, Again the explanation 
lies with the assay temperature used. Figure 35 showed 
that the response to temperature of the dibucainc inhibition 
of the EfEf phenotype is more pronounced than the others. 11 
At 37 0 C, the temperature which the Patient exhibits the 
sensitivity, the dibucaine number is similar to that of the 
af 
predictably sensitive E, E, phenotype. 
These temperature studies on the inhibition of bonzoyl- 
choline hydrolysis have clearly shown that accurate tempera- 
ture control is essential for precise phenotype categorisation, 
which_only adds to the technical strictures of the method. 
On a more general topic the finding of the different 
temperature-activity relationships of the allelic cholin, 
esterase isoenzymes provides important factual evidonco on 
the vexed problem of a standard temperature for clinical 
enzyme assays (King, 1972). In this controversy one of the 
first questions to be considered is whether the actual 
assay temperature and the standard temperature need be one 
and the same. If there is no compulsion for this then it 
is possible to conduct an assay at the temperature giving 
greatest advantages for each individual enzyme and then 
convert to the standard temperature. This reduces to the 
question of whether temperature correction factors are 
feasible and valid. In the present instance, although 
lengthy and cumbersome, following determination of the 
phenotype, the appropriate correction factors can be used. 
This however could not be done for varying proportions of 
isoenzymes as encountered with lactate dehydrogenase or 
alkaline phosphatases. The studies with the thiocholine 
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esterd, also show that the correction factors vary with the 
substrate employed. From these facts it was concluded that 
at best temperature conversion factors can only give 
approximations and their present indiscriminate use should 
be avoided. As a necessary consequence of this, the assay 
and standard temperatures must be the same. 
The principle has been applied further and on the 
temperature-activity differences between human serum enzymes 
and the enzymes in commercial quality control sera, limits 
of valid use of the latter have been described (King, 
Henderson and Morgan, 1972). 
The failure to precisely classify the allelic variants 
at any tcmperattire other than 25 
0C raises questions apart 
from those already discussed under the appropriate sections, 
and in particular the basic question of defining the variants. 
Gonetics 
I As the work of Lehmann and co-workers on haemoglobin 
(Lehmann and Huntsman, 1966; Lehmann and Carrell, 1969) and 
Harris and colleagues on enzymes (Harris, 1970) has shown, 
protein polymorphism is the rule rather than the exception. 
A non-lethal-mutation occurs, is passed on and a balance 
is eventually achieved with the remainder of the population. 
Such mutations occurring initially in the DNA coding may 
result in a simple substitution of a single amino-acid at 
any point in the polypeptide chain with variations down to 
an incomplete or nonsense chain. The latter possibilities 
of course are examples of "silent genes". Depending upon 
the change in properties attending upon the simple sub- 
stitution and its point in the chain diverse alterations 
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in the-three-dimensional protein conformation will result 
with consequent alterations in stability and enzymic 
characteristics. In our present state of knowledge of 
enzymes, unlike haemoglobin, we are not capable generally 
of differentiating such mutations by specifying the actual 
change in molecular structure. Instead such variants are 
differentiated by relatively crude procedures such as 
electrophoresis or by precipitation, inactivation or 
inhibition by reagents, antibodies or physical means such 
as heat. The means by which the mutations are differentiated 
is of necessity therefore the terms in which the mutations 
are defined. In the present instance the first allolic 
cholinesterase isoenzyme to be differentiated from the 
usual was termed the "atypical" and was def ined by its 
relative resistance to inhibition by dibucaine under specific 
assay conditions. Sodium fluoride not only achieved the s-, ime 
but revealed a further sub-differentiation (Harris and 
jVhittaker, 1961) attributable to another allelic variant 
and for obvious reasons termed the fluoride-resistant enzyme. 
These mutations were therefore defined in terms of the 
inhibition of 50 pll benzoylcholine hydrolysis. in phosphate 
buffer of pIl 7.4 at, or near, 25 0C by 10 11M dibticaine or 
50 VM fluoride. In view of the interdependence of all 
factors influencing enzyme activity it would be most unlikely 
therefore if the definition of the allelic isoenzymes were 
retained when the conditions of determination were altered. 
Since dibucaine and succiny1dicholine act as simple 
competitive inhibitors it is possible by manipulating 
substrate and inhibitor concentrations to maintain the 
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definit-ive inhibitions at other temperatures and with other 
substrates. However these studies have shown (Figures 56 - 
58) that the inhibition by fluoride is complex and this in 
conjunction with the profound effect of temperature on the 
I 
inhibition (Figure 39) is responsible for the failure to 
precisely differentiate the mutations other than under the 
definition conditions. 
By the use of other inhibitors such as chloride 
(Whittaker, 1968b; King and Dixon, 1970), formaldehyde 
(Whittaker, 1969) and n-butyl alcohol (Whittaker, 1968a) 
the presence of further variants has been postulated. From 
these present investigations the correlations between 
succinyldicholine inhibition and others (Figures 23 to 28) 
tend to support this and reasoning from other similar protein 
mutations strongly advises that a large number of structurally 
similar cholinesterases exist. This proposition did not gain 
any support from the family survey on the Jsland of Scalpay. 
However if the original postulate is correct then starting 
with the mother and father it is possible that two different 
usual and two different atypical genes were segregating 
between the propositus and his siblings. Only in the homozy- 
gote, usual or atypical, can the genetic compositions be 
identical but the numbers, four atypical homozygotes is too 
small to draw any conclusions from the narrow scatter of 
inhibitor numbers obtained (Table 16). 
The postulate that there is a quantitative genetic 
control of serum cholinesterase (Wetstone, 11oneyman and 
McComb, 1965) in addition to the well established qualitative 
I 
control receives no support from these investigations. 
13 r,, 
I 
Certainly the mechanisms which control type need not control 
amount but if the mechanism controlling quantitative pro- 
duction is uncoupled from that controlling type then it is 
to be expected that the rate of syntheis of the two allelic 
proteins will be separately affected. The thermodynamic 
data herein derived suggests that quantitatively there is 
equal gene synthesis. This can only be accepted as a mean 
or average assessment however since the values used in the 
calculations were such themselves. Reasoned extrapolation 
from other enzymes would make it seem more likely that the 
quantitative differences observed in serum cholinesterase 
activities in a normal population are mediated by environ- 
mental and hormonal rather than genetic influences. As 
discussed earlier the numerically large values attached to 
serum cholinesterase activity are a reflection of its, 11serum 
specificity" and the relative range span, that is, the ratio 
of upper to lower limits of normal actiity, is small compared 
to other enzymes. 
Pharmacology 
The problems associated with the mixing of depolarising, 
and non-depolarising relaxants are well surmnarised by Wylie 
and Churchill-Davidson (1972). However the literature does 
not appear to contain any report of the inhibition of cholin- 
esterase by the non-depolarising relaxant, pancuronium, and 
thus finding would theoretically appear to further Complicate 
anaesthetic practice. 
This initial finding of cholinesterase inhibition by 
pancuronium related to benzoylcholine hydrolysis but was 
also found with an acetylthiocholine substrate and would 
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therefore appear to be a true anti cholinesterase action. 
While an ant iacetylchol inest erase activity has also been 
shown (Figure 59) this effect only occurred in vitro at 
concentrations not likely to be obtained in blood. However 
it is stated that a concentration of 10- 
5M 
pancuronium is 
required at the neuromuscular junction for blockade (Goodman 
and Gilman, 1970) and at this concentration there is some 
inhibition of acety1cholinesterase with consequent depolaris- 
ing action. The manufacturer's data (Organon Laboratories) 
states that the maximum effect is evident after 2-21 minutes 
and, depending upon dosage and anaesthetic techniques, lasts 
about 45 minutes. On the results of the experiments 
described herein it would certainly seem ill-advised to 
administer pancuronium before suxamethonium since the 
pancuronium inhibition, particularly of the usual homozygote, 
would reduce the hydrolysis of the suxamethonium. Even 
administration of pancuronium after suxamethonium but before 
-the effects of the latter had passed off, would seem to be 
less than ideal. 
On these in vitro experiments it is difficult to 
understand why a partial "dual block" is not obtained by 
administration of pancuronium alone. When both relaxants 
are administered it is apparently standard anaesthetic 
practice to give suxamethonium first and one is assured that 
no untoward reactions are obtained under these circumstances. 
In only two cases of "Scoline apnoeall among the many which 
are of non-predictably sensitive phenotype, one a usual 
homozygote and one an atypical heteroxygote was it found 
that pancuronium had been administered and in the accepted 
sequence. 
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Bioclýemlstry and Physiolog 
Paigen (1971) stated "The most sensitive and accurate 
test for changes in protein 
structure is relative thermo- 
stability. The probability that 
a random aminoacid substitution 
produces a protein with altered 
thermolability is more than 50c,, o 
This probability is higher than 
for any other test, and the 
necessary measurements can 
generally be made with consider- 
able accuracy in dilute solutions 
of crude enzyme". 
By "thermolability" Paigen obviously referred to 
denaturation by incubation at a set temperature and the 
sensitivity of this has been demonstrated by Walsh, Lowell 
and Neurath (1966) in two carboxypeptidase A allelomorphs 
differing only in the antepenultimate C-terminal aminoacid 
residue and by Langridge (1968) in induced muttations of the 
0-galactosidase of E. Coli. However as far as the writor is 
aware the experiments described herein are the first in 
which differential temperature analysis has been employed 
in the recognition of enzyme molecular forms. The principle 
has considerable potential. King (1972) has suggested that 
it could be applied to other enzyme species and in fact har. 
used it in differentiating human macroamylase from the 
normal a-amylase (Henderson, King and Imrie, 1973; Imrie, 
King and Henderson, 1973). 
The studies on the hydrolysis rates of the thiocholin- 
esters would indicate that the relative affinity for butyryl- 
thiocholine shown by the usual enzyme is not shared by the 
fluoride-resistant variant and less so by the atypical 
isoenzyme. Indeed the last shows almost equal activity with 
acetylthiocholine and butyrylthiocholine (Figure 61) almost 
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a tendency towards the substrate specificities of acetyl- 
cholinesterase. The similarity in the inhibition by 
pancuronium of the atypical homozygote and erythrocyte 
acetyleholinesterase (Figure 59) offers support to this 
premise. If therefore as has been suggested (Jamieson, 
1963; Koelle, 1963) the phy. §iological role of cholinesterase 
is not dissimilar to that of acety1cholinesterase then the 
atypical homozygote is at'no disadvantage in normal circim- 
stances. Indeed the enzyme will function at substrate 
concentrations not only inhibitory to acetylcholinesterase 
but even to the usual varianý although it is highly improbable 
that such concentrations will be found in vivo. 
The principle of differential substrate analysis 
illustrated by the above thiocholine ester studies (Figure 
61) has been employed with pyruvate and 2-oxobutyrate as 
substrates for lactate dehydrogenase (Wilkinson, 1972). In 
these laboratories this has been extended by the use of 
hydroxypyruvate (McQueen and King, 1971a, b) and glyoxylate 
(King, Young and Naghizadeh, 1973; Young, Naghizadeh, King 
and Morgan, 1973). 
_Speculations 
and Prospects 
In their erudite review of the mechanism of hydrolysis 
by cholinesterase Davies and Green (1958) critically examined 
the kinetic evidence available and convincingly concluded 
that histidine was present in the anionic active site of 
cholinesterase. 
With regard to the allelic cholinesterase isoenzymes 
the difference in substrate and inhibitor specificities is 
most evident with positively charged compounds (Kalow and 
13 
Davies, 1958; Davies, Marton and Kalow, 1960) 
differences in the anionic sites. Harris and 
(1963) have pointed out that the differe . ntial 
fluoride and high concentrations of chloride 
necessarily conflict with this view. 






or transversions and Epstein (1967) has pointed out that 
this generally results in an aminoacid substitution which 
conserves the properties of the polypeptide. In this particular 
instance this proposition gains support from the lack of 
difference in electrophoretic mobilities of the variants 
which in itself could suggest the substitution of an aminoacid 
with unionised side chain being substituted by another or 
by one the side chain of which is uncharged at p1I 8.6. The 
imidazole side chain of histidine is uncharged at p1l S. 6 
the p1l at which protein electrophoresis is usually performed. 
Equally well the substitution could be for histidino and the 
clectrophoretic separation of the variants at p1l 9.7 (Liddell, 
Lehmann, Davies and Shank, 1962) would require the substituent 
side chain to have a less negative charge than imidazole at 
this p1I. 
Photo-oxidation in the presence of methylene blue 
which specifically decomposes histidine and tryptophan was 
used in demonstrating a functional role for imidazole groups 
in chymotrypsin, (Cohen and Oosterbaan, 1963). This pro- 
cedare or the blocking of the imidazole ring by selective 
sulphonylation below pIl 5 should elucidate this possibility. 
If histidine has a function in the cholinesterase active 
site then photo-oxidation or sulphonylation would destroy 
I 
or impair the activity of usual homo:, ýygote sera. If 
substitution of the histidine i. --; the mutation which results 
in the inhibitor-resistant varinnts then such homozygous 
sera would be unaffected, unless of course using the photo- 
oxidation process, tryptophan were the substituent. 
Accepting the above circumstantial evidence that 
histidine is a functional component of the active site of 
cholinesterase and further that the allelic variants arise 
from its substitution there are seven possible one-point 
transitions and transversions which could occur in its 
genetic coding (CA - C/U). These mutations could result in 
substitutions by aspartic acid (GA - C/U), tyrosine (UA - C/U), 
arginine (CG - C/U), proline (CC - C/U), 'Ieucine (CU - C/U), 
asparagine (AA - C/U) and glutamine (CA - G/A). Tryptophan 
is not a possible substitution from a single-point mutation. 
Of the possible substituents it can be reasoned that the first 
four would not have uncharged side-chains at pH 8.6 and less 
negative dharges than imidazole at pil 9.7. Tile al: Lphatic 
side chain of leucine and the amides of asparagine and 
glutamine do fulfill both conditions. 
The finding of anomalous inhibitor numbers at term 
pregnancy in patients possessing the fluoride-resistant 
gene is important as this constitutes the first recording 
of a cholinesteraso mutation outside the control of the 
structural gene. Since this modification apparently only 
occurs in the fluoride-resistant enzyme this is further proof 
that there is a structural differenco between this variant 
and the others. Further if the po.,; tulate is correct that the 
fluoride-resistant molecule is modtfiod by the action of 
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oxytocinase then since the aminopeptidase only splits off 
N-terminal residues it is in this position that the fluoride- 
resistant variant differs from the usual and atypical iso- 
enzymes. 
Again, oxytocinase has a high affinity for N-terminal 
cystine; leucine aminopeptidase for leucine but also for 
phenylalanine, tyrosine, histidine and tryptophan. If 
therefore the future studies proposed with leucine amino- 
peptidase (page 126) do not yield similar alterations in 
inhibition characteristics as found in term-pregnancy this 
could constitute evidence that the N-terminal residue was 
not an amino-acid readily attacked by leucine aminopeptidase. 
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